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Abstract 
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder and a main cause of 
dementia in the elderly. The main pathological hallmarks of AD are the accumulation of insoluble 
aggregates of amyloid--peptides (A), which are proteolytic cleavage products of the amyloid- 
precursor protein, and insoluble filaments composed of hyperphosphorylated tau protein. Familial 
forms of AD can raise the production of A peptides. 
Synaptic damage is a critical aspect of AD, and the best correlate with cognitive impairment 
ante mortem. Synapses, the loci of communication between neurons, are characterized by signature 
protein combinations arrayed at tightly apposed pre- and post-synaptic sites. The most widely studied 
trans-synaptic junctional complexes, which direct synaptogenesis and foster the maintenance and 
stability of the mature terminal, are conjunctions of presynaptic neurexins and postsynaptic 
neuroligins. The presynaptic neurexins bind with the neuroligins on the postsynaptic membrane. This 
pairing is implicated in synaptic signalling and the determination of whether a synapse will be 
excitatory or inhibitory. At the postsynaptic density, neuroligin-1 is specific for glutamatergic 
synapses, whereas neuroligin-2 is indicative of a GABAergic synapse. The neuroligins mediate 
connection with the presynaptic terminal mainly through -neurexin, which occurs in different 
isoforms derived from alternatively spliced transcripts. Fluctuations in the levels of neuroligins and 
neurexins can sway the balance between excitatory and inhibitory neurotransmission in the brain, 
and could lead to damage of synapses and dendrites. 
The main objective of the research set out below was to investigate possible disruptions of 
nerve-cell connections in AD through assay of the trans-synaptic neurexin and neuroligin proteins. 
The project explored differences in neuroligin and neurexin expression across different brain regions 
at various stages of the progression of the disease. I also investigated whether any differences 
occurred at the level of transcription or translation of the proteins. Additional work focused on a 
genetic study and the association between the NRXN-3 gene and AD. 
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To identify the differences in the level of protein expression, a sensitive immunodetection-
assay using recombinant protein standards was developed to measure concentrations of neuroligin-1, 
neuroligin-2 and -Neurexin-1 in AD cases and matched controls. Two regions that are 
pathologically affected in the AD brain, the hippocampus and the inferior temporal cortex, and one 
relatively spared region, the occipital cortex, were studied. Quantification showed higher expression 
in AD cases than in controls of both post-synaptic neuroligin-1 and pre-synaptic -neurexin-1. The 
expression of neuroligin-1 and -neurexin-1 was higher in AD hippocampus than in this region in 
controls, but the difference only reached significance for neuroligin-1. In contrast, the expression of 
neuroligin-2 protein was lower overall in AD cases than in controls. Lower expression in AD cases 
was seen in all areas and reached statistical significance in inferior temporal cortex. 
A mass spectrometry approach was employed to validate the quantification of these proteins 
using with two novel methods, multiple reaction monitoring (MRM) and sequential window 
acquisition of all theoretical fragment ion spectra (SWATH). Using these high-throughput techniques 
I identified several hundred synaptic proteins, including neuroligins and neurexins. However, an 
insufficient number of peptides was identified for each of these proteins, which precluded their 
quantification by these approaches. 
Protein data from the immunodetection assay were correlated with mRNA transcript levels by 
using quantitative real-time PCR assays, which were established for neuroligin-1, neuroligin-2 and 
-neurexin-1 transcripts in the same areas of AD cases and controls. Quantification revealed 
significantly lower expression of all three transcripts in AD hippocampus and inferior temporal 
cortex, but no difference in occipital cortex, compared with controls. Expression of the three 
transcripts was found to correlate with disease progression as indexed by the AD pathological 
markers A, neurofibrillary tangles, and neuronal loss. However, APOE genotype had no effect on 
mRNA transcript levels. 
To look for a genetic association between the NRXN-3 gene and AD, I attempted to 
replicate a published report that the single nucleotide polymorphism rs17757879 was a tag for the 
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gene in a Spanish cohort. AD cases and controls were genotyped by a Taqman assay to explore the 
association between rs17757879 in NRXN-3 and AD in an Australian Caucasian population. 
Overall, the data did not show a significant association between rs17757879 and AD. When the 
subjects were partitioned by gender, there was a trend toward a significant association between 
rs17757879 and the disease in males only. When alleles were divided according to the presence or 
absence of the T allele (CT plus TT compared with CC) association reached significance, and 
indicated that the T allele was protective against AD in males. 
The data from this project provides further understanding of the molecular characteristics of 
the neurexin-neuroligin complex in AD. An understanding of the roles of these molecules will likely 
open new therapeutic avenues for the treatment of AD. 
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Chapter 1 
1 Introduction 
1.1 Epidemiology and history 
Alzheimer’s disease (AD) is the most common form of organic dementia. It affects more than 
20% of people aged 65 years or older. It ultimately leads to the death of affected individuals on 
average 9 years after diagnosis (Reynolds, 2001). Worldwide, approximately 27 million individuals 
are affected by the disease (Ferri et al., 2005); and 4.6 million new cases arise every year. 8% of all 
medical costs in the United States of America are related to dementia. Between regional populations 
of 60 years old, people from North America and Western Europe are thought to show the highest 
prevalence and incident rate of AD, followed by people from Latin America and china (Fig. 1.1). 
Among western societies, prevalence and increase display with a cohort effect with individuals born 
later having a lower risk than individuals born earlier in the past century (Christensen et al., 2013, 
Matthews et al., 2013, Rocca et al., 2011, Schrijvers et al., 2012). The mortality from AD is 
predicted to increase dramatically over the next two to three decades as achievements in treating 
cancer and heart disease allow more individuals to reach the age of risk for dementias (Morgan, 
2010). 
 
Fig. 1.1. Global prevalence of AD 
The story of Alzheimer’s disease begins at the beginning of the 20th century, on November 
25, 1901 when a 51-year-old woman, her name Auguste D, was admitted to the Frankfurt State 
Asylum where she was examined by young psychiatrist Alois Alzheimer. The patient had a striking 
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group of symptoms such as cognitive impairment, loss of social appropriateness, a progressive 
decline in memory, and loss of capacity to communicate. Doctor Alzheimer remained interested in 
Auguste D’s case until her death in Frankfurt on April 8, 1906. Alzheimer requested the patient brain 
to be sent to Munich to study in his new neuropathology laboratory and he described the clinical and 
pathological findings at a conference in Tubingen on November 3, 1906. The title of his presentation 
was ‘On a peculiar disease process of the cerebral cortex’ and the reports of this conference were 
published the following year (Alzheimer et al., 1995). Alzheimer reported that on post-mortem 
examination of Auguste’s autopsy brain he found plaques, tangles and atherosclerotic alterations. 
The novel aspect in the 1906 case was their occurrence in an unusually young patient; however, 
Alzheimer did not claim to have discovered a new disease. Alzheimer’s case notes were missing for 
approximately a century but were revealed in the basement of the University of Munich by Konrad 
Maurer, which led to one of the basic publications of recent times about AD (Maurer et al., 1997) 
comprising a photograph of Auguste D and examples of Alzheimer’s handwritten notes on Auguste’s 
cognitive status. Two years later Professor Manuel Gräber and his team extracted and tested DNA 
and found that Auguste did not carry the 4 allele of the apolipoprotein E gene (Gräber et al., 1998), 
however the team were not able to screen for genetic mutations associated with early onset disease. 
The main feature of AD is memory loss. Memory is now considered to be a collection of 
mental abilities that use multiple systems and components within the brain. Memory researchers 
have characterised six major memory systems, which are: Episodic memory, Semantic memory, 
Short-term memory, Simple classical conditioning (which involves the pairing of two stimuli), 
Procedural memory, and Priming (which occurs when a prior encounter with a particular item 
changes the response to the current item). In AD, cognitive researcher found some of the six major 
memory systems to be highly impaired and others to be relatively preserved (Gold and Budson, 
2008). Episodic memory, which is critical for remembering new events, is considered to be the most 
clinically relevant in patients; its impairment is one of the earliest symptoms of AD (Gold and 
Budson, 2008). Other studies have shown semantic memory to be impaired in AD, with patients 
exhibiting particular deficits in naming categorized items (Tippett et al., 2007). The impairment of 
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semantic memory has often been related to pathology in the anterior and inferolateral temporal lobes 
and the frontal lobes, which leads to a loss of the dendritic arbor on neurons in these cortical regions 
(Davies et al., 2004). Other features of AD such as cognitive decline appear after the development of 
memory impairment. Language function and visuospatial skills are affected relatively early. 
Language dysfunction includes reduced vocabulary in spontaneous speech. However, impairment of 
motor functions usually only appears at late disease stages. 
1.1.1 Diagnosis (Clinical and post mortem) 
The clinical criteria usually used for the diagnosis of AD are based on the Diagnostic Manual 
of Mental Disorders, Fourth Edition (DSM- IV) and follow the criteria of the National Institute of 
Neurological and Communicative Disorders and Stroke and the Alzheimer’s Disease and Related 
Disorders Association (NINCDS-ADRDA; McKhann et al., 1984). Different screening tests have 
been established during the last years, however the Mini Mental State Examination (MMSE) is the 
most widely used. The Community Screening Instrument for Dementia (CSI-D) was developed to be 
used in cross-cultural studies. It is composed of language expression, attention and calculation, 
orientation to place and time, language comprehension, and memory recall. The CSI-D instrument 
correlates with the Mini Mental State Examination (MMSE) and 10-word-list–learning task (Liu et 
al., 2005). 
A general neurologic examination is usually normal in the demented patient with AD. 
Continuing gait problems can occur in the severe stages of AD, with a noticeably increased risk for 
falls. At present no laboratory test is available to confirm the diagnosis of AD. The main 
neuropathologic criteria for AD are those propagated by the National Institute on Aging (NIA) and 
National Institute of Neurological and Communicative Disorders and Stroke (NINCDS; Mirra et al., 
1993). 
Both DSM-IV and NINCDS-ADRDA criteria are based on history and neurologic 
examination, and current indication proposes that both have fallen behind because of new advances 
in scientific knowledge. Different biomarkers have been identified based on structural Magnetic 
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Resonance Imaging (MRI), molecular imaging and cerebrospinal fluid (CSF) analyses Structural 
MRI in patients with AD displays atrophy in the hippocampus that is predictive of future cognitive 
decline. 
On the other hand, post-mortem diagnosis of AD needs proof of the existence of 
neurofibrillary tangles (NTF) and -amyloid (A) in the brain and cases of dementia without these 
alterations must be classified as non-Alzheimer dementias. Brain alterations found in cases clinical 
diagnosed with AD often include both A and NFT (Braak et al., 2011). The main method used for 
staining A uses thioflavine S, which is insensitive and can determine NFT changes as well. Specific 
antibodies for the pathologic proteins are commercially available; yet, practical considerations limit 
their application to small sections and well-equipped laboratories. The use of modern silver methods 
that take advantage of the physical development of the nucleation sites and avoid variable 
ammoniacal silver solutions known as Gallyas techniques is recommended (Braak et al., 1988, Braak 
and Braak, 1991b). These methods are simpler to use and much more reliable, and can be applied to 
routinely fixed autopsy material even if it has been stored for decades in formaldehyde. 
1.2 Genetics of AD 
The first study signifying a genetic factor for AD was published when early reports focused 
on the constant progress of AD-like disease in Down’s syndrome patients after age 40, and the 
increased risk of disease in family members of AD patients (Harris, 1982). However, there are two 
different types of AD genetics, which are early onset AD (EOAD) and late onset AD (LOAD). 
1.2.1  EOAD genetics 
Genetic linkage studies and candidate gene analysis led to the identification of the three early 
onset familial AD (EOFAD) genes. The amyloid precursor protein (APP) gene on chromosome 21 
was the first one found to have a mutation that causes EOFAD (Goate et al., 1991). The association 
between Trisomy 21 (Down’s Syndrome) and AD allowed the researchers to focus on chromosome 
21 as the possible locus for an AD gene. Linkage of one locus on chromosome 21 was found in 
extended AD families with the autosomal dominant form of EOAD (St George-Hyslop et al., 1987). 
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A missense mutation in the APP gene at exon 17, which partially encoded the A peptide and led to 
a valine to isoleucine change at amino acid 717, was identified in some of the families included in 
the study (Goate et al., 1991). Afterward, 26 other mutations have been identified within APP from 
74 EOFAD families (Theuns et al., 2006). These studies delivered strong support for the amyloid 
hypothesis discussed in detail in the related section of this thesis. 
Linkage analysis studies led to the characterization of the second EOFAD gene, Presenilin-1 
PSEN1 on chromosome 14. Genome-wide studies found a significant association of a locus on 
chromosome 14 with EOFAD (Mullan et al., 1992, Schellenberg et al., 1992, St George-Hyslop et 
al., 1992). PSEN1 mutations are the most common known genetic mutations that lead to EOFAD, 
with 157 pathogenic PSEN1 mutations identified among 347 EOFAD families. The PSEN2 gene was 
found in a linkage study associated with EOFAD. A candidate gene study of PSEN2 identified 
sequence homology to PSEN1 that had a segregating mutation resulting in an asparagine to 
isoleucine substitution (Asn141Ile; Levy-Lahad et al., 1995). Simultaneously, a candidate gene study 
found different missense mutations in the same gene (Rogaev et al., 1995). 
1.2.2 LOAD genetics 
A genome search conducted among both EOAD and LOAD families found a novel locus on 
chromosome 19 that has a strong effect on LOAD (Pericak-Vance et al., 1991). Biochemical studies 
of lipids in AD brains using an antibody to Apolipoprotein E (APOE), a protein which has special 
relevance to nervous tissue, found that APOE immunoreactivity was associated with amyloid in both 
senile plaques and neurofibrillary tangles (Namba et al., 1991). Given that the APOE gene mapped to 
the locus recognized by the Pericak-Vance et al. (1991) linkage study, this allowed investigation of 
the genetic and biological associations of APOE with AD. In vitro studies showed that APOE binds 
A and that APOE 4, a particular allelic form of APOE, is found at a higher frequency in LOAD 
cases than in controls. The APOE gene is polymorphic, including three alleles, 2, 3 and 4, which 




 residues. These genes encode the corresponding apolipoproteins APOE2, 
APOE3 and APOE4, and produce six possible genotypes (Zannis et al., 1981, Zuo et al., 2006). 
APOE proteins have significant functions in mediating the uptake and distribution of cholesterol, and 
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each isoform is associated with specific lipoprotein elements (Puglielli et al., 2003). The 3 allele is 
the most common, found among 70–80% of the population. The corresponding APOE3 protein is 
involved in multiple functions in neuronal biology including neuronal remodelling and repair 
following injury (Boyles et al., 1989, Corder et al., 1993, Mahley, 1988). The 4 allele found in 12% 
of individuals. It is related to memory deficit and significantly increases the risk of AD. The APOE4 
protein inhibits dendrite outgrowth (Corder et al., 1993, Nathan et al., 1994). The 2 allele, found in 
5% of the population, could have a protective effect against the development of AD. The APOE 2 
allele has been shown to reduce cortical A, senile plaques and NFTs (Corder et al., 1994, Nagy et 
al., 1995, West et al., 1994). A population based prospective study found that 55% of AD cases are 
in the APOE 4/4 group (Myers et al., 1996), while 27% of people who carry APOE 3/4 develop 
the disease and 9% of APOE 3/3 carriers develop AD. 
Genome-wide association studies on AD on 6,000 cases and 10,000 controls showed 
associations of two new genes, CLU and PICALM, with LOAD as well as APOE (Lambert et al., 
2009, Harold et al., 2009). CLU encodes the protein clusterin, which has important roles in the 
clearance of cellular debris and mechanisms of apoptosis, lipid metabolism and cell proliferation 
(Rosenberg and Silkensen, 1995, Viard et al., 1999, Wong et al., 1994). PICALM encodes the protein 
phosphatidylinositol binding clathrin assembly protein, which has significant functions in the 
dynamics of endocytosis (Tebar et al., 1999). Nevertheless, different published findings have shown 
contradictory results between research groups and ethnic populations; and effect sizes are generally 
very modest. APOE is the gene with the most significant association with AD and the most studied 
gene in AD pathophysiology. 
In addition, a recent study found that a rare functional variant (R47H) in the TREM2 gene had 
a similar effect size to the 4 risk allele of apolipoprotein E in AD. TREM2 encodes a type I 
membrane protein that creates a receptor-signalling complex with the TYRO protein tyrosine kinase-
binding protein (TYROBP), which activates the immune responses in macrophages and dendritic 
cells (Paloneva et al., 2002). TREM2 is expressed throughout the central nervous system, and shows 
high concentrations in white matter, hippocampus and neocortex. An association was found between 
P a g e  | 7 
R47H and LOAD in North American and European populations (Niemitz, 2013). An additional 
study detected the R47H variant in GWAS on an Icelandic LOAD population (Guerreiro et al., 
2013). Since the TREM2 risk variant modifies TREM2 protein function, these results suggest that 
TREM2 impairment could reduce phagocytic clearance of amyloid proteins and thus impair a 
protective mechanism in the brain. 
1.3 Pathological hallmarks of AD 
1.3.1 Neurofibrillary tangles 
Neurofibrillary tangles are a neuropathological hallmark of AD. They are composed of 
abnormally phosphorylated microtubule-associated protein  (MAPT). The MAPT gene is located on 
chromosome 17. Alternative splicing of exons 2, 3, and 10 leads to the production of six MAPT 
isoforms that are differentially expressed during brain development (Sergeant et al., 2005). The 
phosphorylation of MAPT controls its binding to microtubules and enhances their assembly. A 
normal level of phosphorylation is needed for optimal MAPT activity, while hyperphosphorylation 
disrupts its biological function. This modifies various processes that are controlled by the appropriate 
organization of the microtubule network (Alonso et al., 1994, Li et al., 2007). The relationship 
between A and MAPT in pathogenesis is not well understood. It has been suggested that changes in 
ion homeostasis and oxidative stress due to A aggregation destabilize phosphatases and kinases that 
control MAPT phosphorylation. As a result, MAPT hyperphosphorylation leads to synaptic 
dysfunction and neuron loss (Butner and Kirschner, 1991, Goode and Feinstein, 1994). 
Neurofibrillary tangles occur in other AD brain lesions, i.e., thickened neurites in senile 
plaques and neuropil threads. They are also found in other neurodegenerative diseases, such as 
progressive supranuclear palsy, dementia pugilistica, corticobasal degeneration, Pick’s disease, 
Downs syndrome, and Parkinson’s disease, which has led to the hypothesis that they are responsible, 
at least in part, for the neuronal damage (Joachim et al., 1987, Wood et al., 1986). This hypothesis is 
strengthened by the observation that mutations in the MAPT gene lead to the accumulation of paired 
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helical filaments in frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17; 
Clark et al., 1998, Hong et al., 1998, Hutton et al., 1998). 
There is older evidence that dementia correlates with intracellular NFT (Cummings et al., 
1998). Clinicopathological research related tangle load in the frontal cortex with agitation and 
aberrant motor behaviour (Tekin et al., 2001). Semi-quantitative post-mortem measurements of NFT 
in the hippocampus from demented patients showed that increased tangle load was linked to 
increased severity of aggressive behaviours and the presence of chronic aggression. These results 
suggest a pathogenic link between neurofibrillary tangle load in hippocampus and aggressive 
behaviours in dementia patients (Lai et al., 2010). Nevertheless, as discussed further below, current 
opinion strongly endorses synaptic loss as the key pathogenic feature of AD (Selkoe, 2002). 
In recent years several approaches have been made in animal models to therapeutically target 
tau pathology (Brunden et al., 2009). Different speciﬁc approaches aim to inhibit the creation of tau 
oligomers and ﬁbrils, such as Targeting tau aggregation, Targeting microtubule stabilization, 
Targeting tau folding and Targeting tau phosphorylation. Blocking tau/tau aggregation with small-
molecule drugs is difﬁcult because of the large surface areas that are involved in such interactions 
(Brunden et al., 2009). Targeting microtubule stabilization was performed by treating mice that had 
axonopathy and amyotrophy with the microtubule-stabilizing drug paclitaxel. These latter mice 
showed significant improvement of fast axonal transport (Ishihara et al., 1999). However, none of 
these approaches has yet been translated into clinical practice. In contrast, the clinically used drug 
Memantine, which is a non-competitive NMDA receptor antagonist, does sway the excitation-
inhibition balance away from over-excitation in AD cases. 
1.3.2 -Amyloid 
The second component essential for AD diagnosis is the senile plaque. Glenner and Wong 
(1984a, 1984b) and Masters et al. (1985) reported that the 42-residue amyloid -peptide, A42, is 
the main constituent of senile plaques. There are two main forms of -amyloid, a 40- (A40) and a 
42- (A42) amino acid peptide, although peptide length can range from 39 to 43 amino acids. There 
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is an additional N-terminally truncated species (Ingelsson et al., 2004). A42 builds up earlier in 
amyloid plaques and aggregates into fibrils more quickly than A40 in vitro (Jarrett et al., 1993, 
Roher et al., 1993). A is derived from a large amyloid precursor protein (APP) that undergoes 
multiple proteolytic cleavages. APP is an integral membrane protein that moves to the endoplasmic 
reticulum via its signal peptide and is subject to post-translational modifications. Heterogeneous 
forms of APP result from alternative splicing and different post-translational modifications (Hung 
and Selkoe, 1994, Selkoe et al., 1988, Weidemann et al., 1989). Neurons express high levels of the 
695-residue isoform (Haass et al., 1991). The enzyme -secretase first works on APP to cleave off a 
large soluble ectodomain fragment, sAPP, located in the lumen/extracellular space, and to leave an 
83-residue C-terminal fragment (CTF83) within the membrane. APP molecules not cleaved by -
secretase can be cleaved by -secretase to generate sAPP and C-terminal fragment 99 (CTF99), a 
99-residue peptide in the membrane (Seubert et al., 1993). The latter is then cleaved by -secretase to 
produce A and a 55-residue cytosolic peptide, the APP intracellular domain (AICD; Selkoe, 2001). 
Amyloid deposits may be present in AD brain up to a decade before the emergence of 
cognitive symptoms (Ingelsson et al., 2004, Mintun et al., 2006). Since Amyloid was a key 
component of Alzheimer’s own seminal paper some authorities require the presence of A for a 
diagnosis of AD, but tissue loads of plaques do not correlate well with dementia. The dominance of 
A in theories of AD pathogenesis derives from genetic studies on mutations of APP and presenilin 
(PS) genes in familial AD cases. Possession of the disease allele of any one of these genes leads to 
greater production of A or to a predominance of the A42 form, which has a propensity for 
misfolding and aggregation (Chapman et al., 2001, Selkoe, 1998). Several AD transgenic mice have 
been produced that have the mutant forms of human APP and PS1 or PS2 genes. They develop 
amyloid aggregates in the brain and show cognitive impairment (Ashe, 2001), although neuronal loss 
requires additional transgenic influence. 
1.3.3 Synaptic loss and synaptic proteins in AD 
While there is a significant negative correlation of synapse numbers and synaptic markers 
with cognitive decline in AD, neither neurofibrillary tangles nor senile plaques show strong 
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statistical association with clinical AD severity (Terry et al., 1991). Assays of synapses and synaptic 
markers in the AD brain (Bancher et al., 1993) and in transgenic mouse models (Buttini et al., 2005) 
support the hypothesis that synaptic degeneration and damage take place early in the development of 
the disease. Light and electron microscopy were used to study the form and density of synapses in 
the dentate gyrus of double-transgenic APP/PS1 mice. Both the numbers of synapses per unit volume 
and the morphology of the remaining synapses are affected in plaque-free regions of these animals 
(Alonso-Nanclares et al., 2013). Disrupted synaptic connections would result in neural dysfunction, 
and lead to the dementia and cognitive impairment observed in AD and other neurodegenerative 
disorders (Terry et al., 1991). Loss of synaptic connectivity could follow changes in pre- or post-
synaptic proteins. These proteins are located in synaptic vesicles, the cytoplasm, and the terminal 
membranes. Proteins may be altered differentially in different diseases. There is a link between 
changes in synaptic proteins and terminal loss in AD (Reddy et al., 2005, Tannenberg et al., 2006). 
Neuroimaging of autopsy brain supports a link between grey matter loss and synaptic protein 
reduction (Heindel et al., 1994). Nonetheless, synaptic proteins are dynamic, and their levels can be 
changed in animal models by memory and learning training, behavioural tasks, or administration of 
drugs (Sindi et al., 2014). Not all synaptic proteins are equally affected in specific brain regions in 
AD: these proteins are located in different compartments of synaptic terminals, play different roles, 
and can be enriched differentially in excitatory and inhibitory terminal classes. 
Levels of synaptic proteins vary among brain regions. The hippocampus is affected earlier 
than other regions in AD progression, and is the most affected region in late stages of the disease 
(Honer et al., 1992, Perdahl et al., 1984, Sze et al., 1997). Frontal cortex synaptic protein levels are 
lower in AD brain than in control brain; reported differences between AD frontal cortex and other 
AD brain regions are inconsistent (Lassmann et al., 1992, Sze et al., 1997, Tannenberg et al., 2006). 
1.3.4 Synaptic disruption by -amyloid 
Mechanisms underlying the failure of synaptic plasticity and the disruption of memory in AD 
are not clearly understood. Two opposing notions have been put forward to explicate this issue. 
Under normal physiological conditions, A may play a role in synaptic plasticity, and its deficiency, 
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through aggregation, could lead to abnormal functioning of the synapse. Alternatively, A could be 
responsible for synaptic disruption in AD. In the normal synapse, neuronal activity might regulate 
the production and secretion of A by controlling APP processing upstream of -secretase activity 
(Kamenetz et al., 2003). A levels in brain interstitial fluid are influenced by synaptic activity on a 
time scale of minutes to hours (Cirrito et al., 2005). In an acute brain slice model, the impact of 
synaptic activity on A levels is linked to synaptic vesicle exocytosis. Synaptic activity can alter A 
metabolism and area-specific A accumulation (Cirrito et al., 2005). Inhibiting - and -secretase 
activity may result in reduced levels of A that would enhance toxicity and the death of neurons, 
should A promote neuronal survival (Plant et al., 2003). 
Conversely, in vitro and in vivo studies have explored possible molecular and signalling 
mechanisms that promote synaptotoxic effects of A (Dinamarca et al., 2008, Haass and Selkoe, 
2007, Klyubin et al., 2005, Rowan et al., 2007, Selkoe, 2008). Koh et al. (1990) demonstrated that 
A peptides and glutamate are together more neurotoxic to cultured neurons than either agent alone. 
The mechanism of A synaptic toxicity is complex, because different multimeric forms of A 
exhibit effects ranging from reversible alterations in synaptic form and function to neuronal loss. 
High levels of A reduce glutamatergic synaptic transmission and lead to synaptic loss (Hsia et al., 
1999, Kamenetz et al., 2003, Mucke et al., 2000). Intracerebroventricular injection of soluble 
synthetic A40 dimers rapidly reduces the plasticity of excitatory synaptic transmission at doses 
(10–42 pmol) comparable to natural A concentrations (Hu et al., 2008). 
1.3.5 Oligomeric A and excitatory synapses 
Koffie et al. (2009) used Array tomography to assess the impact of free A on synaptic loss 
in double-transgenic APP/PS1 mice. They showed that amyloid plaques in these mice are enclosed 
by a halo of oligomeric A. Examination of more than 14,000 synapses revealed a 60% loss of 
excitatory synapses contiguous to the halo. Deposits of oligomeric A were linked to a subset of 
excitatory synapses that were smaller than those that did not interact with oligomeric A. In green 
fluorescent protein (GFP) Tg2576 APP mice, multiphoton live imaging revealed disruption of 
neurons and a lower dendritic spine density than in age-matched controls (Spires et al., 2005). 
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Axonal immunostaining and colocalization studies of synaptophysin and PSD-95 proteins showed a 
similar loss of pre- and post-synaptic partners near plaques in human autopsy brain (Spires et al., 
2005). 
A can affect the role of glutamate NMDA receptors (NMDARs) and eliminate induction of 
NMDAR-dependent LTP in the neuron (Shankar et al., 2007, Snyder et al., 2005). When NMDARs 
were quantified by biotinylation in cultured cortical neurons treated with A, there was an 80% 
reduction in subunit protein. Application of a -secretase inhibitor reduced the A concentration and 
returned NMDAR levels to normal. A oligomers also induce the endocytosis of NMDARs by a 
mechanism involving 7-nicotinic acetylcholine receptors (Snyder et al., 2005). Ronicke et al. 
(2011) showed that NMDAR-2B activation mediates A-induced LTP disruption. Application of an 
NMDAR-2B antagonist to hippocampal slice treated with A oligomer abolished the disruption. 
1.3.6 Oligomeric A and prion proteins 
Lauren et al. (2009) showed that the cellular prion protein PrP
c
 is a receptor for A oligomers 
with nanomolar affinity. The binding of PrP
c
 to A oligomers leads to loss of LTP. In hippocampal 
slices, anti-PrP
c
 antibodies reduce the binding of oligomeric A to PrPc and prevent synaptic 
disruption. Deletion of PrP
c
 improves cognitive function in transgenic mice over-expressing mutant 
APP (APPswe and PS1E9), reduces premature neuronal death, and reverses the memory deficit 
(Gimbel et al., 2010). Antibody blockade prevents the PrP
c
-enhanced neurotoxicity of A oligomers 
(Kudo et al., 2012). 
1.3.7 Other A synaptic targets 
Excitatory synapses are formed and maintained by the homophilic trans-synaptic binding of 
N-cadherin (Fannon and Colman, 1996). A luciferase-complementation assay was used to show that 
N-cadherin enhances APP dimerization and the production of A (Asada-Utsugi et al., 2011). 
Application of A down-regulates N-cadherin expression, which weakens synapses and can further 
increase A production via interaction with the PS1 complex (Ando et al., 2011, Andreyeva et al., 
2012). 
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Other synaptic junction proteins play roles in A production. Expression of 4 and 3 
integrin is increased in neurons in the vicinity of plaques and tangles in AD autopsy brain tissue 
(Akiyama et al., 1991, Van Gool et al., 1994). Studies using integrin-blocking antibodies revealed 
that A accumulation and neurotoxicity in human cortical primary neurons are mediated by 21 
and 51 integrins. The 21 and 51 integrin signalling pathways may be critical to A 
neurotoxicity in AD (Wright et al., 2007). 
1.4 Cell adhesion molecules 
Protein complexes that link pre- and post-synaptic membranes have significant functions in 
regulating neural networks. Neurotransmitters released from the presynaptic terminal acting on 
receptors located on the post-synaptic membrane convey information between neurons at synapses 
(Dalva et al., 2007). Signalling can be facilitated by adhesion molecules, which cooperate across the 
synaptic junction (Bamji et al., 2003, Dalva et al., 2000, Graf et al., 2004, Hall et al., 2000, 
Scheiffele et al., 2000, Umemori et al., 2004). Synaptically localized cell adhesion molecules 
(CAMs) modulate the function of synapses through protein–protein interactions and signalling 
cascades, and also direct the formation of new synapses. Various CAMs organize synapse formation, 
control dendritic spine morphology, amend synaptic plasticity, and alter synaptic receptor function. 
These molecules arbitrate function and physical interactions between neurons at several stages in the 
life of a synapse (Fig. 1.2). 
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Fig. 1.2. The function of cell adhesion molecules at the synapse. During 
synaptogenesis, synaptic CAMs help stabilize contacts between neurons and recruit 
synaptic proteins via specific cytoplasmic or extracellular motifs such as PDZ-binding 
domains. Contacts among adhesion molecules may guide the activation of 
intracellular signalling events that lead to synapse maturation. In the mature synapse, 
synaptic CAMs work together with channels and other synaptic proteins to modulate 
their function. VGLUT (Vesicular glutamate transporter), CASK (Calcium/calmodin-
dependent serine protein kinase), AMPAR (-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid receptor), GRIP (Glutamate receptor-interacting protein) 
mGLUR (metabotropic Glutamate receptors). 
Different classes of CAMs play differing roles in synapses. CAMs include neurexins and 
neuroligins, N-cadherin, synaptic cell adhesion molecule-1 (SynCAM-1), and the ephrinB-receptor–
ephrinB system. The most widely described CAM pairing implicated in synaptogenesis and nerve-
terminal stability is the interface between neurexins and neuroligins that are located at pre-synaptic 
and post-synaptic sites respectively. 
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1.4.1 Neurexin–neuroligin complex 
The neurexin family was discovered in 1992 after the recognition that one member of the 
family is a receptor for -latrotoxin, a component of black widow spider venom that causes massive 
neurotransmitter release from the presynaptic terminal (Ushkaryov et al., 1992). Further studies over 
two decades delineated neurexins and their binding ligands, the neuroligins (Ichtchenko et al., 1995, 
1996). Scheiffele et al. (2000) showed that neuroligins occur on the surface of non-neuronal cells. In 
neurons they stimulate synaptic vesicle formation during functional pre-synaptic differentiation in 
contacting axons. Over-expression and knockdown studies in vitro have revealed that neurexin-
neuroligin complexes are key discriminants in GABAergic and glutamatergic synaptogenesis, and 
that patterns of differences in isoform binding affinities and localization determine this specificity 
and differentiation. 
1.4.2 Structures of neurexins and neuroligins 
1.4.2.1 Neurexins 
Neurexins are a family of highly polymorphic brain-specific proteins that are products of the 
three neurexin genes NRXNI, NRXNII, and NRXNIII. Each gene encodes two transcripts, -neurexin 
and -neurexin, which are expressed from upstream and downstream promoters of the same gene 
respectively (Fig. 1.3). 
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Fig. 1.3. Structure of - and -neurexins. A, -Neurexins consist of an N-terminal 
extracellular sequence containing the following: a signal peptide (SP); six laminin A, 
neurexin, and sex hormone binding protein (LNS) domains, three epidermal growth 
factor (EGF)–like sequences, and an O-glycosylation region (O-Glyc). There are five 
sites of alternative splicing in the extracellular sequence (S1–S5), which are indicated 
by arrowheads. The N-terminal extracellular region is followed by a carboxy-terminal 
sequence, which contains a transmembrane (TM) region as well as a short 
cytoplasmic region that comprises the PDZ II interaction site. B, The N-terminal 
extracellular sequence in -neurexins consists of a signal peptide, one LNS domain, 
and an O-Glyc region. There are only two alternative splice sites in -neurexins, as 
indicated. 
Molecular studies of NRXN transcripts have identified two alternative splice sites in the -
neurexins and five in the -neurexins. In consequence, at least six neurexins isoforms can be 
generated from these different genes: three -NRXNs, I, II and III, and three -NRXNs, I, II 
and III (Jarrett et al., 1993, Ullrich et al., 1995, Ushkaryov et al., 1994). The five alternative splice 
sites in -NRXN (S1-S5) are scattered among six laminin–neurexin–sex-hormone–binding protein 
(LNS) and three epidermal growth factor (EGF)–like domains (Fig. 1.3). -NRXNs are usually 
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truncated forms of -NRXNs containing a single LNS domain (Fig. 1.3). Alternative splicing and N- 
and O-glycosylation add additional diversity to produce up to 1000 isoforms (Missler et al., 1998). 
As will be discussed later, alternative splicing of neurexins controls their roles at synapses. The 
range of alternative splicing provides a potent cellular mechanism for constructing a huge number of 
different cell-surface proteins that could be expressed in sub-populations of cells, giving specificity 
and variety for processes such as adhesion and recognition between cells as well as ligand–receptor 
interactions. In situ hybridization studies have shown that mRNA encoding both - and -neurexins 
can be expressed in the same neuron. Conversely, different types of NRXNs are widely distributed 
among diverse types of neurons (Ichtchenko et al., 1995). Immunofluorescence analysis and the roles 
of neurexins as -latrotoxin receptors show that the localization of neurexins is predominantly pre-
synaptic (Sugita et al., 1999, Ushkaryov et al., 1992). Nevertheless, it has not been confirmed 
whether this localization is exclusive: some studies indicate that the deletion of genes encoding -
neurexins also has post-synaptic effects (Kattenstroth et al., 2004, Taniguchi et al., 2007). 
1.4.2.2 Neuroligins 
There are three sets of neurexin-binding ligands in the mammalian brain: dystroglycan, 
neurexophilins, and neuroligins (NLGNs). The most intensively studied ligands are the neuroligins, 
which were discovered by affinity purification (Ichtchenko et al., 1995). Three genes coding 
neuroligins, NLGN1, NLGN2, and NLGN3, have been found in mice and rats; they are mostly 
expressed in the central nervous system (CNS; Ichtchenko et al., 1996). Five genes encoding 
neuroligin family members have been detected in human tissues, NLGN1, NLGN2, NLGN3, NLGN4, 
and NLGN4Y, with a sequence identity in their extracellular domains of more than 70% (Ylisaukko-
oja et al., 2005a). All neuroligin isoforms are post-synaptic transmembrane proteins. Neuroligin-1 is 
usually expressed in neurons at excitatory postsynaptic sites and found connected to NMDAR, 
postsynaptic density–95 (PSD-95) and synaptic scaffolding molecule (S-SCAM) at the synaptic 
junction and postsynaptic densities (Hirao et al., 1998, Ichtchenko et al., 1995, Kurschner et al., 
1998, Song et al., 1999). Neuroligin-2 is expressed mainly at inhibitory neuronal sites in CNS but is 
also expressed in pancreas, lung endothelia, and colon (Varoqueaux et al., 2004). Human neuroligin-
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3 is expressed in glia and dorsal root ganglia cells (Gilbert et al., 2001, Philibert et al., 2000). 
Expression of NLGN4 mRNA in human tissues is at its highest level in the heart; it is expressed only 
at low levels in the brain, pancreas, skeletal muscle, and liver (Bolliger et al., 2001, Nguyen and 
Südhof, 1997). Neuroligin-4Y, the gene for which is located in the Y chromosome, differs from 
neuroligin-4 by 19 amino acids and has also diverged in sequences within its introns (Bolliger et al., 
2001, Jamain et al., 2003; Fig. 1.4). 
 
Fig. 1.4. Neuroligin structure. The N-terminal extracellular sequence of neuroligins 
consists of a signal peptide (SP), cholinesterase-like domain (CLD) and a 
carbohydrate-attachment region for O-linked glycosylation (O-Glyc). The 
cholinesterase-like domain of neuroligin-1 contains two alternative splice sites (A and 
B) with insert sequence A1 and B, whereas neuroligin-2 contains one splice site (A) 
with insert sequence A2. Neuroligin-3 has one alternative splice site (A) with two 
insert sequences, one homologous to A1, the second homologous with A2 (A). The C-
termini of all neuroligins are identical and consist of a single transmembrane region as 
well as a short cytoplasmic sequence containing a type I PDZ-recognition motif. 
The extracellular domain of neuroligin-1 has two alternative splice sites (A and B), whereas 
neuroligin-2, neuroligin-3 and neuroligin-4 have one conserved alternative splice site (A). The 
variations among family members are due to differences in the insert sequences. In neuroligin-1, the 
insert at site A, called A1, has a calculated charge of+8 and an internal disulfide bond between 
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Cys172 and Cys181, whereas the insert at site B, which is unique to neuroligin-1, contains an N-
glycosylation consensus sequence at Asn303 (Hoffman et al., 2004). Neuroligin-2 has one insert at 
site A called A2; it has a calculated charge of –5 and lacks an internal disulfide bond. Neuroligin-3 
has two inserts at splice site A: one is homologous with the neuroligin-1 insert, and the second is 
homologous with neuroligin-2 insert (Ichtchenko et al., 1995, 1996; Fig. 3). Neuroligin-4 inserts 
have not yet been clearly delineated. 
Neuroligins are members of a protein family that possess a cholinesterase-like domain 
(CLD), and are known as cholinesterase-like adhesion molecules (CLAMs). All family members 
(glutactin, neurotactin, and gliotactin, as well as the neuroligins) lack one or more of the residues that 
are essential for catalytic activity. The function of the N-terminal sequence in neuroligins is 
heterophilic adhesion. Hence, this domain mediates the interaction between receptor and ligand, 
rather than the interaction between enzyme and substrate. Neuroligins lack a serine residue that is 
essential for enzymatic function in cholinesterases; important nearby residues are histidine and 
glutamic acid, which are close to the third disulfide loop (Holmquist, 2000, Hoffman et al., 2004). 
Two of the three disulfide loops in all members of CLAM family are conserved in 
acetylcholinesterases (Zeev-Ben-Mordehai et al., 2003). 
Members of the CLAM family form 3D structures that are very similar to that of 
acetylcholinesterase (AChE). Approximately 65% of the CLD is conserved between the 
cholinesterase superfamily and CLAM family members. The structure of AChE has three loops, 
which are stabilized by disulfide bonds that permit the right positioning of the enzyme active site. 
The first part of CLD is totally conserved between the families; it includes the first and second 
disulfide-bonded loops. The second part of the CLD is conserved only in the area of the cysteine 
residue. The majority of the conserved structures in CLAM proteins are those essential for shaping 
the - and -hydrolase folds and positioning the first component of the active site in the enzyme. 
The second part of the conserved CLD structure positions the other two components at the catalytic 
site and forms the mouth of the catalytic gorge. CLAM proteins differ from AChE by either total or 
partial loss of the third disulfide-bonded loop, which appreciably changes the conformation of the 
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gorge mouth and hence abrogates catalytic site function (Fig. 1.5). The review by Gilbert and Auld 
(2005) gives more detail on the 3D structure of the CLD in AChE and CLAM family proteins. 
 
Fig. 1.5. The 3D structure of CLD models of CLAM family protein in Drosophila 
acetylcholinesterase. A, the catalytic site; B, the first disulfide-bonded loop; C, the 
second disulfide-bonded loop; and D, the third disulfide-bonded loop. The domain in 
the third loop in the CLAM family is the most divergent in sequence. In vertebrates 
the neuroligin third loop is reduced in size, resulting in a considerably shorter loop, 
while this loop is not present at all in invertebrate neuroligins. 
Comparisons of the structures of cholinesterase family members with neuroligins have 
significantly increased our understanding of the relationship between structure and function in the 
neuroligins (Hoffman et al., 2004). Consideration of 2- and 3-dimensional analyses indicates that the 
CLD is a possible target for ligands to associate with CLAM family members, particularly to mediate 
neuroligin–neurexin binding. Over-expression of AChE decreases -neurexin levels in vitro and in 
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vivo, as well as having a negative effect on glutamatergic synapses in vitro, which suggests there is 
crosstalk between the neuroligin–neurexin complex and AChE (Andres et al., 1997). 
1.4.3 Neuroligin–neurexin interactions 
The neuroligin–neurexin interaction is controlled by different molecular and cellular 
mechanisms, including oligomerization, calcium binding, and alternative splicing. 
1.4.3.1  Oligomerization mechanisms 
Neuroligin-1 has five N-glycosylation sites as well as a domain rich in serine and threonine 
residues next to the transmembrane sequence that contains a number of sites for O-linked 
glycosylation (Ichtchenko et al., 1995). Blocking N-glycosylation in neuroligin-1 enhances its 
binding to neurexin to form the neuroligin–neurexin oligomer (Comoletti et al., 2003). In contrast, 
deglycosylation of neurexins does not influence neuroligin binding affinity. 
1.4.3.2 Calcium-dependent mechanisms 
The extracellular domains of neuroligin and neurexin bind to each other in the presence of 
calcium ion (Ca
2+
; Ichtchenko et al., 1995). With recombinant neuroligin-1 and -neurexins, binding 
occurs at differing concentrations of Ca
2+
 for different alternatively spliced isoforms (Nguyen and 
Südhof, 1997). Structural studies of the -neurexin LNS2 domain show that a splice site generates 
highly variable surfaces surrounded by Ca
2+
 ions (Sheckler et al., 2006). Ca
2+
 binding has low 
affinity and is decreased below detectable levels by the addition of 8- to 15-residue splice inserts. In 
consequence, Ca
2+
-dependent interactions of neurexins may be affected by changes in Ca
2+
 
concentration that are within the estimated variations within the synapse as a result of synaptic 
activity (Nguyen and Südhof, 1997). 
1.4.3.3 Alternative splicing mechanisms 
Neurexins exhibit a great deal of alternative splicing that produces more than 2,000 variants 
(Tabuchi and Südhof, 2002). The splice insert sequences and their locations are preserved between 
NRXN genes and between species, indicating that alternative splicing plays a significant role. 
Alternative splicing is not as extensive in neuroligin, but it takes place in the significant CLD 
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domain. The alternatively spliced regions in neuroligins and neurexins are the sites of interactions 
between them (Fig. 1.6). Alternative splicing changes binding affinity, and affects synapse 
development and neuronal functions in vitro (Boucard et al., 2005, Chih et al., 2006, Graf et al., 
2006). 
 
Fig. 1.6. Neurexin–neuroligin splice sites and the possible binding pairs. Splicing at 
site B in neuroligin and at site 4 in -neurexin-1 controls binding affinity and synapse 
function. In -neurexin, the presence of the 30-residue insert at site 4 decreases the 
affinity of binding, especially with neuroligin-1, which has an insert at site B (+B). 
This sequence can maintain high-affinity binding with neuroligin-1, which does not 
have an insert at site B (–B), or with neuroligin-2, which also does not have a B splice 
site. Similarly, -neurexins that do or do not contain an insert at site 4 can attach to 
B+ neuroligins (with splice site B included). In this case, the regulation of the 
interaction between the two proteins does not occur due to the presence of the B insert 
(9 amino acids), but takes place as a result of its N-linked glycosylation. Additional 
studies are required to verify how alternative splicing of neuroligin-1 (at site B) and 
-neurexins (at site 4) controls the binding of particular isoforms of these proteins as 
well as their adhesive properties. 
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1.4.3.4 Neuroligin/neurexin interactions and synaptic localization 
The roles of neuroligins and neurexins in specifying synapse formation as either excitatory or 
inhibitory have been delineated by studies conducted in vitro. Over-expression of neuroligin proteins 
increases synapse numbers, whereas knockdown of the same proteins decreases synapse numbers 
(Chih et al., 2005). Scheiffele et al. (2000) showed that expressing neuroligins in normal cells can 
stimulate pre-synaptic differentiation in contacting axons. On the other hand, the expression of 
neurexins in neurons can lead to clustering of proteins in post-synaptic dendrites (Graf et al., 2004). 
 
Fig. 1.7. The role of alternative splicing of the neurexin–neuroligin complex in 
determining synaptic function as either excitatory or inhibitory. Neurexins and 
neuroligins possess extracellular domains that are modified at different locations by 
alternative splicing. Splice site 4 (S4) of -neurexin and location B of neuroligin-1 
change the proteins’ binding specificity for their neuroligin or neurexin partners and 
change their capability to stimulate glutamatergic over GABA (-aminobutyric acid)–
mediated synaptogenesis. Each neurexin isoform binds a specific neuroligin isoform 
that guides the creation of specialized synapses. -neurexin that does not have the 
alternative splice site S4 (-neurexin1 [–S4]) pairs neuroligin-1s that has the inclusion 
of splice site B (neuroligin-1+B). The addition of the S4 in -neurexin prevents 
neuroligin-1 pairing and decreases accumulation of post-synaptic proteins that are 
specific to glutamatergic synapses. Conversely, -neurexin with an S4 (+S4) has high 
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affinity for neuroligin-2 and guides the formation of GABA-signaling synapses. On 
the post-synaptic membrane, neuroligin-1+B isoforms interact with -neurexin. On 
the other hand, –B isoforms can pair both neurexin types. neuroligin-1+B is confined 
to glutamatergic synapses. The majority of neuroligin-2 proteins that lack the B site 
have an alternative splice site at location A to guide their specific localization to the 
GABAergic synapse. 
In consequence, neuroligin–neurexin binding in vitro can control both the pre- and post-
synaptic sides of the synapse. The organization of synapse configuration as excitatory or inhibitory is 
controlled by the diverse neurexin and neuroligin types incorporated, as well as the splice variants 
that occur in the extracellular domain. Neuroligin-1 is located in excitatory synapses and supports the 
development of excitatory specializations, depending on alternative splicing (Fig. 1.6). Conversely, 
neuroligin-2 is located in inhibitory synapses and preferentially stimulates the formation of inhibitory 
contacts (Chih et al., 2005). Alternative splicing in the extracellular domain of neuroligins guides 
neuroligin–neurexin binding between neurons, and controls excitatory/inhibitory synapse formation 
(Boucard et al., 2005, Chih et al., 2006; Fig. 1.7). 
1.4.4 A role for the neuroligin–neurexin complex in triggering amyloid deposition in AD? 
Acetylcholinesterase interacts with senile plaques in AD brain. Both bovine AChE and 
human and murine recombinant AChE accelerate the accumulation of either wild-type or mutant A 
peptide as amyloid. The interaction of AChE and A does not depend on the subunit composition of 
the enzyme or on the presence of the AChE active site (Inestrosa et al., 1996). The neurotoxicity 
elicited by AChE–A complexes is more than that induced by the A alone (Inestrosa et al., 1996). 
Affinity-purified AChE increases the accumulation of APP in glial cells in selective brain regions in 
a concentration-dependent manner. The increased expression of APP in astrocytes and microglia 
induced by AChE is due to the activation of glial cells (von Bernhardi et al., 2003). Tg2576 mice, 
which express human APP and develop plaques at 9 months, crossed with transgenic mice 
expressing human AChE, produce F1 animals that express both transgenes in the brain. The F1 
cerebral cortex displays plaques at 6 months that are stained by thioﬂavin S and antibodies against 
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A40 and A42. Plaques accumulate in the hybrid mice 50% sooner than in the parental line and 
plaque quantity increases with age (Rees et al., 2003). 
Given that neuroligins have an extracellular sequence containing a domain that is 
homologous with AChE, and given that the CLD site in neuroligin lacks important residues (Scholl 
and Scheiffele, 2003), neuroligin has been proposed as a synaptic protein candidate that may affect 
A accumulation in AD. Fluorescence spectroscopy and surface plasmon resonance analysis show 
an interaction between oligomeric forms of A and the extracellular domain of neuroligin-1 with a 
Kd in the nanomolar range (Dinamarca et al., 2011, 2012), whereas the interaction between A and 
neuroligin-2 is very weak. Immunoprecipitation assays confirmed that A oligomers react with 
neuroligin-1 but not with neuroligin-2. Studies of A polymerization in a thioflavin-T assay showed 
that neuroligin-1 stabilized A accumulation in vitro. Neuroligin-1 behaved as a nucleating factor for 
A accumulation by inducing the formation of A oligomers (Dinamarca et al., 2012). These data 
suggested that neuroligin-1 stabilizes oligomeric assemblies of A in the glutamatergic synapse, 
where they may bind to neuroligin-1 in the post-synaptic membrane. This complex might then act as 
a local aggregation seed for more A oligomers that affect the post-synaptic region and promote 
synaptic toxicity in AD. 
1.4.4.1  Proteolytic processing of neuroligins and neurexins in AD 
Several studies have demonstrated that AD-related proteolytic enzymes can regulate synaptic 
efficacy by processing synaptic CAMs (Cartier et al., 2009, Mabb and Ehlers, 2010, Malinverno et 
al., 2010). Metalloproteases and -secretase are intramembrane aspartyl proteases that cleave single-
transmembrane proteins; both are implicated in AD. They cleave a range of substrates, the most 
extensively studied of which is APP. Other substrates include proteins involved in synapse 
maintenance such as EphRs, ephrins, cadherins, and nectin. PS1/-secretase can cleave full-length E-
cadherin and a transmembrane C-terminal fragment, which is a key regulator of the Wnt signaling 
pathway (Marambaud et al., 2002). PS1/-secretase regulates the processing of nectins in PS1-/- 
and+/+ primary hippocampal neurons. Lack of PS1/-secretase inhibits the processing of nectin-1 
and nectin-3 to their C-terminal fragments and leads to the accumulation of the full-length proteins 
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(Kim et al., 2011). PS1-dependent intramembrane cleavage followed by nectin shedding takes place 
at synapses, and is regulated during synaptic plasticity. In mice and rats, metalloproteases and -
secretase reduce the levels of synaptic proteins on both sides of the synapse to weaken synaptic 
transmission (Restituito et al., 2011). Activity-dependent substrate cleavage by these enzymes is a 
novel mechanism of synaptic regulation to alter synaptic transmission. 
A number of neuroligin-1 peptide fragments have been detected by immunoblotting in rat and 
mouse neuronal cultures (Suzuki et al., 2012), which indicates that neuroligin-1 undergoes 
proteolysis. The metalloproteinase ADAM10 cleaves the amino-terminus, extracellular domain of 
neuroligin-1, while the carboxy-terminus region is cleaved by -secretase. Addition of NMDA and 
soluble -neurexin to the medium in cell culture experiments increases the quantity of neuroligin-1 
N-terminal fragments (Suzuki et al., 2012), suggesting that neuroligin-1 cleavage can be stimulated 
by neuronal activity. The overstimulation of glutamate receptors that occurs in excitotoxic 
environments, such as AD-affected brain areas, could mediate synaptic damage. 
Increased neuron activity in vivo decreases synaptic levels of neuroligin-1. Reducing the 
action of metalloproteases by inhibitors like MMP9 blocks this effect, probably by mitigating the 
activity-induced cleavage of neuroligin-1 (Peixoto et al., 2012). This finding may provide a treatment 
avenue for neuroligin-mediated synaptic damage in AD. Peixoto et al. (2012) showed that cleavage 
of neuroligin-1 occurs at single activated dendritic spines and involves NMDA receptors and Ca
2+
-
calmodulin-dependent kinase (CaMK) signaling leading to the destabilization of presynaptic -
neurexin1. The cleavage of neuroligin-1 weakens the synapse by rapidly decreasing presynaptic 
transmitter release (Suzuki et al., 2012). Together, these data suggest that the acute activity 
stimulated by cleavage of neuroligin-1 is a local homeostatic mechanism to control structural and 
functional synaptic plasticity. 
The mechanism that controls neurexin function at synapses is not fully understood. The PS/-
secretase complex can process neurexins and inactivation of the complex stimulates the 
accumulation of neurexin at the pre-synaptic terminal in vivo and in vitro. Different familial AD 
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mutations in PS1 affect -neurexin-1 processing differently: some stimulate the processing of -
neurexin-1, whereas others have the opposite effect. Inhibition of PS and neurexin accumulation at 
sites controlled by neuroligin-1 suggests that PS organizes the processing of neurexins at 
glutamatergic synapses, and that impairment of neurexin processing by PS could involve at least part 
of a proposed familial AD pathogenesis pathway (Saura et al., 2011). Processing of neurexin-3 by 
-secretase produces an ~80-kDa extracellular N-terminal domain designated soluble neurexin-3 
and the transmembrane C-terminal fragment neurexin-3-CTF. Further processing of the C-terminal 
fragment by -secretase produces a 12-kDa intracellular domain neurexin-3-ICD (Bot et al., 2011). 
Mutated forms of PS1 that are associated with familial AD include PS1-L166P, PS1-P436Q, and 
PS1-9, which alter the catalytic core of -secretase and lead to a partial loss of enzyme function. The 
effect of these mutations on neurexin-3 processing has been elucidated by over-expressing them in 
Chinese hamster ovary cells stably expressing neurexin-3. The mutated proteins increase neurexin-
3-CTF levels and decrease neurexin-3-ICD formation (Bot et al., 2011). These data suggest that 
mutated forms of PS1/-secretase impair neurexin-3 processing and may cause the accumulation of 
the intracellular neurexin-3 C-terminal fragment. 
1.4.4.2 Neuroligins and neurexins in learning and memory 
Experiments on transgenic mice have revealed that overexpression of neuroligin-1 protein 
elicits learning and memory deficits, impairment of the induction of long-term potentiation (LTP), 
alterations in spine morphology, and reduced synaptic plasticity by altering the excitatory to 
inhibitory synapse ratio in hippocampus (Dahlhaus et al., 2010). Silencing of neuroligin-1 in the 
amygdala of mice showed that this protein plays an essential role in the storage of associative fear 
memory (Kim et al., 2008). Subsequent physiological experiments revealed that the lower 
neuroligin-1 levels weaken NMDA receptor-mediated currents and inhibit LTP (Jung et al., 2010). 
neuroligin-1 knockout mice show abnormalities in spatial learning and memory that are associated 
with impaired hippocampal LTP and a reduced NMDA/AMPA receptor ratio at corticostriatal 
synapses (Blundell et al., 2010). These data suggest that steady neuroligin-1 levels are essential for 
NMDA receptor-mediated synaptic transmission, which plays a central role in synaptic plasticity and 
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long-term memory formation in the amygdala of adult animals (Kim et al., 2008). NLGN3 R451C 
mutant mice exhibit impaired social interactions but improved spatial learning. Unexpectedly, these 
behavioural changes are induced by the stimulation of inhibitory synaptic transmission, with no 
effect at excitatory synapses. On the other hand, deletion of NLGN3 did not cause much alteration, 
indicating that the R451C substitution is a gain-of-function mutation. These results suggest that 
increased inhibitory synaptic transmission could play an important role in autism spectrum disorders 
(Taniguchi et al., 2007). Hines et al. (2008) manipulated transgenic mice overexpressing neuroligin-1 
and neuroligin-2 under the control of the Thy1 promoter, which leads to expression in various brain 
regions at early stages of development. Several abnormalities resulted from an increased expression 
of neuroligin-2, but not of neuroligin-1. A slight alteration in neuroligin-2 expression culminated in 
distended contacts at frontal cortex synapses and a general reduction in the excitatory to inhibitory 
synaptic ratio. These animals also showed impaired social behaviour and anxiety. A study using 
neuroligin-1 and neuroligin-3 knockdown showed that neuroligin-1 alternatively spliced at site B is 
required for LTP expression in young CA1 pyramidal cells, but that neuroligin-3 does not appear 
essential for LTP support (Shipman and Nicoll, 2012). 
Neurexin and neuroligin proteins at sensory-to-motor neuron synapses play roles in the gill-
withdrawal reflex in Aplysia, which exhibits sensitization (Shipman and Nicoll, 2012, Choi et al., 
2011). Reducing neurexin in the presynaptic sensory neuron or neuroligin in the postsynaptic motor 
neuron eliminates long-term facilitation and enhances the associated presynaptic growth elicited by 
frequent pulses of serotonin. These data suggest that activity-dependent regulation of the neurexin-
neuroligin contact could govern trans-synaptic signalling that is essential for the storage of long-term 
memory. An altered function of synaptic cell-adhesion molecules that leads to reduced excitatory 
synaptic transmission is a potential treatment target for neurological disorders. Such alterations may 
provide the neural basis for an imbalance in excitatory and inhibitory transmission and the 
behavioural changes related to disorders such as AD. Neuroligin-1 expression can modulate synapse 
morphology and LTP; abnormal synapse morphology, reduced synaptic plasticity, and deficits in 
learning occur in several neurological disorders, including AD. 
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1.5 Thesis outline 
1.5.1 Chapter 2 
Fluctuations in the levels of the synaptic proteins neuroligin-1 or neuroligin-2 in relation to 
synaptic loss in AD. This chapter describes the development of an immunodetection assay to 
quantify neuroligin-1 and neuroligin-2 proteins in autopsy brain tissues. Truncated versions of 
neuroligin-1 and neuroligin-2 were constructed, cloned, expressed, and purified. Different 
concentrations of the engineered protein were mixed with constant amounts of native protein 
extracted from tissue. Recombinant truncated protein separated clearly from the target protein as a 
sharp band. A standard curve with multiple points was created to show band intensity against 
quantity of standard in the different lanes on the same gel. The chapter then shows the successful use 
of the immunodetection assay in achieving precise estimates of the quantities of neuroligin-1 and 
neuroligin-2 present in each sample. 
1.5.2 Chapter 3 
Using the immunodetection assay from Chapter 2, concentrations of neuroligin-1 and 
neuroligin-2 were accurately quantified in hippocampus, inferior temporal cortex and occipital cortex 
autopsy tissue from 15 AD cases and 15 controls. These concentrations were compared between the 
two groups. Further statistical analyses assessed the effects of sex and the pathological severity of the 
disease on neuroligin-1 and neuroligin-2 protein levels. In addition, a similar immunodetection assay 
was used to quantify -neurexin in hippocampus, inferior temporal cortex and occipital cortex 
autopsy tissue from 15 AD cases and 15 controls. 
1.5.3 Chapter 4 
The aim of this chapter was to validate the data obtained from quantification of neuroligin-1, 
neuroligin-2 and -neurexin by using multiple reaction monitoring MRM assays, which are based on 
mass spectrometry and SWATH techniques, in AD cases and controls. This included sample 
preparation, validation and optimization of the best transitions and the actual quantification of the 
neuroligin and neurexin isoforms. 
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1.5.4 Chapter 5 
This chapter describes the development of a real time PCR assay to quantify neuroligin-1, 
neuroligin-2 and -neurexin transcripts in human autopsy brain tissues. The concentrations of theses 
transcripts were measured in hippocampus, inferior temporal cortex and occipital cortex from 14 AD 
cases and 14 controls, and then compared. 
1.5.5 Chapter 6 
The aim of this chapter was to confirm the association between Alzheimer disease and the 
single nucleotide polymorphism (SNP) rs17757879 in NRXN3 in an Australian Caucasian 
population using a case-control association approach, by using genomic DNA from the Queensland 
Brain Bank. 
1.5.6 Chapter 7 
Conclusions and future directions. 
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Chapter 2 
2 Development of an immunoassay to quantify neuroligin-1 and neuroligin-2 
2.1 Aim of the research 
1. To develop an immune-detection assay to quantify neuroligin-1 and neuroligin-2. 
2. To clone, express and purify recombinant truncated neuroligin-1 and neuroligin-2 protein 
standards. 
2.2 Introduction 
The use of brain autopsy tissues in neurobiological research has increased in recent years. 
Biochemical and proteomic experiments on human tissue are an essential component in establishing 
the roles that many proteins and pathways play in neurological disorders. Estimates of protein levels 
in autopsy brain tissue from cases and controls contribute to our understanding of the pathogenesis of 
disease. Recent developments in technology have been responsible for massive amounts of data on 
protein expression in different diseases, and have helped to delineate several drug targets. These 
approaches require that the molecular and biochemical state of the tissue is well maintained. Ideally, 
the target proteins should be undamaged and biologically active. Several studies have assessed the 
stability of transcripts and proteins isolated from human autopsy brain tissues (Johnson and Ferris, 
2002, Johnston et al., 1997, Köpke et al., 1993, Yasojima et al., 2001). Various factors affect post 
mortem yields of DNA, mRNA and protein, such as the method of tissues preparation, tissue pH, 
storage conditions, time in storage, and post-mortem interval (PMI; Kingsbury et al., 1995, Leonard 
et al., 1993, Ludes et al., 1993, Lukiw et al., 1990, Palmer et al., 1988, Schramm et al., 1999). It has 
been shown that cells can be obtained from human autopsy brain tissues and maintained alive in 
culture (Verwer et al., 2002). 
Proteomics uses several quantitative and qualitative techniques to detect the proteins in a 
tissue that differ in expression, for example in response to a disease. These include 2-dimensional 
differential gel electrophoresis (2D-DIGE), mass spectrometry (MS) and Western blotting. 2D-DIGE 
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has a limited capacity to detect alterations in expression or post-translational modification in low-
abundance proteins. Mass spectrometry needs high expression levels for protein quantification and 
requires large amount of starting material, which is an issue for work on human tissue. It also 
involves various steps that could affect protein integrity or lead to degradation. 
Western blotting (immunoblotting) is used to detect the presence of a particular protein in a 
complex biological extract. Although quantification can be problematic, immunoblotting can be 
effective in finding statistically significant alterations in the levels of protein linked to disease. As in 
gene expression, minor changes in protein expression in the brain might have major consequences in 
the tightly regulated CNS. More-complicated proteomic techniques may be unable to detect small 
significant differences in protein regulation, and simpler but more sensitive biochemical techniques 
needed to confirm any alterations found. Immunoblotting depends on three basic steps: (1) gel 
electrophoresis to separate a mixture of protein based on size; (2) effective transfer of separated 
proteins to a solid support; and (3) precise recognition of the protein of interest by selective primary 
and secondary antibodies. The band of the target protein is then visualized on the blotting membrane 
by using either X-ray film or an imaging system. 
Immunoblotting is one of the most common laboratory techniques due to its advantages in 
time, simplicity, and cost. Data obtained from immunoblotting are simple to interpret, distinctive, 
and unmistakable. Often when a result does not match expectations, there can be indications of what 
must be investigated to find the reason. Nevertheless, there are several limitations of the method, 
such as incomplete protein transfer from the gel to the membrane, the availability of specific 
antibodies for protein recognition, and the small number of proteins that can be detected in one 
assay. 
In this chapter I develop an immune-detection assay to specifically quantify neuroligin-1 and 
neuroligin-2 proteins in human autopsy brain tissue. -NRXN protein was purchase from Life 
Technology Company, therefore was not included in this chapter. The strategy to sensitively and 
precisely quantify neuroligin-1 and neuroligin-2 concentrations used known amounts of recombinant 
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expressed truncated versions of neuroligin-1 and neuroligin-2 respectively to construct standard 
curves. I used this to identify small but significant differences between cases and controls, which 
might not have been detected by other techniques due to large variations in the levels of individual 
proteins. These measures of the exact molar concentrations of the proteins in my data set allowed me 
to assess and contrast alterations in levels of synaptic adhesion molecules at the synapse. 
2.3 Materials and Methods 
Truncated recombinant versions of the proteins that contained the relevant epitopes for the 
primary antibodies used, in the N-terminus of neuroligin-1 and the internal region of neuroligin-2, 
were constructed. This permitted me to accurately measure native protein levels in autopsy brain 
tissue by in-gel immunodetection. The truncated proteins were smaller than their target proteins to 
allow easy separation by electrophoresis. The engineered transcript proteins were expressed in a 
bacterial system and purified, and a known amount added to each AD case and control sample lane 
in the gel. Each truncated protein separated clearly from its target protein as a sharp band. A standard 
curve with multiple points was created derived from the band intensities produced by adding 
differing known quantities of standard to different lanes on the gel. This method was used to achieve 
very precise estimates of the quantities of neuroligin1 and neuroligin-2 present in each sample. 
2.3.1 Recombinant neuroligin-1 and neuroligin-2 protein standards 
A modified 5' end was integrated into the design of the forward primers to facilitate 
directional cloning into the vector from Invitrogen, which has a 4-nucleotide overhang sequence. The 
reverse primers were designed against the sequence upstream of the stop codon to permit expression 
of a downstream histidine tag. Using the Champion™ pET Directional TOPO® Expression Kit 
system (Life Technologies Pty Ltd, Invitrogen, Mulgrave, Vic, Australia), PCR products can be 
directionally cloned by adding four bases to the forward primer (CACC). The overhang in the 
cloning vector (GTGG) invades the 5' end of the PCR product, anneals to the added nucleotides, and 
results in production of a PCR product at the right orientation. With this system the PCR amplicon 
can be cloned at very high efficiency. 
P a g e  | 34 
 The forward and reverse primers sequences that were used to amplify a fragment of each 
protein are listed in Table 2.1. 
The cDNA used to amplify the PCR product was prepared from frozen tissue that was stored 
at –80°C in 0.32 M sucrose. Pieces of frozen human autopsy tissue about 1 cm3 were weighed and 
homogenized on ice in 10 (w/v) of TRIzol® (Invitrogen) using a motor-driven homogenizer 
(Polytron®, Kinematica, Bohemia, NY, USA). The homogenate was incubated for 5 min at room 
temperature and 0.2 (v/v) of chloroform was added and the incubation continued at RT for 2–3 min 
with shaking. The homogenate was centrifuged for 20 min at 10 000  g at 4°C and the top layer 
transferred to a new tube. 0.1 (v/v) of isopropanol was added and the mixture incubated for 10 min 
at RT, then centrifuged at 10 000  g for 15 min at 4°C. The pellet was resuspended in 1 ml of 75% 
ethanol and centrifuged at 20 000  g for 20 min at 4°C. The final pellet was dried and resuspended 
in 50 µl of pure water and incubated at 60°C for an additional 10 min. 
Table 2.1. NLGN1 and NLGN2 PCR and cloning details. 
 NLGN1 NLGN2 
Forward Primer 5'-CAC CAT GGC ACT GCC 
CAG AT-3' 
5'-CAC CTA CGT GCA GAA 
CCA GAG C-3' 
Reverse Primer 5'-ACC AGC TCG ATA CCA 
CAT AGC CTA A-3' 
5'-CCG ACT ACC AGT CTC 
CCG TCT AA-3' 
Size of PCR amplimer 
& recombinant protein 
1069 bp between nucleotides 421 
and 1491; 38 kDa 
1035 bp between nucleotides 465 
and 1510; 40 kDa  
Location of epitope  Residues 33–61 near N-terminus Internal region  
Sizes of native form 4861bp 4621 bp 
To reverse transcribe the RNA, DNase I was added to get rid of any contaminating genomic 
DNA. 1 µl of 10 DNase I reaction buffer (Fermentas Inc, Hanover, MD, USA) was added to 3 µg 
of RNA, then 40 U of RNase OUT (Fermentas) and 1 U of RNase-free DNase (Fermentas) were 
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added and the mixture incubated at 37°C for 30 min. EDTA was added to a final concentration of 
2.27 mM and the mixture incubated at 75°C for 5 min. cDNA was formed by adding the following: 
0.82 µg of DNase, 300 µM dNTPs (Promega Corp., Sydney, NSW Australia), 1 µg of Oligo (dT)12–
18 primers (Promega), and 0.5 µg of random hexamers (Promega). Nuclease-free MilliQ H2O was 
added to make the volume to 12 µl and the mixture incubated for 5 min at 65°C. The following 
reagents were added to perform the reverse transcriptase step: 5 first-strand buffer, 4.8 mM 
dithiothreitol (DTT), 40 U of RNaseOUT and 400 U of Superscript III Reverse Transcriptase® 
(Invitrogen). The mixture was incubated at 25°C for 5 min, then 50°C for 60 min and 70°C for 15 
min. To eliminate any residual contamination by RNA, 2U of DNase-free ribonuclease H 
(Invitrogen) was added and the incubation continued for 20 min at 37°C. The cDNA was stored at –
20°C. 
The PCR product of NLGN1 was amplified from cortical cDNA by incubating 1 µl of cDNA 
with 1 µl of 10 mM dNTPs, 1 µl of NLGN1 10 µM forward and reverse primers (final concentration 
0.2 µM), 5 µl of 10 Pfu buffer without MgSO4 (200 mM Tris-HCl, pH 8.8 at 25°C), 100 mM 
(NH4)2SO4, 100 mM KCl, 1% (v/v) Triton X-100, 1 mg/ml BSA), 4 µl of 25 mM MgSO4 (final 
concentration 2 mM) and 0.5 µl (1.25 U) of Pfu DNA polymerase. The PCR was performed using 
the following conditions: initial denaturation at 95°C for 2 min, then 35 cycles with denaturation at 
95°C for 30s. A gradient PCR cycler was used to get different annealing temperatures for different 
reactions at 58°C and 62°C for 30s and extension at 72°C for 2 min. Final extension was at 72°C for 
10 min. The PCR products were loaded onto a 1% agarose/ethidium bromide gel and run for 1h at 
100V. 
The PCR product of NLGN2 was amplified from cortical cDNA by incubating 1 µl of cDNA 
with 10 mM dNTP mixture (final concentration of each dNTP 200 µM), 10 µl buffer B (60 mM Tris-
SO4, 18 mM (NH4)2SO4, 2 mM MgSO4, pH 9.1), 10 µM NLGN2 forward and reverse primers (final 
concentration 200 nM), 1 µl of Elongase enzyme mix, finally topped up to 50 µl with MilliQ H2O. 
The following conditions were used to perform the amplifications: pre-amplification denaturation at 
94°C for 30s, then 35 cycles with denaturation at 94°C for 30s. A PCR gradient cycler was used to 
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get different annealing temperatures for different reactions for optimizations: 58°C, 60°C, 62°C and 
64°C, with gradient annealing for 30s. Extension was performed at 68°C for 1 min. After the 35 
cycles were completed a final extension at 68°C for 10 min was performed. The PCR products were 
loaded onto a 1% agarose/ethidium bromide gel and run for 1h at 100V. 
2.3.1.1 PCR clean-up 
To purify NLGN1 and NLGN2 PCR products from primers, nucleotides, polymerase and salt, 
and to obtain concentrated cDNA, I used the QIAquick PCR purification kit (QIAGEN Pty Ltd, 
Doncaster, VIC, Australia) as per the manufacturer’s specification. 
2.3.2 Topo cloning reaction 
The purified PCR products of NLGN1 and NLGN2 were ligated into Topo vector at a 0.5:1 
molar ratio of PCR product to vector. The ligation reaction was carried out in 6 µl total volume, 
which included 0.5 µl of purified PCR product, 1 µl salt solution, 1 µl Topo vector and 3.5 µl of 
MilliQ H2O. The reaction was mixed gently and incubated for 5 min at room temperature. The 
mixture was placed on ice for the E. coli transformation (see next). 
2.3.2.1  Transformation of E. coli 
pET TOPO NLGN1 and NLGN2 constructs were transformed into competent E. coli (One 
Shot® TOP10 Chemically Competent E. coli; Invitrogen) by adding 3 µl of the TOPO® Cloning 
reaction product (previous section) into a vial of the E. coli preparation and the reaction mixed gently 
and incubated on ice for half an hour. Cells were heat-shocked for 30s at 42°C without shaking and 
the tubes immediately transferred to ice. 250 µl of Super Optimal broth with Catabolite repression 
(S.O.C.; 2% Tryptone, 0.5% Yeast Extract, 10 mM NaCl, 2.5 mM KCl, 10 mM MgCl2, 10 mM 
MgSO4, 20 mM glucose) was added to the vial at room temperature and the mixture shaken 
horizontally (200 rpm) at 37°C for 1h. 100 µl and 200 µl of each transformation reaction were spread 
on pre-warmed LB agar + carbenicillin plates and incubated overnight at 37°C. 
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2.3.2.2 PCR colony screening 
Colonies obtained from the plates were streaked on new LB agar + carbenicillin plates and 
grown overnight at 37°C. Each growing colony was tip patched and incubated in a reaction 
containing 50 µl 2% Triton pH 12.4 (0.03 mM), 10 µl 6 loading dye (11 mM EDTA, 3.3 mM Tris-
HCl, 0.017% SDS, 0.015% bromophenol blue, pH 8.0) and 50 µl of the bottom layer of a 
chloroform/phenol/isoamyl alcohol 25:24:1 saturated with 10 mM Tris and 1 mM EDTA, pH 8.0. 
Tubes were vortex and centrifuged for 10 min at 13,000  g. The top layer of the mixture was loaded 
onto a 1% agarose/ethidium bromide gel with a 1 kbp ladder and run at 100V for 1h. Colonies with 
the right insert were identified from the banding pattern (Genomic DNA, Vector 5764 bp, insert 
NLGN1 and NLGN2 ~1000 bp). 
2.3.2.3 Plasmid purification 
A QIAprep Spin Miniprep Kit (QIAGEN) was used to purify high-copy plasmid DNA of 
NLGN1 and NLGN2 from 5 ml overnight cultures of E. coli in LB as per the manufacturer’s 
specifications. 
2.3.2.4 PCR screening 
PCR screening was used to analyse positive transformants of NLGN1 with the following 
reaction: 1 µl of 10 µM dNTPs, 1 µl of NLGN1 10 µM forward and reverse primers (final 
concentration 0.2 µM), 5 µl of 10 Pfu buffer without MgSO4 (see above), 4 µl of 25 mM MgSO4 
(final concentration 2 mM) and 0.5 µl (1.25 U) of Pfu DNA polymerase. Colonies with inserts were 
resuspended into the reaction mixture and PCR performed using the following thermal cycling: 
initial denaturation step of 2 mins at 95°C, then 35 cycles of a 30s, 95°C denaturing step, 58 ± 4°C 
gradient annealing for 30s, and a 2 min, 72°C extension step which was followed by a final extension 
step of 72°C for 10 min. 
2.3.2.5 Restriction enzyme analysis 
Restriction analysis of purified NLGN2 plasmid was conducted to confirm the presence and 
the correct orientation of the insert. The NEB cutter tool (New England BioLabs, Hitchin, UK) was 
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used to find non-overlapping open reading frames in DNA sequences of the E. coli genetic code and 
the sites for all Type II and commercially available Type III restriction enzymes that cut the 
sequence just once. Restriction enzyme APAI (New England Biolabs), which cut the insert at 
nucleotide 666 and cut the vector at nucleotide 5029, was used. The following reaction was 
conducted to perform NLGN2 restriction analysis in 20 µl: 2 µl of 10 NEBuffer, 0.2 µl of BSA 
100, 5 µl of purified plasmid, 0.5 µl of APAI enzyme and 12.3 µl of sterile deionized water. The 
mixture was incubated for 3h at 37C in a water bath and then for additional 10 min at 70°C, then 
loaded into a 1% agaros/ethidium bromide gel and run for 1h at 100V. 
2.3.2.6 Sequencing 
NLGN1 and NLGN2 constructs were sequenced using Illumina (San Diego, CA, USA) 
HiSeq2000 next generation sequencing at Australian Genome Research Centre to confirm that the 
NLGN1 and NLGN2 genes were in frame with the appropriate N-terminal or C-terminal fusion tags. 
The forward and reverse reaction mixtures of NLGN1 and NLGN2 were sent in 12 µl total volume 
(600 ng of plasmid and 0.6 µl of pET100/D-TOPO® T7 forward primer or 0.6 µl of reverse primer 
for pET100/D-TOPO® T7 reverse primer). 
2.3.2.7 Expression 
Successfully sequenced NLGN1 and NLGN2-PET101/D-Topo clone (plasmid) were 
transformed into BL21 Star™ (DE3), which is included with each Champion™ pET directional 
TOPO® Expression Kit. 0.5 µl of each plasmid DNA was loaded into thawed vial of BL21 Star™ 
(DE3) and mixed gently. Cells were incubated on ice for 30 min, then heat-shocked for 30s at 42°C 
without shaking. The tubes were immediately transferred to ice and 250 µl of room temperature SOC 
medium was added to each tube. The mixtures were incubated at 37°C for 60 minutes with shaking 
(200 rpm). Each entire transformation reaction was added to 10 ml of LB containing 10 µl 
Ampicillin antibiotic and grown overnight at 37°C with shaking. 
Because different recombinant proteins have different characteristics, pilot expression was 
performed in which a time course for expression was studied to determine the best condition for 
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protein expression. 500 µl of the overnight cultures were inoculated to 10 ml of LB containing 10 µl 
of Ampicillin and grown for 2h at 37°C with shaking (200 rpm) until the cells had reached mid-log 
phase (OD600 0.5–0.8). Each culture was split into two (5 ml each) and 0.5 mM IPTG final 
concentration (250 µl of 200 µM) added to one sample to induce expression. 500 µl aliquots were 
taken from each culture as a zero time point sample and centrifuged for 1 min at 13,000 rpm. 
Supernatants were aspirated and pellets were then frozen at –20°C. Cultures were kept in the 
incubator at 37°C with shaking and aliquots taken every hour up to 4h. At each time point, 500 µl 
from the induced and uninduced cultures were taken and centrifuged for 1 min at 13,000 rpm, the 
supernatants were discarded, and the pellets stored at –20°C for analysis. 
2.3.3 Analysing expression 
To analyse the pilot expression of NLGN1 and NLGN2, 10% of SDS separating gels were 
prepared by mixing 3.54 ml of MilliQ H2O, 3.75 ml of 1M Tris (pH = 8.8), 100 µl of 10% SDS, 2.5 
ml 40% Acrylamide, 100 µl of 10% APS (Ammonium persulfate) and 10 µl of TEMED (NNNN-
tetramethylenediamine). 4% stacking gels were prepared by mixing 3.77 ml of MilliQ H2O, 625 µl 
of 1M Tris (pH = 6.8), 50 µl of 10% SDS, 500 µl of 40% acrylamide, 50 µl of 10% APS and 5 µl of 
TEMED. Sample pellets from the pilot expression of NLGN1 and NLGN2 were thawed, suspended 
into 80 µl of 1 sample buffer, and boiled for 5 min at 100°C. 16 µl of each pellet and SDS-sample 
buffer mixture was loaded onto the gel and run for 45 min at 150V. Gels were stained with 
Coomassie Brilliant Blue (Sigma-Aldrich Pty Ltd, Castle Hill, NSW, Australia) in 50% methanol 
and 10% glacial acetic acid for 1h, then destained overnight with 45% methanol and 5% acetic acid. 
Gels were visualized on the Odyssey Infrared Imaging System (LI-COR Biotechnology, Cambridge, 
UK) at a scan intensity of 8 using the 700/800 nm fluorescence channel. 
2.3.3.1 Scaling up expression for purification 
To scale-up expression to 50 ml, 500 µl of overnight culture (previous step) was inoculated 
into 10 ml of LB containing 10 µl of ampicillin and grown overnight at 37°C with shaking (200 rpm) 
until the OD600 reached 1.0. One ml of the overnight culture was inoculated into 50 ml LB with 50 µl 
of Ampicillin and grown for 2h at 37°C with shaking (200rpm) until the cells reached mid-log phase 
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(OD600 = ~0.5). 1 mM IPTG was added to each culture to induce expression and the incubation 
continued at 37°C with shaking for 4h. Cells were harvested by centrifugation for 10,000 rpm for 10 
minutes at +4°C. 
2.3.3.2 Purification 
Recombinant truncated neuroligin-1 and neuroligin-2 protein was purified under denaturating 
conditions using the Ni-NTA spin column kit (Qiagen) as per the manufacturer’s instructions. Cells 
from 50 ml cultures of neuroligin-1 and neuroligin-2 were thawed for 15 min and pellets were 
resuspended and lysed in 1 ml of 1 PBS and 5 µl of 20 mg/ml lysozyme, 10 µl DNAase and 7 ml of 
buffer B, denaturing lysis/binding buffer (7 M urea, 100 mM NaH2PO4, 100 mM Tris-HCl, pH 8.0). 
The mixtures were agitated at room temperature for 1h until the solution become translucent. To 
pellet the cellular debris, 700 µl of lysates were centrifuged at 12,000  g for 30 min at room 
temperature (25°C). The supernatant was collected and 20 µl of the cleared lysates saved for SDS-
PAGE analysis. 
2.3.3.3 Western blotting 
To validate the expression and purification of neuroligin-1 and neuroligin-2 recombinant 
protein, western blotting was used. Proteins eluted from NI-NTA columns were mixed with 3 SDS-
sample buffer (1:3 SDS buffer: protein) and loaded into 10% polyacrylamide gels. Proteins were 
separated for 30 min at 200V, then transferred to polyvinylidene difluoride (PVDF) membranes for 
90 min at 100V. Membranes were blocked with 1% skim milk in PBST for 1h with shaking, then 
incubated overnight at 4°C with blocking solution plus mouse monoclonal primary antibody against 
neuroligin-1 (1:20000 Neuroligin-1 (A-4): sc-365110, Santa Cruz Biotechnology Inc, Dallas, TX, 
USA) or goat polyclonal primary antibody against neuroligin-2 (1:20000 Neuroligin-2 (R-16): sc-
14089, Santa Cruz). Membranes were washed 3  10 min each in PBST and incubated at RT in the 
dark for 1h in skim milk blocking solution and PBST plus 1:20000 rabbit anti-goat 680 secondary 
antibodies (Invitrogen), then washed 3  10 min in PBST followed by 3  10 min in PBS. Finally, 
the membranes were dried and washed with methanol and visualized by the Odyssey infrared 
imaging system at  = 700 nm. 
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2.3.4 Quantification of neuroligin-1 and neuroligin-2 recombinant proteins 
The concentrations of neuroligin-1 and neuroligin-2 proteins were determined against a 
standard curve of BSA based on band intensity from the Odyssey imaging system. 
2.3.4.1 Quantification of neuroligin-1 and neuroligin-2 endogenous protein 
Variant amounts of purified neuroligin-1and neuroligin-2 were loaded onto separate SDS-
PAGE gels. Standard curves were created by plotting the intensity of each neuroligin-1 and 
neuroligin-2 band from the Odyssey imaging system against known amounts of recombinant 
truncated neuroligin-1 and neuroligin-2 proteins respectively. This method allowed me to accurately 
quantify the the endogenous proteins using the standard curve present on each gel. This reduced both 
gel to gel and well to well variation during quantification (Agarwal et al., 2008). 
2.4 Results 
2.4.1 NLGN1 cloning 
 
Fig. 2.1. Agarose ethidium bromide gel of NLGN1 PCR products. Bands in lanes 2–5 
represent temperature gradients 56–64°C. These bands represent the NLGN1 amplicon 
and were identified at 1069 bp, which is the correct size, under UV. 
To accurately quantify neuroligin-1 protein expression in human brain membrane samples, 
neuroligin-1 truncated protein was used as standard with different known concentrations. The 
fragment of neuroligin-1 amplified from occipital cortex cDNA corresponded to amino acids 421 to 
1491, which contains the antigenic epitope amino acids 33 to 61 near the N-terminus recognised by 
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the Santa Cruz antibodies. Bands of the correct size (1069 bp) of the NLGN1 amplicon were detected 
under UV light on an agarose ethidium bromide gel (Fig. 2.1). 
PCR products of NLGN1 were purified using the QIAquick PCR purification kit (Qiagen) 
and cloned into pET100/D-TOPO vector. The PET101/D-TOPO vector contains N-terminal or C-
terminal polyhistidine (6His) tags that facilitate the purification on a nickel column such as Ni-
NTA. The pET TOPO® vectors have a T7/lac promoter to induce the expression of the protein of 
interest in high levels of IPTG. The T7lac promoter contains a lac operon sequence that assists in 
binding to lac repressor and has a role to further repress T7 RNA polymerase-induced basal 
transcription of the gene of interest in BL21 Star™(DE3) cells. The pET TOPO® vector has 
advantages for rapid directional cloning. Therefore, the vector was transformed into One Shot 
TOP10 E. coli. Quick screening for the successful insert of NLGN1 into the TOPO vector was 
analysed by using phenol/chloroform/isoamyl alcohol (Fig. 2.2). 
 
Fig. 2.2. Gel photo of quick screening for the successful insert (PCR product of 
neuroligin-1) into the TOPO vector. This technique gives rough confirmation of the 
successful ligation by the size of both insert and vector in the gel. Random selection 
of the colonies obtained from the transformation reaction in plates was done. These 
colonies were streaked on one plate and incubated overnight. Streaked patch colonies 
were treated with 2% Triton X-100 pH 12.4, then with phenol/chloroform/isoamyl 
alcohol (25:24:1) and loaded into the gel. The first lane in the gel represents the DNA 
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ladder standard, while lanes 2–19 show the treated colonies. Wells number 9 and 18 
roughly show the successful ligation due to its size, which is slightly higher than the 
rest of the colonies in the gel. 
To further analyse the successful transformation of NLGN1, analysis was conducted to 
confirm the presence and correct orientation of the insert by using a restriction enzyme with one 
specific site in the vector and one in the insert. NEB cutter from New England Biolabs was used to 
find the best restriction enzyme that cut the NLGN1 insert. Plasmid digestion was performed as 
described in Section 2.3.2.5. 
2.4.1.1 NLGN1 AGRF sequencing 
AGRF sequencing was conducted to confirm the correct sequence and proper orientation of 
the insert for subsequent expression. See appendix for this chapter. 
 
Fig. 2.3. SDS-PAGE of neuroligin-1 expression. Cultures were treated with or without 
IPTG to induce expression in (+) samples, and then run on SDS-PAGE for 45 minutes 
as described in Methods. Lane 1, protein marker; lanes 2, 4, 6 and 8, induced protein 
expression at 1, 2, 3, and 4h; lanes 1, 3, 5, and 7, no IPTG induction at 1–4h. The 
expected size of the recombinant truncated protein was 40 kDa. 
 Precision plus 
Protein  
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2.4.1.2 Neuroligin-1 expression 
The purified plasmid of pET100/D-TOPO constructs of neuroligin-1 were transformed into 
BL21 Star™(DE3) One Shot E. coli for the expression studies. A time course of expression up to 4 
hours was performed to determine the best conditions for the expression neuroligin-1. SDS-PAGE 
was used to analyse neuroligin-1 expression and the Odyssey system used to visualize the 
Coomassie-stained gel (Fig. 2.3). 
2.4.2 NLGN2 cloning 
Neuroligin-2 recombinant truncated protein was used as a standard to accurately quantify 
neuroligin-2 native protein in human brain. PCR was used with human brain cDNA and primers 
(outlined in Table 1) to amplify a fragment of human neuroligin-2. The amplimer corresponds to 
amino acids 465 to 1510 and contains antigenic epitope. PCR optimization was done to generate the 
best conditions for amplifying NLGN2 with the Pfu enzyme. Figure 2.4 shows the PCR products. 
 
Fig. 2.4. PCR products of neuroligin-2. First lane is the 1 Kb ladder standard, lanes 2-
4 are the PCR product of neuroligin-2 with annealing temperatures of 56, 58, 60, 62, 
and 64°C respectively. 
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Neuroligin-2 restriction analysis was conducted to confirm the presence and correct 
orientation of the insert by using a restriction enzyme with one specific site in the vector and one in 
the insert. 
NLGN2 PCR products were purified and cloned as described in Methods. Quick screening for 
the successful insertion into the vector is shown in Fig. 2.5. 
 
Fig. 2.5. Quick screening for the successful insert (PCR product of neuroligin-2) into 
the TOPO vector. Lane 1, DNA ladder, lanes 2–16, treated colonies. Wells #8 and 12 
show successful ligation at slightly higher size than the rest of the extracts. 
2.4.2.1 Neuroligin-2 expression 
pET100/D-TOPO NLGN2 plasmid was transformed to BL21 Star™(DE3) One Shot E. coli. 
Pilot expression from 1–4 hours was conducted to determine the best expression conditions for 
neuroligin-2. Expression of neuroligin-2 protein was analysed by SDS-PAGE and Odyssey system 
was used to visualize the Coomassie-stained gel. 
P a g e  | 46 
 
Fig. 2.6. SDS-PAGE of neuroligin-2 expression. Cultures were treated with (+) IPTG 
to induce expression, run on SDS-PAGE and stained as described in Methods. Lane 1, 
MW marker; lanes 2, 4, 5, 8, and 9, induced protein expression at 0, 1, 2, 3, and 4h; 
lanes 3, 6, 7, and 10, without IPTG induction at 1– 4h. The expected size of the 
recombinant protein is 40 kDa. 
2.4.2.2 Neuroligin-1 and neroligin-2 purification 
Maximum levels of recombinant neuroligin-1 and neuroligin-2 expression were attained at 4h 
after IPTG induction. Both proteins were purified on Ni-NTA columns from an upscale expression 
of 50 ml following 4h of IPTG addition (Figs 2.7 and 2.8). 
 
Fig. 2.7. Neuroligin-1 protein purificationon Ni-NTA columns. The second lane 
shows the whole lysate, the third lane the supernatant followed by flowthrough of the 
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supernatant, lanes 5 and 6 wash #1 and wash #2 respectively. The last two lanes that 
show the final eluates have the correct size of the recombinant truncated protein, 
38KDa. 
 
Fig. 2.8. Neuroligin-2 protein purification on Ni-NTA columns. Details as for Fig. 
2.7; the last two lanes represent the final elutes and have the correct size of truncated 
recombinant protein, 40KDa. 
 
Fig. 2.9. Quantification of neuroligin-1 and neuroligin-2 recombinant proteins. The 
concentrations of neuroligin-1 and neuroligin-2 proteins were determined against a 
standard curve of known quantities of BSA based on band intensity in the Odyssey 
imaging system. The final concentration of neuroligin-1 was 21.39 ng/µl while the 
final concentration of neuroligin-2 was 24.27 ng/µl. 
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Fig. 2.10. Neuroligin-1 recombinant standard. Different concentrations of truncated 
recombinant neuroligin-1 were loaded onto the gel (10–100 ng). Details as Fig. 2.11. 
 
Fig. 2.11. Neuroligin-2 recombinant protein standard. Different concentrations of 
truncated recombinant neuroligin-2 were loaded onto the gel (10–100 ng). Details as 
for Fig. 2.11. 
2.5 Discussion 
Human post-mortem brain tissues have been used widely to find novel biomarkers in 
neurodegenerative disease, including AD. Different proteomic approaches can be used to find 
biomarkers and protein differences in AD, such as 2-dimensional gel electrophoresis, 2D-DIGE, and 
liquid chromatography based high-resolution tandem mass spectrometry, LCMS. The separation of a 
protein in 2-DIGE is based on the charge (isoelectric point) and the molecular weight. This 
separation leads to different pattern of protein spots that can then be recognized using MS methods to 
identify and quantify the proteins. 2-DIGE separation has good resolving power; utilization of 
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different dyes permits quantitative analysis, and allows increased sensitivity, reproducibility, and 
throughput in proteome analysis (Friedman et al., 2004, 2007). 2D-DIGE has a significant function 
in detecting proteins with posttranslational modifications (PTMs), because phosphorylation and 
glycosylation can have impacts on the isoelectric point and molecular weight of proteins. Hence, 
2DIGE can be used to compare different samples, because the size (area) and intensity of spots alter 
according to variations in the expression of proteins. For these reasons, 2D-DIGE has been used to 
find biomarkers in CSF and plasma in neurodegenerative diseases such as AD (Castano et al., 2006, 
Davidsson et al., 2001, Hu et al., 2007). 
An essential and informative phase in protein biomarker discovery is to identify quantitative 
differences in protein expression between diseased cases and controls. Utilizing 2-DIGE to quantify 
expression has limitations: it can’t be used to quantify hydrophobic proteins such as membrane-
bound proteins, and it is not applicable to proteins/peptides smaller than 15 kDa. It cannot detect 
differences when protein alterations are modest. This is a significant concern for studies of the 
human brain, where small changes in expression might have a marked impact over time. 
There are simple and accurate proteomic techniques that can be used for validation, such as 
enzyme-linked immunosorbent assay (ELISA) and Western blotting. Western blotting is one of the 
less-expensive proteomic techniques, is quick to perform, sensitive, and needs less starting material, 
which are key considerations for work with human autopsy tissue. It can be used to identify and 
quantify a protein in a mixture by separating the protein in a gel based on its molecular weight. The 
protein is then transferred from the gel to a membrane, which is incubated with labelled antibodies 
specific to the protein of interest. Unbound antibody is washed off and the bands then visualized by 
an imaging system such as the Odyssey. If the primary antibodies are selective for the protein of 
interest, the visible band(s) represent that protein. The intensity of the band parallels to quantity of 
protein present. The use of a protein standard improves the quantification of the protein present. 
Western blotting can give inaccurate results across gels. An internal control for protein 
quantification is essential for reliable, precise comparison of protein levels. Using a truncated 
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recombinant protein as standard in each gel minimizes errors due to the gel to gel variations. In this 
chapter, truncated recombinant human neuroligin-1 and neuroligin-2 proteins were successfully 
prepared to aid expression studies in human autopsy brain tissues. They allow accurate measurement 
of the native protein levels by in-gel immunodetection. The recombinant proteins are smaller than 
the native proteins; a known amount is added to each lane in the gel for use as a standard. The 
recombinant truncated protein separated clearly from their target proteins as sharp bands. A standard 
curve was created from the band intensities of standard in the different lanes on the gel; the use of 
the technique will be elucidated in the next chapter. It gives precise estimates of the quantities of 
neuroligin-1 and neuroligin-2 present in each sample, and can detect the proteins in the pmol per µg 
concentration range that is necessary to quantify proteins within the synapse. A comparison of the 
levels of neuroligin-1 and neuroligin-2 with other synaptic proteins is also possible with this method. 
The Odyssey infrared imaging system has a wide and linear dynamic range to quantify high and low 
signals on the same Western blot. It provides images with low background, high signal to noise 
detection, and clear, sharp, and reproducible bands. 
Some limitations are associated with the quantification of proteins by immunodetection. 
These include incomplete protein transfer from the gel to membrane, and nonspecific binding of 
some antibodies. Staining of the polyacrylamide gel after transformation resolves this problem. 
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Chapter 3 
3 Quantification of neuroligin-1, neuroligin-2 and -neurexin-1 proteins 
3.1 Aims of the research 
1. To quantify the expression of the synaptic proteins neuroligin-1, neuroligin-2 and -neurexin-
1 in human post-mortem brain tissues from AD cases and controls. 
2. To evaluate differences in expression in three different regions of the brain (hippocampus, 
occipital cortex and inferior temporal cortex) in AD cases and controls. 
3. To assess the impact of age and gender on expression. 
4. To investigate expression according to the pathological severity of the disease. 
3.2 Introduction 
Synaptic transmission is crucial for nervous system function, and its disruption is considered 
an important cause for many neurobiological diseases, including AD. The progressive loss of 
synaptic proteins and hence neurological function in dementia has been a topic of interest since the 
relationship between synaptic loss and AD was first reported (Davies et al., 1987). Further studies 
have shown that synapse and synaptic protein loss have substantial effects on function in AD 
(DeKosky and Scheff, 1990, Scheff et al., 1990, Terry et al., 1991). Synapse loss is the major 
correlate of cognitive impairment. Synaptic weakening is considered to be a general component in 
the pathological alterations linked to dementia, and is the best correlate with dementia ante mortem 
(DeKosky and Scheff, 1990). An approximate 30% decrease in synapse number per cortical neuron 
has been observed in AD brain (Walch-Solimena et al., 1993). Synaptic pathology occurs early in 
AD progression and it is more strongly correlated with dementia than are senile plaques and NFT 
(Terry et al., 1991). Synaptic alterations in AD have been verified by electron microscopy as well as 
by proteomic approaches (Zhou et al., 2013, Masliah et al., 2001, Davies et al., 1987, Chang et al., 
2013). Gene expression assays using brain autopsy tissues from AD cases and controls have shown 
lower levels of different gene transcripts involved in synaptic vesicle trafficking (Liang et al., 2008). 
The mechanisms of synaptic pathology in AD are not totally clear, although several synaptic proteins 
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such as synaptophysin and gephyrin have been related to synaptic disruption in the disease (Agarwal 
et al., 2008, Tannenberg et al., 2006). It is not clear whether other synaptic proteins are involved in 
synaptic dysfunction in AD. Moreover, it remains unclear how synaptic organization, involving 
presynaptic, postsynaptic, and synaptic membrane proteins, is changed in AD. 
3.2.1 Fluctuations of synaptic proteins in AD 
Different studies have been conducted to quantify synaptic protein levels in human autopsy 
brain tissues from AD cases. For example, synaptophysin concentrations are lower in specific brain 
areas (Reddy et al., 2005, Lassmann et al., 1992, Honer et al., 1992, Hamos et al., 1989). However, 
different studies have shown contradictory results. Reduced synaptophysin levels were only detected 
at advanced stages of AD by Davidsson and Blennow (1998). The discrepancies between different 
studies may be due to differences in the region of brain tissue tested. 
Dynamin I is a presynaptic terminal protein and functions in synaptic vesicle recycling (Liu 
et al., 1996). Quantification studies have revealed lower dynamin I mRNA and protein levels in the 
superior frontal gyrus of AD cases than in controls (Yao et al., 2003). A major component of the 
postsynaptic density (PSD) is the -subunit of calcium/calmodulin-dependent protein kinase II 
(CaMKII), which comprises 2% of total protein in rodent hippocampus and 1% of total protein in 
the forebrain (Ziff, 1997). No difference in CaMKII level was observed in the hippocampi of AD 
cases and controls (Simonian et al., 1994). N-cadherin is a member of the cell-adhesion molecules 
that has important functions in neurite outgrowth, synaptic junctional complex formation, and 
synaptic stability (Shapiro and Colman, 1999, Tang et al., 1998). It is located with synaptophysin, 
synapsin I, PSD95, and GluR1 at the synapse both in the pre-synaptic membrane and on the PSD 
(Benson and Tanaka, 1998, Tanaka et al., 2000, Tang et al., 1998). Tannenberg et al. (2006) found 
that the level of N-cadherin protein was higher in all brain areas of 15 AD cases than in 15 controls. 
This might be explained by the increase in synaptic apposition length that occurs in AD (Scheff et 
al., 1990). 
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Complexin I is synaptic protein that controls inhibitory neurotransmitter release, while 
complexin II regulates excitatory neurotransmitter release. Both are membrane proteins that have 
roles in synaptic vesicle docking to the presynaptic membrane, which in turn mediates 
neurotransmitter release (Ono et al., 1998, Yamada et al., 1999). The expression of both complexins 
was significantly lower in all AD brain areas than in controls, but the ratio of complexin II to 
complexin I was not altered. These data show a loss of regulation of neurotransmitter release in AD 
in preserved presynaptic terminals. Quantitative immunohistochemistry in the entorhinal cortex from 
AD brain cf age-matched controls showed significantly higher levels of PSD-95 that positively 
correlated with -amyloid and phosphorylated tau proteins (Leuba et al., 2008b). Quantifying these 
different types of synaptic proteins has proved fruitful in measuring the degree of synapse loss in 
AD. Further study of the roles of these and related molecules could illuminate mechanisms behind 
the synaptic loss and dysfunction that are characteristics of the disease. 
3.2.2 Measurement of synapses and synaptic proteins 
Electron microscopy was the first method used to quantify synapses, which were detected by 
thickening of the synaptic membrane, in a brain with cognitive decline, (Davies et al., 1987). One 
limitation of this approach is the ability to quantify only small areas of tissue. It also requires the use 
of preserved and rapidly fixed material, which limits its use with much autopsy tissue. 
Antigen-specific immunochemical methods detect synapse loss in AD through the 
quantification of different synaptic proteins involved in the synaptic cycle. The immunochemical 
techniques utilized in the research of AD brain autopsies have linked synaptic loss with A oligomer 
proteins as well as recognized synapse loss as the best correlate to AD. 
Reliable and accurate techniques are able to precisely quantify proteins specific to different 
phases of the synaptic cycle. They can be correlated to disease stage as well as the region where the 
protein is expressed by using immunohistochemistry, enzyme-linked immunosorbent assay (ELISA) 
and immunoblotting methods. Immunohistochemistry measures synaptic protein levels by labelling 
synaptic proteins linked to presynaptic terminals or synaptic vesicles (Hamos et al., 1989). The 
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relative quantification of synaptic proteins can be measured via optical density of immunoreactive 
regions of the cortex. Utilizing immunoblotting to quantify synaptic density and synaptic proteins in 
neurological disease gives reproducible and specific results (Masliah et al., 1991). Acurate 
quantifications for neuroligin-1, neuroligin-2 and -neurexin were performedby using internal 
standard higher and lower than the unknown protein concentration in each gel in this chapter. 
3.3 Materials and Methods 
3.3.1 Tissue collection 
All brain tissues were obtained from the Queensland Brain Bank, which is located at the 
School of Chemistry and Molecular Bioscience at The University of Queensland. It is a part of the 
Australian Brain Bank Network, and offers services for Australian and international clinicians and 
researchers to study neurological diseases. Autopsies for this study were obtained with informed 
written consent from the next of kin. Diagnosis of AD was validated by examination of the tissue by 
qualified neuropathologists (Halliday et al., 2002). Tissues were dissected from specific areas of AD 
and control brains and stored in 0.32 M sucrose at –80°C (Dodd et al., 1986). 
3.3.2 Case selection and neuropathological severity score 
Fifteen cases and 15 controls were selected with an average age of 77 years for the AD cases 
and 76 years for the controls (Table 3.1). The average post mortem delay for the AD cases was 
approximately 27 hours while for the controls it was 25 hours. Tissue from three different areas —
hippocampus (Hipp), occipital cortex (OC) and inferior temporal cortex (ITC) — was obtained from 
each brain. 
These cases were all collected between 1993 and 2003. During this time, Alzheimer’s disease 
was classified using the CERAD neuropathologic assessment based on Mirra et al. (1993). The 
Braak & Braak system was not used by the neuropathologists who did the Brain Bank examinations 
during that time. The CERAD assessment is a combination of 1. A gross examination to determine if 
cerebrovascular disease was present. 2. Semi-quantitative analysis of the degree of cortical atrophy 
and ventricle enlargement. 3. Visual examination of the hippocampus and entorhinal cortex for 
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atrophy. 4. Examination of the pallor of the substantia nigra and locus ceruleus. 5. Examination of 
the blood vessels for atherosclerosis or obstruction, ischemic events or other anomalies. 6. Semi-
quantitative assessment of the presence and number of neocortical senile plaques (silver-positive 
neurites). 7. Evaluation of the substantia nigra for Lewy bodies, neuronal loss, gliosis and NFTs to 
rule out Parkinson’s disease. 8. Evaluation of clinical presence of dementia. The combination of 
these assessments result in a level of certainty of the diagnosis of AD: Definite (A), Probable (B), 
Possible (C). To determine the Braak & Braak level of these cases we used The National Institute for 
Aging and Ronald and Nancy Reagan Institute of the Alzheimer’s Association (NIA-Reagan 
Institute) combined criteria, which suggests that the two effectively correlate to one another in broad 
categories. Since further examination of these pathological samples is not possible due to the time 
that has elapsed since their collection, the exact Braak & Braak staging level cannot be determined. 
However, each area of each brain was given a neuropathological severity score from 0 to 3 according 
to the abundance of AD hallmarks NFT and A, and the extent of neuronal loss (Tannenberg et al., 
2006; Table 3.2). This allowed us to rate disease severity in each of three areas from each case, 
effectively tripling the number of samples available for determining the influence of pathology on 
expression, and also eliminating the averaging of pathology across tissue regions that is inherent in 
the Braak staging approach (Tannenberg et al., 2006; Table 3.2). Pathological score is a composite of 
three measures; in occipital cortex, A plaques are generally quite common, whereas neither tangles 
nor cell loss usually occur in this area except at very late disease stages. The pH of samples was not 
measured as it has no effect on the protein quality. Trabzuni et al. (2011) found that pH has no great 
effect on RNA or protein levels, and so is not a factor. That study assessed the influence of post-
mortem delay and tissue pH as predictors of gene expression measured on 1266 Affymetrix Exon 
Arrays. The study found that post-mortem delay and brain pH had negligible effects on array 
performance. 
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Table 3.1. Details of AD cases and controls. 
Subject# Age, y PMD(h) Gender APOE 
AD1 65 34.83 M 3,4 
AD2 82 54.92 M 3,4 
AD3 72 25.00 M 3,3 
AD4 79 26.33 M 4,4 
AD5 92 48.00 F 3,3 
AD6 61 12.00 F 3,3 
AD7 84 18.42 M 3,4 
AD8 70 16.00 F 3,4 
AD9 87 35.50 F 3,3 
AD10 81 1.67 F 3,3 
AD11 82 41.25 F 3,4 
AD12 75 4.00 M 4,4 
AD13 73 48.00 M 4,4 
AD14 82 15.38 F 3,3 
AD15 66 18.83 M 3,4 
Average 77 ± 8.4 26.7 ± 15.9 8M, 7F 
 
NC1 78 4.00 F 3,4 
NC2 87 21.50 F 2,3 
NC3 57 9.75 F 3,3 
NC4 82 46.83 M 3,3 
NC5 85 24.50 M 2,3 
NC6 81 21.43 F 3,3 
NC7 74 85.25 M 3,3 
NC8 68 43.67 F 3,4 
NC9 72 15.42 F 3,3 
NC10 74 24.00 F 3,3 
NC11 71 7.75 F 3,4 
NC12 78 16.25 M 3,3 
NC13 68 28.17 M 2,2 
NC14 84 16.53 M 3,4 
NC15 76 24.00 F 3,3 
Average 76 ± 7.6 25.9 ± 11.3 6M, 9F 
 
AD, Alzheimer’s disease case; NC, normal control; M, male; F, female 
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Each area of each brain was given a neuropathological severity score from 0 to 3 according to 
the abundance of AD hallmarks NFT and A, and the extent of neuronal loss (Tannenberg et al., 
2006; Table 3.2). 
Table 3.2. Neuropathological score 
Subject# Hipp ITC Occ 
AD1 3 3 1 
AD2 3 3 1 
AD3 2 2 1 
AD4 3 3 1 
AD5 3 3 1 
AD6 3 3 2 
AD7 3 3 3 
AD8 2 3 2 
AD9 2 2 1 
AD10 1 2 1 
AD11 3 3 3 
AD12 3 3 1 
AD13 1 3 3 
AD14 2 1 1 
AD15 3 3 1 
NC1 0 0 0 
NC2 1 0 0 
NC3 0 0 0 
NC4 0 0 0 
NC5 0 0 0 
NC6 0 0 0 
NC7 0 0 0 
NC8 0 0 0 
NC9 1 0 0 
NC10 0 0 0 
NC11 0 0 0 
NC12 0 0 0 
NC13 0 0 0 
NC14 0 1 0 
NC15 0 0 0 
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3.3.3 Membrane preparations 
Tissues were homogenized in 10 (w/v) of 0.32 M sucrose at 4°C, and centrifuged for 10 min 
at 500  g in a Beckman JA20 at 4°C. The supernatant of the homogenate was centrifuged again for 
about 20 min at 12 000  g at 4°C. The final pellet was resuspended in 10 ml of 50 mM Tris-HCL, 
pH 7.4. Total protein concentrations were estimated by the Lowry et al. (1951) method. Samples 
were frozen at –80°C for long-term storage. 
3.3.4 Quantification of neuroligin-1, neuroligin-2 and -neurexin-1 proteins 
Different amounts of neuroligin-1, neuroligin-2 and -neurexin-1 recombinant protein 
ranging from 10 ng to 100 ng were mixed with each of the membrane protein samples (~30 µg). 
Only one replicate was performed for each sample due to tissue limitations for some of the cases 
used in the current study. All samples were diluted 2:3 with SDS buffer (1.7% SDS, 5% glycerol, 
1.55% DTT, 58 mM Tris-HCl, pH 6.8, with 0.002% bromophenol blue). The samples were heated 
for 5 min to 95°C, loaded onto 8% SDS-PAGE, and run for 35 min at 200V in running buffer (150 
mM glycine, 20 mM Tris, 0.1% SDS). Recombinant -neurexin-1 protein was purchased from 
Abnova (Walnut, CA, U.S.A). The truncated proteins neuroligin-1 (38kDa), neuroligin-2 (40Kda) 
and -neurexin-1 (36kDa) separated clearly from the target protein (110 kDa, 95 KDa and 46 kDa, 
respectively) as sharp bands. A standard curve was created by plotting the intensity of the truncated 
band against its concentration using Odyssey software. 
Proteins were then transferred from the gel to the PVDF membrane (Immobilon®-FL, 
Millipore, Billerica, MA, USA) in transfer buffer (10 mM NaHCO3, 3 mM Na2CO3, pH 9.9, with 
20% methanol). After transfer, the membrane was blocked in 1% skim milk in phosphate-buffered 
saline (PBST; 137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 2 mM KH2PO4, 0.1% Tween-20, pH 
7.4) with agitation for 1h at room temperature. A 1:10,000 dilution (2 µl/20,000 µl of blocking 
solution) of neuroligin-1, neuroligin-2 and -neurexin-1 primary antibodies was added to the 
corresponding membrane and all membranes were incubated overnight at 4°C with agitation. The 
membranes were washed with PBST three times for 10 min each. A 1:2, 0000 dilution of secondary 
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antibody (Alexa Fluor 680, goat anti-mouse IgG, Molecular Probes, Invitrogen) in 1% skim 
milk/PBST was added to neuroligin-1 membrane. A 1:2, 0000 dilution of secondary antibody (Alexa 
Fluor 680 of rabbit anti-goat IgG, Molecular Probes, Invitrogen) in 1% skim milk/PBST was added 
to both neuroligin-2 and -neurexin-1. All membranes were agitated for 1h at room temperature in 
the dark. Membranes were then washed with PBST three times for 10 min each followed by 
phosphate-buffered saline (PBS) twice for 10 min each. The intensities of the recombinant and target 
proteins bands were assessed using the LI-COR Odyssey scanner at 700 nm. 
3.3.5 Data analysis 
The intensities of the unknown bands fell within the intensity values of the lowest and highest 
concentrations of the recombinant proteins standards. Normal probability plots of each set of protein 
concentrations indicated that the data distribution was positively skewed. Box-Cox transformations 
performed with the Statistica software package (Tulsa, OK, USA) stabilized the variances and gave 
linear normal probability plots. Multiple comparisons were evaluated by ANOVA with appropriate 
post-hoc tests. Differences were considered statistically significant at P < 0.05. Mean and S.E.M. 
values were converted back to the original scale of measurement for presentation in text and figures. 
3.4 Results 
To quantify neuroligin-1, neuroligin-2 and -neurexin-1 in autopsy tissues, the 
immunodetection protocol with recombinant truncated neuroligin-1, neuroligin-2 and -neurexin-1 
proteins as standards was optimized as outlined in Chapter 2. This minimized error from gel to gel 
variations and allowed precise quantification. Membrane preparations from all samples gave sharp 
bands with the anti-neuroligin-1 antibody at ~110 kDa, anti-neuroligin-2 antibody at 95 kDa and 
anti--neurexin-1 antibody at 46 kDa (Figs 3.1, 3.2 and 3.3). The molecular masses of the bands 
were confirmed by measuring their migrations against those of the markers. Normal probability plots 
of the levels of each protein in each brain areas indicated that the data distributions were positively 
skewed (Fig. 3.4). Box-Cox transformations stabilized the variances and gave linear normal 
probability plots for neuroligin-1 (Fig. 3.5A), neuroligin-2 (Fig. 3.5B) and -neurexin-1 (Fig. 3.5C). 
P a g e  | 60 
 
Fig. 3.1. Representative immunoblot of neuroligin-1 in hippocampus and inferior 
temporal and occipital cortices from two controls and one AD case selected at 
random. Neuroligin-1 recombinant truncated protein was detected at 38 kDa MW. 
Endogenous neuroligin-1 ran at 110 kDa and was quantified as described in the text. 
 
Fig. 3.2. Representative immunoblot of neuroligin-2 in the three brain areas from two 
controls and two AD cases selected at random. Neuroligin-2 recombinant truncated 
protein was detected at 40 kDa MW. Endogenous neuroligin-2 protein ran at 95 kDa 
and was quantified as described in the text. 
 
Fig. 3.3. Representative immunoblots of -neurexin-1 in the three brain areas from 
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two controls and two AD cases selected at random. -Neurexin-1 recombinant 
truncated protein was detected at 36 kDa MW. Endogenous -neurexin-1 protein was 
detected at 46 kDa and was quantified as described in the text. 
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Fig. 3.4. Normal probability plots for A, neuroligin-1, B, neuroligin-2 and C, -
neurexin-1 concentrations in unadjusted values. Shapiro-Wilks testing showed that 
most untransformed data distributions deviated significantly (P < 0.01) from normal 
as shown in the in-graph boxes. 
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Fig. 3.5. Normal probability plots for Box Cox transformations of A, neuroligin-1, B, 
neuroligin-2 and C, -neurexin-1 concentrations. Shapiro-Wilks testing showed the 
transformed data distributions did not deviate significantly (P > 0.25) from normal as 
shown in the in-graph boxes. 
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3.4.1 Post-mortem delay and age at death 
In order to obtain accurate results in the current study, post-mortem delay (PMD) and age at 
death were matched as closely as possible between the two groups. Some neurochemical research 
has shown that the quality of some proteins is not affected by PMD, while others have found that 
PMD and age can impact protein degradation. Furthermore, the levels of some proteins vary with age 
due to processes such as neuronal homeostasis, protein regulatory mechanisms, degradation 
pathways and increased oxidative stress. In the current study, regression analyses were performed to 
assess the effect of PMD and age on the expression of the three proteins; these were non-significant. 
To ensure there were no subtle influences of these potential confounds, a series analyses of 
covariance on neuroligin-1 and neuroligin-2 proteins showed there was no significant effect of either 
factor, alone or in combination, on expression values in combined subjects and areas, and that 
ANCOVA did not significantly reduce error variances. There was no significant effect of PMD or 
age on neuroligin-1 concentration (F1,88 = 0.356, P = 0.85 and F1,88 =1.457, P = 0.23; Figs 3.6A and 
3.6B), nor was there a significant effect of either PMD or age on neuroligin-2 concentration 
(F1,88 = 0.651, P = 0.42 and F1,88 =1.036, P = 0.31 respectively; Figs 3.6C and 3.6D). This allowed 
the expression values to be assessed by analyses of variance without further normalization. For -
neurexin-1, significant associations were observed between protein expression and both age and 
PMD (F1,88 =13.619, P < 0.001 and F1,88 = 5.480, P = 0.021 respectively; Figs 3.6E and 3.6F). To 
maintain consistency with the analyses of the other two proteins, and because AD cases and controls 
were reasonably well matched, ANOVA was also used for statistical testing of -neurexin-1, but this 
issue needs to be revisited with a larger data set. 
3.4.2 Neuroligin-1 expression by case-group 
ANOVA showed that the overall neuroligin-1 protein concentration was significantly higher 
in AD cases than in controls (F1,26 = 4.646, P = 0.041; Fig. 3.7). Expression differed significantly 
according to brain region (F2,52 = 14.100, P < 0.001; Fig. 3.8), being highest in hippocampus and 
lowest in inferior temporal cortex across all subjects, and each area differing significantly from both 
others (P < 0.05 in all instances, Newman-Keuls). 








Fig. 3.6. Regression analyses of protein concentrations against age and PMD. A, 
neuroligin-1 expression on age and B, PMD; C, neuroligin-2 expression on age and 
D, PMD; E, -neurexin-1 expression on age and F, PMD. 
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Although the Group  Area interaction was not significant, post-hoc testing showed that 
expression in AD hippocampus was significantly higher than in both AD occipital cortex (P = 0.027) 
and AD inferior temporal cortex (P < 0.001), and also higher than in normal control hippocampus (P 
= 0.021; Fig. 3.8). Post-hoc analysis showed that the neuroligin-1 level was significantly higher in 
AD cases than in controls in both hippocampus (P = 0.036) and occipital cortex (P = 0.04). Values in 
inferior temporal cortex did not differ significantly (P = 0.09, Fig. 3.8). 
 
Fig. 3.7. Overall neuroligin-1 expression by case-group. Protein levels were averaged 
across the three areas studied (hippocampus, inferior temporal cortex and occipital 
cortex) in each group; *, significantly higher than in controls (n = 15, both groups). 
Error bars represent S.E.M. 
3.4.3 Neuroligin-1 level by gender 
No significant differences were observed in males between AD cases and controls. The level 
of neuroligin-1 in AD females was higher than in control females, but this was not statistically 
significant (Fig. 3.9). Regionally, post-hoc testing showed that the level of neuroligin-1 in the 
hippocampus was significantly higher in AD females than in AD males and significantly higher in 
AD females than in control females. There were no gender differences in either the occipital cortex 
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Fig. 3.8. Neuroligin-1 protein by case-group and area. HP, hippocampus; OC, 
occipital cortex; ITC, inferior temporal cortex; *, significantly different from the level 
in the corresponding control sample, P < 0.05 by post-hoc Newman-Keuls test. 
 
Fig. 3.9. Overall neuroligin-1 expression by gender. Neuroligin-1 protein 
concentrations were averaged across the three brain regions in AD cases and controls 
partitioned by gender. 
3.4.4 Neuroligin-1 level and APOE genotype 
The most common genotype among the population is APOE 3; seven of the 15 normal 
controls in this study were 3,3 homozygotes and all but two had at least one 3 allele; the latter 
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had one 3 allele, and non had an 2 allele. About 50% of AD cases carry at least one copy of the 
risk-factor 4 allele: this was true of 9/15 AD cases here, three of whom were 4,4 homozygotes; 
four normal controls had one 4 (three with one 3) allele, none was an 4,4 homozygote. The 
lowest frequency APOE allele is 2, found in 2–8% of the population (Schellenberg, 1995). This 
allele was only found in normal controls here, two of whom were ,3, another 2,2: all three of 
these subjects would have been at reduced risk of AD. 
 
Fig. 3.10. Neuroligin-1 expression by group, gender, and and area. Details as Fig. 3.9; 
*, significantly higher than in female controls and †, significantly higher than in AD 
males, P < 0.05 by Newman-Keuls test. 
 
Fig. 3.11. APOE genotype and neuroligin-1expression in AD. AD cases were divided 















































Fig. 3.12. Neuroligin-1 expression by APOE genotype, group, and area. Key as for 
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As the full range of six APOE genotypes was not represented in both groups we classified the 
subjects according to the number of 4 alleles they possessed to study genotype–phenotype 
interactions. Although the Group Nº of 4 alleles interaction was significant (F1,25 = 5.608; P = 
0.026), in essence because AD cases with no 4 alleles differed from all other subjects (P ≤ 0.01, 
Newman-Keuls), this result must be treated with caution because these few AD cases were 
confounded by gender: all were female (Fig. 3.11). Similarly, the Area  Group  Nº of 4 alleles 
interaction was significant (F2,52 = 3.281, P = 0.045), and a significantly higher neuroligin-1 level 
was found in AD cases with no 4 than in comparable controls in both hippocampus and occipital 
cortex (Fig. 3.12), but again, these effects are not statistically reliable. No significant differences 
were found in neuroligin-1 level between cases and controls in inferior temporal cortex (Fig. 3.12). 
3.4.5 Neuroligin-1 expression and severity of disease 
The impact of the severity of the disease on neuroligin-1 protein was studied. Tissue samples 
were divided according to the extent of A and tau deposition and the degree of neuronal loss, and 
given a score from 0 to 3 by an experienced neuropathologist blinded to diagnosis (Tannenberg et al., 
2006). In the AD cases, no sample had a score of zero; and because almost all control tissue samples 
gave scores of zero it was not possible to make an across-group comparison: so the analysis was 
confined solely to samples from AD cases. A slightly higher level of neuroligin-1 was found at 
pathological score 2 in all three areas, but this was not significant. The concentration of neuroligin-1 
was lower at pathological score 3 in all areas, but post-hoc testing showed no significant difference 
in neuroligin-1 level between tissue samples with differing pathological scores (Fig. 3.13). Regional 
expression did not vary significantly with pathological score (F2,42 = 1.142, P = 0.33; Fig. 3.14). 
3.4.6 Neuroligin-2 expression in AD cases and controls 
Overall expression of neuroligin-2 protein was significantly lower in AD cases than in 
controls (F1,28 = 4.690, P = 0.039; Fig. 3.15). Newman-Keuls post-hoc testing showed a significantly 
lower neuroligin-2 level in inferior temporal cortex in AD cases than in controls (P = 0.021). Levels 
in the other two areas were also lower in AD cases than in controls, but not statistically significant  
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Fig. 3.13. Overall expression of neuroligin-1 and pathological severity. AD tissue 
samples undifferentiated by region were divided according to pathological severity 
(PS) score between 1 and 3. No difference was statistically significant. 
 
Fig. 3.14. Pathological severity and regional neuroligin-1 protein expression. There 
were no differences in expression with pathological severity in any area by Newman-
Keuls post-hoc testing. 
(Fig. 3.16). When AD cases and controls were combined, the inferior temporal cortex showed the 
highest expression level of neroligin-2 compared to the occipital cortex and the hippocampus (see 
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Fig. 3.15. Total neuroligin-2 protein concentrations averaged across the three areas 
studied; *, significantly lower than in controls, P < 0.05. 
 
Fig. 3.16. Neuroligin-2 protein expression by area. Key as for Fig. 3.8; *, significantly 
lower than in the same area in controls, P < 0.05 by Newman-Keuls post-hoc test. 
3.4.7 Neuroligin-2 level and gender 
The influence of gender on neurolign-2 protein expression was significant by ANOVA (F1,86 
= 13.461, P < 0.001; Fig. 3.17). No significant differences were found between AD cases and 
controls in hippocampus or occipital cortex in either sex. Neuroligin-2 protein level was lower in AD 
males than in control males in inferior temporal cortex, whereas the reverse was true for females in 
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Fig. 3.17. Neuroligin-2 expression by case-group and gender. Neuroligin-2 
concentrations were averaged across all areas studied in AD cases and controls. 
Newman-Keuls post hoc test showed that expression was significantly lower in male 
AD cases than in male controls (*; P < 0.001) or female AD cases (†; P = 0.002). 
 
Fig. 3.18. Gender effects on neuroligin-2 protein expression. In inferior temporal 
cortex: *, significantly lower than in male controls; †, significantly lower than in AD 
females; both P < 0.001, Newman-Keuls post-hoc tests. 
3.4.8 Neuroligin-2 level and APOE genotype 
Neuroligin-2 protein expression was significantly lower in AD APOE 4 carriers than in AD 
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(F1,86 =0.212, P = 0.64; Fig. 3.20). Although the Group  Area  APOE interaction was not 
significant (F2,52 =1.316, P = 0.27), some differences were detected by post-hoc testing (Fig. 3.21). 
 
Fig. 3.19. Expression of neuroligin-2 by Nº of APOE 4 alleles in AD cases. Key as 
for Fig. 3.10; *, significantly different from cases without at least ne e4 allele, see 
text for details. 
 
Fig. 3.20. APOE 4 genotype, neuroligin-2 expression and group. Key as for Fig. 












































































Fig. 3.21. Neuroligin-2 expression by group, APOE, and area. Key as for Fig. 3.10. 
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AD APOE 4 carriers than in matched controls in hippocampus (P = 0.046). A trend 
was seen in AD APOE 4 non-carriers cf controls in occipital cortex (P = 0.071). 
3.4.9 Neuroligin-2 expression and severity of disease 
Overall neuroligin-2 protein expression was highest at the moderate stage, and lowest at the 
severe stage, but not statistically significant (F2,42 = 0.389, P = 0.68; Fig.3.20); neither was the PS  
Area interaction (F4,36 = 0.696, P = 0.59; Fig 3.21), although some post-hoc tests were. 
 
Fig. 3.22. Neuroligin-2 protein expression and disease severity. Key as for Fig. 3.12. 
 
Fig. 3.23. Neuroligin-2 expression by area and disease severity. Key as for Fig. 3.12. 
There was no variation in expression with pathological severity in either hippocampus 
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showed that neuroligin-2 level at the moderate stage of AD was significantly higher 
than at the mild and severe stages, P < 0.05. 
3.4.10 -neurexin-1 by case-group and brain region 
Even though the level of -neurexin-1 was slightly higher in AD cases than in controls, the 
case-groups did not differ significantly (F1,86 = 0.157, P = 0.91; Fig. 3.24). Expression did not differ 
significantly by brain region between case-groups (F2,52 = 0.125 P = 0.88; Fig. 3.25). 
 
Fig. 3.24. Overall -neurexin-1 expression by case-group. Values were averaged 
across areas as described under Fig. 3.7. 
 
Fig. 3.25. Expression of -neurexin-1 protein by case-group and area. No difference 
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3.4.11 -neurexin-1 level and gender 
The effect of gender on -neurexin-1 expression was analysed. The Group  Gender 
interaction was not significant (F1,86 = 0.662, P = 0.42; Fig. 3.26), nor was the Group  Gender  
Area interaction (F2,52 = 0.059, P = 0.942; Fig. 3.27). 
 
Fig. 3.26. -neurexin-1 expression by case-group and gender. Details as for Fig. 3.16. 
 
Fig. 3.27. -neurexin-1 protein expression by goup, sex and area. See text for details. 
3.4.12 -Neurexin-1 level and APOE genotype 
The Group  Nº of APOE 4 alleles was significant (F1,26 = 6.431, P = 0.017), due to higher 
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Fig. 3.28. APOE genotype and -neurexin-1 by case-group. Key as for Fig. 3.10. 
Newman-Keuls post-hoc testing showed that expression was significantly higher in 
AD APOE 4 carriers than in control 4 carriers (APOE2), P < 0.001. 
The brain region by group and 4 interaction was also significant (F2,52 = 5.376, P = 0.0075), 
most notably in inferior temporal cortex (Fig. 3.29). However, these and the statistics on overall 
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Fig. 3.29. APOE4 genotype effects on regional -neurexin-1 expression by case-
group. Key as for Fig. 3.10. Newman-Keuls post hoc test showed significantly higher 
expression in AD cases carrying at least one APOE 4 allele (APOE2) than in the 
equivalent controls in inferior temporal cortex, P = 0.004. Expression in AD cases 
carrying at least one APOE 4 allele (APOE2) was significantly higher (P = 0.006) 
than in AD cases without an APOE 4 allele (APOE1) in inferior temporal cortex. 
3.4.13 -neurexin-1 expression and severity of disease 
When AD tissue samples were divided by pathological score without regard to brain region 
there was no significant variation in -neurexin-1 expression (F2,40 = 2.481, P = 0.10; Fig. 3.30). 
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Pathological  Score Area interaction was not significant (F4,36 = 0.528, P = 0.71), post-hoc testing 
revealed some regional differences (Fig. 3.31). 
 
Fig. 3.30. neurexin-1 protein expression by pathological severity of disease. Key as 
for Fig. 3.12. 
 
Fig. 3.31. Pathological severity and -neurexin-1 protein expression by region. Key 
as for Fig. 3.12. There were no variations in expression with pathological severity in 
hippocampus. Newman-Keuls post-hoc testing showed significantly lower expression 
in samples with pathological score 2 than in those with scores of 1 or 3 in both 
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3.5 Discussion 
3.5.1 Neuroligin-1 expression in AD 
There is much evidence that alterations in synaptic protein expression could have an impact 
on synaptic loss (Masliah et al., 2001, Arendt, 2009). Various brain autopsy studies have found 
synaptic protein differences between AD cases and controls (Agarwal et al., 2008, Proctor et al., 
2010, Tannenberg et al., 2006). Data from this chapter showed that the overall level of neuroligin-1 
was significantly higher in AD tissue samples than in age- and sex-matched controls, which suggests 
there might be post-synaptic excitatory dysfunction. The level of neuroligin-1 in AD cases was 
significantly higher than in the relevant controls in both hippocampus and occipital cortex, which 
might indicate synaptic toxicity in these two areas. It was surprising not to see significantly higher 
levels in AD inferior temporal cortex, because it is one of the most affected areas in AD. 
Neuroligin-1 levels did not vary with pathological score significantly in any of the three 
areas. However, levels were slightly higher in PS2 samples than in PS1 samples in all three areas, 
and lower in PS3 samples that exhibit the final stage of the disease. The low level in PS3 samples 
could be due to the marked loss of synapses at this stage. Taken together, these results show that 
neuroligin-1 differences in AD vary with both brain region and disease progression, which is 
consistent with documented asynchronous changes in synaptic protein levels in AD (Agarwal et al., 
2008, Kirvell et al., 2006). 
We found that neuroligin-1 level varied regionally. The highest concentration was found in 
control inferior temporal cortex, which is consistent with previous reports of the levels of other 
synaptic proteins such as synaptophysin, dynamin I, N-cadherin, and CaMKII in this area 
(Tannenberg et al., 2006). A higher neuroligin-1 level was observed in female cases than in female 
controls, and levels in AD females were higher than those in AD males. This result suggests that the 
higher expression level of neuroligin-1 could be gender specific. It is noteworthy that the age-
adjusted incidence of AD is higher in females (Schmidt et al., 2008). 
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The overall higher level of neuroligin-1 in AD cases compared with age- and sex-matched 
controls could indicate a role for this protein in excitotoxicity. The -neurexin-1–neuroligin-1 
complex is a powerful inducer of post-synaptic differentiation of glutamatergic synapses in vitro. It 
induces accumulation of, and can bind to, two crucial components of the PSD — PSD-95 and 
NMDAR — at mature synapses. The NMDAR has a critical function in neural circuit development 
and synaptic plasticity (Barria and Malinow, 2002), and selective neuronal death in AD may depend 
primarily on NMDAR activation (Greenamyre and Young, 1989). The function of neuroligin-1 in 
maintaining NMDAR-mediated excitatory post-synaptic currents (EPSCs) could be due to the 
modification of post-synaptic NMDARs rather than alterations in pre-synaptic transmitter release, 
because neuroligin-1 is located at post-synaptic sites (Song et al., 1999). The higher neuroligin-1 
levels in AD cases shown in this study could lead to increased numbers of NMDARs at post-synaptic 
sites, which has been reported recently (Leuba et al., 2014). The higher levels of neuroligin-1 in AD 
cases than in controls, found here in some regions, may reflect higher PSD-95 concentrations in AD 
cases (Leuba et al., 2008a, 2008b, Rubenstein and Merzenich, 2003). 
The higher neuroligin-1 level in AD cases might reflect a reduced rate of proteolytic cleavage 
in the synapse. Most -secretase substrates such as amyloid precursor protein (APP), Notch, ErbB4, 
E-cadherin and ephrinB2 shed their extracellular domains to yield a membrane-tethered C-terminal 
fragment (CTF) and a soluble ectodomain (Beel and Sanders, 2008, De Strooper et al., 1999, Wolfe, 
2008). In addition, ADAM10 cleaves a number of -secretase substrates such as APP, cadherin, and 
Notch (Jorissen et al., 2010, Kuhn et al., 2010, Reiss et al., 2005). Both -secretase and ADAM10 
metalloproteinase regulate neural stem cell numbers by changing Notch signalling in the mature 
synapse (Jorissen et al., 2010). They also mediate the cleavage of several substrates in neurons to 
control synaptic function (Restituito et al., 2011, Rivera et al., 2010). Neuroligin-1 undergoes 
proteolytic processing in rat brain and mouse primary cortical neuronal cultures (Suzuki et al., 2012). 
ADAM10 removes the extracellular domain of neuroligin-1 and -secretase removes the intracellular 
domain from the remaining membrane-tethered fragment of the protein. Incubating cultures with 
NMDA or -neurexin-1 increases N-terminal fragment (NTF)-neuroligin-1 levels. Thus, neuroligin-
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1 cleavage can be controlled by neuronal activity or by binding with -neurexin-1, which offers a 
mechanism for the regulation of neuroligin-1 levels on the neuronal membrane (Peixoto et al., 2012, 
Suzuki et al., 2012). 
Acute neuroligin-1 cleavage destabilizes -neurexin-1 and depresses excitatory 
neurotransmission by reducing the probability of neurotransmitter release. Consequently, inhibiting 
neuroligin-1 cleavage may increase the probability of pre-synaptic release. Neuroligin-1 cleavage 
can alter glutamate transmission and have an impact on post-synaptic dendritic spines (Sindi et al., 
2014). Changes in proteolytic processing of neuroligin-1 might enhance pathophysiology and 
provide a link between neuroligin-1 levels and the PSD in AD cases (Welberg, 2012). In conclusion, 
this study suggests a possible role of neuroligin-1 in the pathogenesis of AD. Its increased level 
could contribute to the dysfunction of excitatory synapses in AD. 
Treatment of cultured cortical neuron with neuroligin-1 increases the number of excitatory 
synapses on GABAergic interneurons. These data suggest that neuroligin-1 enhances the formation 
of new synapse in developing neurons only (Ting et al., 2011). Neuroligin-1 also increases the size 
of excitatory synapse on GABAergic interneurons, which suggest it can strengthen existing synapses. 
Neuronal excitability depends on the balance of excitatory and inhibitory input signals, which is 
regulated by excitatory and inhibitory synaptic contacts. As a result, promoting the effect of 
neuroligin-1 on excitatory synapses can be essential to the role of GABAergic interneurons. The 
overall increase of neuroligin-1 protein observed in the current study could lead to increasing the 
number of excitatory synapses on GABAergic interneurons. 
Synaptophysin was measured in an earlier study from the lab (Tannenberg et al., 2006) and 
we have now compared neuroligin-1 and synaptophysin in the cases that are in common between the 
two studies. We aim to publish this new data soon. We found no difference in synaptophysin 
between AD cases and normal controls in any of the three brain areas studied. The concentration of 
neuroligin and synaptophysin is expressed in ng/µg of total synaptosomal protein in the nerve-
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endings that remain in the preparation. That is, it is a measure of the concentration of each protein 
per synaptosome, and thus should not be affected by atrophy or synapse loss. 
3.5.2 Neuroligin-2 expression in AD 
Neuroligin-2 is a synaptic cell adhesion protein specific for inhibitory synapses. In the current 
study, neuroligin-2 levels were significantly lower in AD cases than in matched controls, signifying 
either a decrease in the number of inhibitory synapses in total or in the density of neuroligin-2 
clusters within such synapses. Neuroligin-2 levels varied with brain region. The highest 
concentration was found in control inferior temporal cortex samples, which is consistent with 
previous reports that higher levels of synaptic proteins such as synaptophysin, dynamin I, N-
cadherin, and CaMKII are found in this region than in other brain regions (Tannenberg et al., 
2006). The level of neuroligin-2 in both the hippocampus and occipital cortex did not differ 
significantly between AD cases and controls. One the other hand, neuroligin-2 in the inferior 
temporal cortex, which is one of the most-affected areas in the AD brain, was significantly lower in 
AD cases than in controls. In occipital cortex and inferior temporal cortex, neuroligin-2 was higher at 
a moderate pathological severity, which indicates it is prone to AD damage. At the severe disease 
stage the level of neuroligin-2 protein in these areas was again lower, which is consistent with the 
marked synaptic loss seen at the final stage of the disease. 
It was very surprising to find no significant differences in neuroligin-2 protein expression in 
the highly affected hippocampus when a significant reduction in neuroligin-2 proteins was observed 
in the AD inferior temporal cortex. Neurodegeneration in AD progresses through the brain in a 
predictable, region-specific manner (Braak and Braak, 1991a). Given that the hippocampus is one of 
the first areas affected in AD and one of the most degenerated, and that the inferior temporal cortex 
is affected after the hippocampus, it would be expected that the inferior temporal cortex would not be 
as degenerated as the hippocampus. The finding reported here could be explained by a specific 
decline of neuroligin-2 protein in the inferior temporal cortex that does not occur in hippocampus. 
More study on the associations between excitatory and inhibitory synaptic proteins in AD may 
provide an explanation of this conundrum with respect to excitotoxicity in AD. 
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The AD-specific paucity of neuroligin-2 was more noticeable in male than in female cases, 
and this underpinned the overall lower neuroligin-2 level in AD cases. Because AD has a higher 
incidence in females than males, the greater lack of neuroligin-2 in male cases appears contradictory. 
It could be explained by the younger average age at death in males than in females in this study, and 
hence the earlier age of disease onset, which would suggest a greater disease severity. Females died 
at a higher mean age, and may have had less-severe disease on average. However, the case numbers 
were limited in this study and it will be better to study more cases to obtain a more conclusive result. 
Neuroligin-2 is crucial for post-synaptic inhibitory function. Data from the current study is 
consistent with a report that deletion of neuroligin-2 impairs inhibitory synapse function as measured 
by evoked synaptic transmission (Chubykin et al., 2007). The paucity of neuroligin-2 in AD cases 
may portray a dysfunction in GABAergic transmission, and is in conformity to a previous report that 
NLGN2 knockout mice have decreased GABAergic transmission (Blundell et al., 2009). The role of 
neuroligin-2 in regulating GABAergic function is further illustrated by a loss-of-function mutation of 
this protein in patients with schizophrenia (Sun et al., 2011). 
3.5.3 -Neurexin-1 expression in AD 
-Neurexin-1 has not been previously quantified in AD cases and controls, and it was 
surprising to find that the level of -neurexin-1 was higher, although not significantly, in AD cases 
than in controls in all three brain regions. This higher level of -neurexin-1 is compatible with a 
previous study that quantified another pre-synaptic cell adhesion molecule, N-Cadherin, in AD cases 
and controls (Tannenberg et al., 2006). The higher levels of -neurexin-1 in AD cases derive from 
the increase in synaptic apposition length that occurs in AD (Scheff et al., 1990). Further work with a 
larger number of cases and controls is required to confirm this. 
The highest level of -neurexin-1 was observed in the inferior temporal cortex, which is 
compatible with previous findings of high synaptic protein abundance in this area. The lowest level 
of -neurexin-1 was observed in the occipital cortex. -Neurexin-1 protein level was found to be 
modulated by the pathology severity of disease. It was lower in all three regions at the moderate 
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severity stage and higher again at the severe stage. This increase in the final stage of AD may be 
triggered by a compensatory mechanism to offset some of the excitotoxic damage. 
This study was the first to examine neuroligin-1, neuroligin-2 and -neurexin-1 in subjects 
with AD. Overall, the data presented suggest a selective synaptic dysfunction in AD. The quantities 
of these synaptic proteins differed in AD in a regionally selective manner. 
The neuropathology of the AD cases used showed a contrasting result in the levels of 
neuroligin-1 and neuroligin-2 proteins, which are specific for glutamatergic and GABAergic 
synapses respectively. Both neuroligin-1 and -neurexin-1 levels were higher in AD cases than in 
controls. Variations in the levels of neuroligins and neurexins could sway the balance between 
excitatory and inhibitory neurotransmissions in the brain, and could lead to damage of synapses and 
dendrites and ultimately to the neuronal death seen in AD. 
3.5.4 APOE genotype and protein expression 
It was surprising to find a significant enhancement of neuroligin-1 levels in cases without an 
APOE 4 allele in the current study. The level of neuroligin-2 did not significantly differ between in 
AD APOE 4 carriers and AD cases without an APOE 4 allele. On the other hand, -neurexin-1 was 
higher in APOE 4 carriers than in AD 4 non-carriers. It must be emphasized that this analysis was 
badly underpowered because there were so few AD cases without an APOE 4 allele and because of 
the overall lack of representation of sufficient numbers of subjects in each allelic category; further 
work on this issue will require a much larger data set. APOE has an important function in 
synaptogenesis, and both APOE 2 and APOE 3 alleles, particularly the former, are protective 
against AD (Rebeck et al., 2002), while APOE 4 increases the risk of AD (Liu et al., 2013). 
Hemizygous and homozygous APOE 3 transgenic mice are protected against neurodegeneration 
compared with homozygous APOE 4 littermates (Buttini et al., 2000). As a consequence, AD cases 
with at least one 4 allele are likely to be more vulnerable to neurodegeneration than AD cases with 
2 or 3 alleles. There were no AD cases with an 2 allele in this study, and very few in the 
Queensland Brain Bank. 
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3.5.5 Limitations of the study 
Neuroligin-1, neuroligin-2 and -neurexin-1 proteins were quantified in AD cases and 
controls matched as closely as possible for age, gender, and post-mortem delay. Nevertheless, some 
data, such as medical history, environmental context, and family history, were missing for some AD 
cases and controls. Environmental factors such as smoking and alcohol dependence can have an 
impact on protein expression in the central nervous system. A meta-analysis of 43 studies showed 
that cigarette smoking significantly increases the risks dementia and cognitive decline (Anstey et al., 
2007). Another study showed a significant association of the NRXN1 gene with nicotine dependence 
in European- and African-American smokers, and indicated that smoking has an impact on neurexin 
levels (Nussbaum et al., 2008). Alcohol use reportedly increases the risk of AD (Piazza-Gardner et 
al., 2013) and influences synaptic protein expression in human subjects (Matsuda-Matsumoto et al., 
2007). Neurexin-3 polymorphisms are reportedly associated with alcohol dependence and altered 
expression of specific isoforms of the protein (Hishimoto et al., 2007). 
A limitation of the current study was the small number of samples with varying degrees of 
pathological severity in the three brain regions. Increasing the number of cases and controls can 
strengthen the study and enhance statistical power. Additional time and effort to extend the study 
would help in replicating the work for validation purposes. 
Some limitations are associated with the quantification of proteins by immunodetection. 
These include incomplete protein transfer from the gel to the membrane; different post-translational 
modifications might alter the efficiency of transfer. Non-specific binding of some antibodies can 
vary between the standard and the endogenous protein. Quantification of proteins by mass 
spectrometer-based assays will aid validation and help determine whether different post-translational 
modifications occur in the neuroligins and neurexins. Therefore, more time and effort should be put 
into the quantification of these molecules by the multiple reaction monitoring and SWATH 
techniques described in chapter 4. 
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Advanced imaging techniques such as FDG-PET can hopefully give new insights into disease 
progression in living subjects, based on the current study. However, at present, PET ligands are not 
available for the neuroligins and neurexins, and it is hard to get resolution down to the level of the 
nerve ending with current clinical scanner technology, but the data presented in this thesis may 
suggest that higher numbers of excitatory synapses will be found in pathologically affected areas of 
the AD brain when the new 7T instruments become available for clinical use. 
The approach to quantification used here is expensive, low-throughput, and time-consuming, 
and required the generation of critical recombinant reagents. The three proteins were identified in 
human brain membrane preparations at ~110 kDa for neuroligin-1, ~95 kDa for neuroligin-2 and ~46 
kDa for -neurexin-1. These predicted molecular weights were obtained from UniProt and it was 
assumed that each antibody used was specific only for the protein of interest and did not cross-react 
with any other protein. This should be verified independently, for example by the techniques set out 
in Chapter 4. The need for high-throughput techniques to explore several of the interesting 
preliminary results outlined in this Chapter was another motivation that led to the Chapter 4 study. 
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Chapter 4 
4 Quantification of neuroligin and neurexin proteins by MRM and SWATH 
4.1 Aims of the research 
1. To identify synaptic proteins in human autopsy brain tissues by mass spectrometry. 
2. To search for neuroligin-1, neuroligin-2, neuroligin-3, neuroligin-4 and neuroligin-4Y 
proteins in human autopsy brain tissue by mass spectrometry. 
3. To search for neurexin-1 and neurexin-1 in human autopsy brain tissue by mass 
spectrometry. 
4. To quantify neuroligins and neurexins with multiple reaction monitoring (MRM) and 
SWATH techniques. 
4.2 Introduction 
A range of experimental approaches is required to assess synaptic processes and their 
adaptive alterations, which are highly ordered and complex (Bard and Groc, 2011, Coba et al., 2009). 
Neuropathological diseases show characteristic molecular changes, with diverse ætiologies, that are 
mainly located at the synapse (Dosemeci et al., 2007, Fernandez et al., 2009, Husi et al., 2000). 
Studying the protein configuration of the synapse in autopsy brain tissues may provide useful 
insights into various diseases (Keller et al., 2007). Molecular and cellular studies of these processes 
have until recently been restricted to techniques that can study one molecule at a time within a 
network. Research into proteins in autopsy tissue is limited by the lack of good paradigms; it is 
essential to develop methods to quantify proteins and their post-translational modifications at the 
synapse as well as to develop strategies to validate the quantification of these entities. 
During the last decade, mass spectrometry (MS)-based proteomic techniques, and 
biochemical fractionation techniques, has allowed researchers to begin investigating the proteomes 
underlying synaptic signalling (Bayes et al., 2011, Cheng et al., 2006, Hahn, 2010, Peng et al., 2004). 
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Many proteins and post-translational modifications can be studied simultaneously, which allows 
investigation of signalling pathways in the context of various other intracellular molecular events. 
4.2.1 Mass spectrometry based techniques 
Protein analysis using MS first requires separating the proteins into fractions using methods 
such as electrophoresis and chromatography (Woods et al., 2012). After fractionation, each protein is 
analysed by MS. The initial fractionation before analysis is important to enhance sensitivity and to 
identify and characterise low-abundance proteins that may be masked in complex mixtures. 
However, some samples can be run in MS without fractionation. 
There are three main parts in a mass spectrometer: the ionization source, the mass analyser, 
and the detector. An ionization source ionizes the peptides in the sample, which then travel through 
the analyser according to their mass:charge (m/z) ratios. The ionized sample then hits the detector 
and spectra are recorded: the spectra are used to identify the proteins (Fig. 4.1) 
 
Fig. 4.1 Example of basic mass spectrometer experiment. The sample is fractionated 
by electrophoresis or HPLC and then digested by an enzyme such as trypsin. The 
digest is ionized in a MALDI-MS or ESI-MS. The ions fly and are sorted through 
different types of mass analysers. The ions are detected and then recorded and a mass 
spectrum is produced. 
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4.2.1.1 Ionization techniques 
Ionization techniques convert uncharged molecules into ions that can then be manipulated in 
electric or magnetic ﬁelds. The most important issue with biological molecules like peptides and 
proteins is to convert polar, zwitterionic molecules into gas-phase ions without degradation. The 
most common ionization methods for biological samples are electrospray ionization (ESI) and 
matrix-assisted laser desorption/ionization (MALDI). 
4.2.1.1.1 Electrospray ionization 
ESI generates ions by spraying an electrically generated ﬁne mist of ions into the inlet of a 
mass spectrometer at atmospheric pressure (Fenn et al., 1989). Ionization is generated from the 
potential difference between the capillary inlets to the mass spectrometer in which the liquid ﬂows 
and small droplets of liquid are formed. The liquid is translocated to a heating device that causes 
evaporation of the solvent. When the droplets reach the point at which charge repulsion exceeds the 
surface tension, ions are desorbed from the droplet to create bare ions, which are then transferred to 
the ion optics of the mass spectrometer. ESI transforms solution-phase molecules into gas-phase 
ions; the ions are created with different charges, which complicates the calculation of molecular 
weight due to a one-to-one association between the m/z value and molecular weight. Multiple 
charging has the advantage of lowering the m/z value detected in the spectrometer, which allows the 
use of less-sophisticated mass analysers. 
4.2.1.1.2  MALDI 
The second ionisation technique, MALDI, uses laser energy to alter molecules into gas-
phase ions. A matrix is mixed with the sample that absorbs the energy of the laser and is used to 
support thermal desorption. 
4.2.1.2 Mass analyser 
The different types of analysers include quadruple (Q), time-of-flight (TOF), and ion trap 
(IT), which have different applications. They differ in their physical principles and analytical 
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performance. MALDI sources are generally coupled with TOF or TOF/TOF mass analysers because 
of their pulse mode of action. Shotgun proteomics liquid chromatography (LC) is associated with 
mass spectrometry for the identification of proteins. The main advantage of LC-MALDI-MS over 
LC-ESI-MS is the robustness of the former in resisting very harsh LC conditions and the high m/z 
range of the TOF mass analyser (Ngounou Wetie et al., 2013, Sokolowska et al., 2013). The 
limitations of LC-MALDI-MS include the difficulty in spotting directly from the LC apparatus. In 
MS, proteins can be recognized by measuring the m/z of gas-phase ions. In general, LC-MS methods 
are valued for their capability to examine complex samples and difficult proteins, such as those 
embedded in membranes, and as a result offer better proteome coverage in comparison to other 
proteomic techniques. 
4.2.1.3 Sample preparation, fractionation, and tags 
Protein quantification is ideally carried out with internal standards that are added to the 
sample before preparation to eliminate differences resulting from the preparation itself. Both label-
based and label-free methods can be used (Gant-Branum et al., 2009). Label-based methods tag 
peptides or proteins before LC separation utilizing one of the three following techniques: 1, isobaric 
tags for relative or absolute quantification, iTRAQ (Applied Biosystems, AB Sciex, Foster City, CA, 
USA; Ross et al., 2004); 2, isotope-coded affinity tags, ICAT (Gygi et al., 1999); and 3, stable 
isotope labelling of amino acids in cell culture, SILAC (Darie et al., 2011, Mann, 2006, Spellman et 
al., 2008). The isotopic labelling approach has some disadvantages due to their elaborate chemistry. 
However, there are several label-free methods, such as multiple reaction monitoring, MRM, and 
sequential window acquisition of all theoretical fragment-ion spectra, SWATH, which have various 
advantages and will be discussed in detail in this chapter. 
4.2.1.4 Proteomic bioinformatics 
Computer processing of MS data allows large-scale and high-throughput analysis that has 
enabled proteomic studies. Different strategies have been established to find unique tandem mass 
spectra of amino acid sequences in publically available databases. All database methods are based on 
matching the theoretical fragmentation pattern of the target peptide with the fragmentation pattern in 
P a g e  | 95 
the tandem mass spectrum. Each match peptide is given a score based on fragment ion frequencies, 
and cross-correlation (Eng et al., 1994, Perkins et al., 1999). Intensity models are used in correlation 
analyses to increase the matches between sequence and spectra, while probability-based methods 
offer a statistical measure for the ﬁt between sequence and spectra (MacCoss et al., 2002, Perkins et 
al., 1999, Sadygov and Yates, 2003). Most of these programs are also appropriate for the study of 
protein modiﬁcations. There are various software packages for the analysis of LC/LC/MS/MS data, 
such as Mascot, PEAKS DP, ProteinPilot, and others. Proteomic studies can produce huge amounts 
of data; hence, a high level of automation of data analysis is required. 
4.2.2 Multiple reaction monitoring (MRM) 
MRM is an MS-based quantification method that is commonly used in triple-quadruple MS 
instruments. It is a robust multiplexed assay for the precise and sensitive detection of protein 
expression levels and post-translational protein modifications (Lange et al., 2008). It is used to 
identify and quantify from ten to a few hundred peptides, but can in principle be used for multiple 
peptides in a single assay. MRM assays can detect and quantify proteins present at low ng per ml 
concentrations, such as has been shown for serum (Keshishian et al., 2007, 2009). MRM also has the 
advantage of high reproducibility (Addona et al., 2009), which makes it a ﬁrst choice for biomarker 
validation. It exploits the unique capabilities of triple-quadrupole (QQQ) MS for quantitative 
analysis. It is a selective workﬂow for mass spectrometry that can only identify a predeﬁned 
combination of precursor and fragment ions. In MRM, the ﬁrst and the third quadruples act as ﬁlters 
to speciﬁcally select predeﬁned m/z values corresponding to the target peptide ion and a speciﬁc 
fragment ion of the precursor peptide (Fig. 4.2). In the second quadruple, which serves as a collision 
cell, the pre-deﬁned peptides in Q1 are selected and fragmented. In quadruple three, transitions 
(precursor/fragment ion pairs) are monitored over time to produce a set of chromatographic traces 
with the retention time and signal intensity for each speciﬁc transition. Two types of mass selection 
with narrow mass windows lead to high selectivity and the successful ﬁltering out of co-eluting 
background ions. Compared to other MS-based proteomic techniques, no full mass spectra are 
recorded in QQQ-based MRM analysis. The non-scanning property of this mode of operation 
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translates into an enlarged sensitivity by one or two orders of magnitude compared with-full scan 
techniques. Furthermore, it gives a linear response over a wide dynamic range of up to ﬁve orders of 
magnitude, which allows the detection of scarce proteins in highly complex mixtures: this is vital for 
systematic quantitative studies. 
 
Fig. 4.2. Diagram of information-dependent analysis (IDA) mass spectrometry and 
MRM mass spectrometry. In IDA, quadruple 1 (Q1) is used to select the most 
abundant precursor ion, which is then fragmented in Q2. Subsequent analysis of all 
fragment ions takes place in Q3. The resulting MS/MS spectrum is used to identify 
the fragmented precursor ions. In MRM, only pre-deﬁned peptides in Q1 are chosen 
for fragmentation in Q2. Pre-selected fragment ions are selectively passed through Q3 
and identified. 
4.2.2.1 Selection of a target protein in MRM 
The ﬁrst step in an MRM assay involves choosing the proteins of interest. MRM can target 
different proteins in one LC-MS analysis after the transitions have been optimized. Choosing the 
protein of interest may depend on previous experiments or relevant information from the literature. 
Different information resources on the Web can be used for this purpose, such as gene expression 
and protein expression data, protein–protein interaction data or the Kyoto Encyclopædia of Genes 
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and Genomes (KEGG) database. Network expansion can be used to enhance an initial set of proteins 
that have been revealed in quantitative screens (Table.4.1). Ideally, internal standards are chosen as 
an invariant reference set to minimize experimental error, such as variable protein amounts per 
sample. 
 Table 4.1. Online information resources relevant to the selection of a set of proteins of interest.  
Gene Expression  GEO http://www.ncbi.nlm.nih.gov/geo/ (Barrett et al., 2007) 
Protein expression ProteinAtlas http://www.proteinatlas.org/  (Uhlén and Pontén, 2005) 
Gene ontology group GO http://www.geneontology.org/  (Karp, 2000) 
Functional group  KEGG http://www.genome.jp/kegg/  (Kanehisa and Goto, 2000) 
Protein-protein interactions IntAct http://www.ebi.ac.uk/intact/  (Kerrien et al., 2007) 
Protein-protein interactions MINT http://mint.bio.uniroma2.it/  (Ferrari et al., 2011) 
4.2.2.2 Selection of the peptide 
After tryptic digestion, each protein produces tens to hundreds of peptides (Picotti et al., 
2007). However, only a few representative peptides for each protein are targeted to identify and 
quantify it in a sample. The right choice of peptides is crucial for the success of MRM. Different 
factors have an impact in choosing the right peptide, such as uniqueness and post-translational 
modiﬁcation. 
4.2.2.3 Uniqueness 
Choosing peptides for targeted MS analysis is crucial. It is important to select unique 
peptides that are specific for the targeted protein or one of its isoforms. Thus, it is critical to choose 
peptides that differentiate between different splice isoforms. Information about splice variants can be 
obtained from Ensembl (www.ensembl.org/), NCBI (www.ncbi.nlm.nih.gov/sites/entrez, 
www.ncbi.nlm.nih.gov/projects/SNP/), and UniProt (http://www.uniprot.org/) databases. Peptide 
Atlas (www.Peptide Atlas.org/) can differentiate between several splice isoforms and different genes 
by reporting the number of genome locations for observed peptides and visualizing the peptide–
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protein relationship by cytoscape, an open source bioinformatics software platform for visualizing 
molecular interaction networks and integrating them with gene expression profiles (Shannon et al., 
2003). 
4.2.2.4 Post-translational modiﬁcations 
In the MRM assay, modiﬁed peptides cannot be identified without being speciﬁcally targeted 
due to mass differences caused by post-translation modifications (PTMs). Observed differences in 
the quantity of a peptide may portray alterations in the abundance of the protein across samples, or 
modiﬁcation of the target peptide. For accurate quantiﬁcation, at least two peptides should be 
monitored for each protein. It is essential to first consult sites such as Uniprot 
(http://www.uniprot.org/) to check that the targeted peptides are not known to be modified, and to 
avoid peptides with cysteine or methionine residues. Post-translation modification may lead to two 
peptides from the same protein displaying different relative abundances across samples. However, 
MRM can be used to quantify peptides with post-translational modiﬁcations if the PTM is known 
and transitions for those peptides can be established. Examples of different types of PTM that have 
been targeted by MRM in other studies include phosphorylation (Unwin et al., 2005, Williamson et 
al., 2006), ubiquitination (Mollah et al., 2007) and acetylation (Griffiths et al., 2007). 
4.2.2.5 Selection of MRM transitions 
In MRM, quantiﬁcation of a peptide needs specific choices of m/z settings for the ﬁrst and 
third quadruple to provide highly sensitive and selective detection of the peptide. The mass and 
predominant charge state of the peptide determines the m/z value used in the ﬁrst quadrupole, while a 
specific fragment ion of the peptide is selected in the third quadrupole. The intensities of individual 
fragment ions resulting from one precursor ion can differ significantly. To attain very sensitive 
results it is best to choose transitions speciﬁc for the most intense fragments. Usually the best 2–4 
transitions for each peptide are chosen for quantitative assays. These choices may be based on data 
from shotgun experiments, which can be obtained from SRMAtlas or Peptide Atlas, or 
experimentally detected on the QQQ instrument. The condition of ionization can have an impact on 
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the charge state distribution as well as the intensity of the ion, which is dependent on the type of 
instrument used and the operating parameters. 
The fragment ion masses of the peptide of interest can be calculated and experimentally 
verified by MRM assay on a QQQ instrument that produces high-performing transitions. If two 
precursor charge states and multiple ions are considered, more than 30 transitions for each peptide 
could be measured. As a result, the number of peptides that can be examined in one LC-MS analysis 
is restricted due to the time required to acquire the data representing each transition. The number of 
transitions monitored can be increased by using scheduled MRM (Stahl-Zeng et al., 2007). The 
principle of this approach is to acquire the transitions of a speciﬁc peptide during a narrow time 
window around its expected elution time, rather than monitoring it across the entire LC-MS run. 
During this time more transitions can be examined so as to obtain the best-performing ones. To 
conduct this type of experiment, the instrument must have a scheduling functionality and the 
retention times of the peptides of interest must be known. The retention times of specific transitions 
can be obtained from previous experiments or predicted by tools such as SSRCalc 
(http://hs2.proteome.ca/SSRCalc/SSRCalc.html; Krokhin et al., 2004), although in most cases RT are 
empirically determined. Another approach is to first study a small number of transitions that are 
chosen based on available MS/MS data. Choosing 2–4 fragment ions from both doubly and triply 
charged precursor ions will produce at least one transition with reasonable performance from which 
to derive retention-time data for subsequent experiments. Restricting the ﬁnal assay to 2–4 transitions 
for each peptide allows the study of many hundred peptides in one LC-MS analysis. 
4.2.2.6 Validation of transitions 
The QQQ MRM assay is a very specific approach using two consecutive mass ﬁltering steps. 
However, an individual precursor/fragment ion combination may not be speciﬁc for a peptide 
targeted in a complex sample. An example of this problem is explained in Fig. 4.3. Incorrect signals 
can develop from other peptides with precursor/fragment ion pairs of identical masses. Peptides with 
the same precursor mass and fragment ion could have closely related sequences and as a result part 
of the transitions may be identical. Distinct sequences could by chance produce mass pairs that are 
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very hard to ﬁlter out in the quadrupoles; this nonspecific signal may be of lower intensity than the 
optimized transitions. When MRM is used to study peptides that are an order of magnitude of less 
abundant than the most abundant peptides, non-speciﬁc signals can be higher than the detection limit 
and sometimes more intense than the signal for the peptide of interest. Because there are no full-
range mass spectra in MRM, signals could be easily mistaken; these would give rise to mis-
quantiﬁcation errors. In consequence, it is essential to validate the primary set of transitions to 
confirm that the quantiﬁed signals produced are from the peptide of interest. Two ways to validate 
the transition are 1, scanning the full MS/MS of the precursor ion to sequence the peptide: the scan 
can be manually checked to confirm that the fragment ions that were selected are the most abundant 
following collision-induced dissociation, CID; 2, parallel acquisition of multiple transitions for a 
targeted peptide. The latter is based on the elution time of peptide: The transitions produce a perfect 
set of ‘co-eluting’ intensity peaks if they are produced from the same peptide. By producing more 
transitions, the capability for a random match is markedly reduced if perfect co-elution is observed. 
Many non-target peptides with similar precursor m/z could produce a plethora of low-intensity non-
canonical fragment ions, which might generate transitions and lead to false quantification. It is 
strongly recommended that parallel acquisition of multiple transitions be checked by another kind of 
validation. The best approach to validate transitions is to acquire MS/MS spectra and sequence it 
from database searching to assure that the derived signals produced are from the peptide of interest. 
This process uses the QQQ tool for the MRM experiment under a protocol known as MRM-triggered 
MS/MS scanning (Unwin et al., 2005). In this procedure, the QQQ instrument is programmed to 
obtain a full fragmentation spectrum whenever a signal for a particular transition is identified. The 
MS/MS spectra produced can be compared with the predicted peptide fragments to confirm that the 
major MS/MS peaks are matched (Figure 4.3). This method provides assurance that the MRM 
signals are derived from the target peptide. 
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Fig. 4.3. Validation of transitions for the peptide VFAQFSSFVDSVIAK, which 
belongs to a protein of interest. A, MRM traces of ﬁve transitions. Two peaks with co-
eluting transitions are apparent at 37.5 and 43.3 min. B, MS/MS spectra of peaks 1, 
top panel and 2, lower panel. Peaks corresponding to the y ions are in red. Although 
MRM transition intensities are higher at 43.3 min, the MS/MS spectrum that 
corresponds to the targeted peptide elutes at 37.5min. If transition intensities at 43.3 
min were used without validation the quantiﬁcation of the peptide would be in error. 
4.2.2.7 MRM software 
There are differences between MRM assays and shotgun proteomic experiments. In shotgun 
experiments, proteins are identified in samples without targeting, based on matching MS/MS spectra 
to databases, while in MRM experiments a software system allows MRM assays to be set up and 
supports the following: 1, choosing the target protein; 2, choosing the peptide signifying the protein 
of interest; 3, choosing the best transitions; and (4) validating the transitions by MS/MS spectra. 
An example of MRM software is Targeted Identiﬁcation for Quantitative Analysis of MRM 
(TIQAM; Lange et al., 2008), which can integrate proteomic data from local experiments and the 
Peptide Atlas database to produce peptides in the best order. It can also generate MRM transition 
lists and detect the best performing transitions from previous MRM experiments. All the peptide and 
transition data is kept in a database to permit recovery of the validated transitions for quantitative 
purpose. There are several other software programs that can help set up MRM experiments, such as 
MRMPilot (Applied Biosystems), SRM Workﬂow Software (Thermo Scientiﬁc), Verify E (Waters), 
Optimizer (Agilent Technologies) and Skyline (MacCoss lab software). 
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 is a novel MS-based proteomics technique to quantify peptides 
and proteins in a sample by a single analysis. It utilizes a data-independent MS/MS acquisition to 
produce complete, high-specificity fragment ion maps that can be queried for the existence and 
quantity of any protein of interest using a targeted data analysis strategy. It utilizes an advanced 
hybrid quadrupole-time of flight mass spectrometer, the TripleTOF 5600® (AB SCIEX, 
Framingham, MA, USA). 
SWATH produces fragment ion information for all precursors in the monitored range. It 
differs from the traditional acquisition assay, which does not depend on precursor ion mass detection 
to trigger MS/MS acquisition. Rather, SWATH systematically fragments all components of a sample 
via a rapidly moving selection window (Fig. 4.4). 
SWATH can produce high-resolution fragment ion chromatograms for each target peptide 
that can be interrogated to detect the peptide of interest, similar to MRM. Using public libraries for 
ion data such as MRMAtlas, or database search software such as ProteinPilot
TM
, the ouput can be 
searched for quantitative data on the target peptides or proteins. SWATH delivers a complete 
qualitative and quantitative archive of the sample that can be interrogated in silico and post-
acquisition as new hypotheses are established. 
MRM and SWATH have become important techniques to study synaptic trafficking events in 
autopsy brain tissue and thereby to explore the ætiology of neural diseases (Craft et al., 2013). 
Neuropsychiatric diseases may result from aberrant synaptic signalling involving different proteins 
that are arrayed in a microdomain-specific manner. Studying the proteomes of synapses in autopsy 
brain will provide an understanding of disorders such as autism, depression, schizophrenia, and AD. 
It will help define targets for novel therapeutics for these disorders. It will allow the assessment of 
protein expression and trafficking with high precision using accurate techniques such as MRM and 
SWATH. Previous studies have successfully utilized MRM to quantify synaptic proteins in 
subcellular fractions prepared from autopsy human brain (Chang et al., 2014a, 2014b). A 
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bioinformatics search showed that these assays can quantify thousands of additional synaptic 
proteins in different model systems. 
 
Fig. 4.4. MS/MS ALL with SWATH Acquisition. The method depends on passing a 
wider window of analytes to the collision cell. More-complex MS/MS spectra are 
produced, which comprise all the analytes within the Q1 m/z window selected. As the 
fragment ions are high resolution, high quality XICs are produce post-acquisition to 
generate data similar to MRM. The Q1 window can be stepped across the mass range, 
collecting full-scan composite MS/MS spectra at each step, with an LC-compatible 
cycle time. This approach allows a data-independent LC workflow. 
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In this chapter, the development of a LC-MRM/MS-based methodology for validation of 
neuroligin-1, neuroligin-2 and -neurexin-1 protein quantification in human autopsy brain tissues 
from AD cases and controls is described. Various optimizations were performed for SWATH to 
obtain the most accurate quantification protocols. 
4.3 Materials and Methods 
4.3.1 Reagents used 
Deoxycholate, trichloroacetic acid, sucrose, acetonitrile, acetone, urea, thiourea, ammonium 
bicarbonate, dithiothreitol, iodoacetamide, trypsin, and formic acid were obtained from standard 
suppliers and were of the highest grades available. The 2-D Quant kit was purchased from GE 
Healthcare Life Sciences, Rydalmere, NSW, Australia. 
4.3.2 Autopsy brain tissue preparation 
The Queensland Brain Bank at the School of Chemistry and Molecular Biosciences, The 
University of Queensland, a node of the Australian Brain Bank Network, provided autopsy brain 
tissue. Donors and the next of kin provided informed written consent for the research. Tissues were 
stored in ice-cold 0.32M sucrose at –80°C. The Medical Research Ethics Committee of The 
University of Queensland approved the project (Certificate #2010000105). 
Sectioning of the tissue was done on dry ice and preparation of the synaptosomes was 
performed as per Etheridge et al. (2009). To prepare the synaptosomes, 0.5 g tissue samples were 
homogenized with ice-cold 0.32 M sucrose (10 w/v) in a motor-driven Teflon-glass homogenizer 
using 8–10 pestle strokes. The mixture was transferred to a 15 ml polypropylene tube and 
centrifuged at 750  g for 10 min at 4°C in a Beckman JA 20 centrifuge (Beckman Coulter P/L, Lane 
Cove, NSW, Australia). The pellet was resuspended in the original volume of 0.32 M sucrose and 
centrifuged at 19,000  g for 20 min at 4°C. The pellet, which contained the crude synaptosomal 
fraction, was resuspended in a 5 ml 0.32 M sucrose, layered onto a gradient of 5 ml of 0.8 M sucrose 
overlying 5 ml of 1.2 M sucrose, and centrifuged at 82,500  g in a swinging bucket rotor (SW41 Ti, 
Beckman L8-60M ultracentrifuge) for 120 min at 4°C. Both myelin (at the 0.32/0.8 M interface) and 
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synaptosome (at the 0.8/1.2M interface) fractions were obtained by aspiration with a Pasteur pipette 
in minimal volumes. Mitochondria formed a pellet that was also retained for future studies. 
4.3.3 Trichloroacetic acid/deoxycholate/acetone precipitation 
Deoxycholate (DOC; 0.4 µg/µl, 20 µl) was added to each synaptosomal fraction (200 µl) to 
give a final concentration of ~0.04 µg/µl. The sample was incubated on ice for 30 min, then 25 µl of 
6.4 M trichloroacetic acid (TCA; 0.65 M final) was added and the sample incubated on ice for 60 
min. Samples were centrifuged at 10,000  g at room temperature for 10 min. The supernatants were 
removed and 1 ml of 90% ice-cold acetone was added to each tube. Samples were vortexed for 3–4s, 
left at –20°C overnight, then centrifuged at 10,000  g at 4°C for 20 min and supernatants removed. 
A second 1 ml of 90% ice-cold acetone was added to each tube, the procedure repeated, and the 
supernatants discarded. The pellets were dried for 5 min and 30 µl of rehydration buffer (8M urea 
and 2M thiourea in 50 mM NH4HCO3) was added. The tubes were incubated for 3h at room 
temperature, then stored overnight at –20°C. Samples were sonicated 3 briefly in an ice bath for 20s 
and frozen overnight at –20°C. This step was repeated three times to allow ice crystals to break up 
the pellets. 
4.3.4 Quantification of samples using the 2-D Quant Kit 
To determine the protein concentration of the samples, a 2-D Quant Kit (GE Healthcare Life 
Science) was used. Colour reagent A (5.15 ml) was mixed with colour reagent B (51.5 µl). A BSA 
standard was prepared between 0 and 4 µg. Each protein sample (2 µl) was placed in a separate tube 
and 100 µl of precipitant was added, including to the BSA standard samples. Tubes were vortexed 
and incubated for 2–3 min at room temperature. Co-precipitant (100 µl) was added and the samples 
mixed by inversion, then centrifuged at 10,000  g for 5 min and the supernatant discarded. Copper 
solution (20 µl) and of Milli QH2O (80 µl) were added and the tube vortexed briefly. Samples were 
aliquoted into a 96-well plate and 200 µl of assay mix (colour reagents A+B) added to each well. The 
plate was incubated for 20 min at room temperature. The absorbance of each sample and standard 
was read at 480 nm and a standard curve created to determine the sample protein concentrations. 
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4.3.5 Reduction and alkylation 
d,l-Dithiothreitol (30 µl of 10 mM; 5 mM final) was added to each sample (30 µl) and the 
mixture incubated at room temperature for 2h. Iodoacetamide (3 µl of 0.5 M; 25 mM final) was 
added and the incubation continued in the dark for 30 min. Finally, an additional 30 µl of 10 mM d,l-
dithiothreitol was added to each sample. 
4.3.6 Trypsin digestion 
Samples were diluted to 2 M in urea with 50 mM NH4HCO3 (26.8 µl). Each sample (76 µg; 
0.63 µg/µl) was then digested with trypsin (15µl, 20 ng/µl) by incubation for 6h at room temperature. 
The same amount of trypsin was added and the incubation continued overnight at 37°C. 
4.3.7 ZipTip sample cleanup 
Samples (10 µl) were aliquoted into Eppendorf tubes and subjected to ZipTip purification 
(Merck Millipore, Kilsyth, VIC, Australia) for sample binding. The ZipTip was washed with 100% 
acetonitrile twice, then equilibrated with 1% trifluoroacetic acid (TFA) twice. Samples (10 µg) of 
peptide digests were bound to the tip by fully depressing the pipette, then aspirated and dispensed 
through 10 cycles for maximum binding of the mixture. The Zip Tips samples were washed with 1% 
TFA twice, then 4 µl of 0.1%TFA in 80% acetonitrile was used to elute the peptides from the tips. 
Buffer B (0.1% formic acid in acetonitrile; 96 µl) was added and the samples placed in mass 
spectrometer tubes. 
4.3.8 Preparation of HPLC-QTRAP 5500 mass spectrometer for MRM analysis 
Chromatography was performed using an 1100/1200 capillary LC (Agilent Technologies, 
Mulgrave, Vic, Australia) with the following buffers: Buffer A (5% acetonitrile, 0.1 % formic acid) 
and Buffer B (0.1% formic acid in acetonitrile). Samples (20 µl) were loaded onto the column trap 
(ZORBAX 300SB-C18, 5  0.3 mm, 5 µm; Agilent Technologies) and washed for 5 min with Buffer 
A delivered at a flow rate of 20 µl/min. A QTRAP 5500 mass spectrometer (AB SCIEX) with a 
TurboSpray ion source in positive ion mode was used to detect the peptides. The settings for the ion 
source were: declustering potential 80V, entrance potential 10V, collision cell exit potential 35V, 
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curtain gas 20 psi, collision gas ‘high’, ionspray voltage 4kV, temperature 150°C, with first and 
second ion source gases set at 20 psi. 
4.3.8.1 Choosing the protein of interest, peptide and transitions 
Targeted protein accession numbers were input to the MRMPilot software, which were: 
neuroligin-1, NP_055747, neuroligin-2, AAM46111) and -neurexin-1, BAA87821.1. Multiple 
tryptic peptides were obtained and the best peptide sequences that had lengths of 4–22 amino acids 
and were free of any known chemical and/or post-translational modifications were chosen. Peptides 
with methionine or cysteine residues were deselected because they are prone to modification 
(oxidation and alkylation, respectively). The best peptides were utilized for automated MRM 
selection and method building. For each peptide at least four MRM transitions were selected. 
4.3.8.2 Verification of peptide selections and development of transitions 
The digested peptides were subjected to analysis with the QTRAP 5500 mass spectrometer in 
MRM-initiated detection and sequencing (MIDAS) mode to produce MS/MS spectra of targeted 
transitions. MIDAS involves MRM-based high-sensitivity product-ion scans and triggers a full 
MS/MS scan for sequence confirmation. All transitions that had peak intensities below 800 cps, as 
well as nonspecific multiple peaks, were excluded. IDA files were exported to MASCOT (generic 
format) for a database search against the UniProt database (MASCOT: 
http://www.matrixscience.com) for human entries with carbamidomethylation as fixed and 
methionine oxidation as variable modifications. The following setting was used for the search: 
Peptide tolerance 0.4Da, MS/MS tolerance 0.4Da, peptide charge 2+, 3+ and 4+. Because none of 
the peptides were matched to the target protein MASCOT search, manual sequencing of the MS/MS 
spectra using PeakView software (AB SCIEX) was performed. 
4.3.9 MS/MSALL with SWATHTM Acquisition 
4.3.9.1 Membrane sample preparation for SWATH 
Brain tissues were slowly frozen and stored in 0.32 M sucrose at –80°C (Dodd et al., 1986). 
Thawed tissues were homogenized in 10 (w/v) of 0.32M sucrose at 4°C in a motor-driven Teflon-
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glass homogenizer at 500 rpm and the suspension centrifuged for 10 min at 756 g. The supernatant 
was centrifuged at 13,700 g at 4°C for 20 min. The supernatant was discarded and the pellet 
resuspended in 50 mM Tris-HCl, pH 7. 
4.3.9.2  Protein extraction, quantification, digestion and ZipTip 
Refer to methods section 4.2.3, 4.2.4, 4.2.5, 4.2.6 and 4.2.7. 
4.3.9.3 Strong cation exchange (SCX) with the LC Agilent fractionator 
The system was equipped with a 4.6  50 mm SCX column (ZORBAX Bio-SCX Series II). 
The following buffers were used for washing and column preparation: Buffer A (0.5% acetic acid, 
2% acetonitrile), Buffer B (0.5% acetic acid, 2% acetonitrile 250 mM ammonium acetate). A sample 
(50 µg) of the reduced and alkylated protein was loaded into the injector port at 0.4 ml/min. 
Proteins were eluted with buffers A and B in 96-well plates according to charge and salt 
gradient. Flow-through fractions (47 in total) were collected in a 96-well plate over 45 min. Adjacent 
fractions were combined to obtain 6 pooled fractions that were subjected to ZipTip clean-up (Section 
4.3.7) for desalting before MS analysis. 
4.3.9.4 In-gel digestion 
Protein concentration was measured with the 2-D Quant protein assay kit (Section 4.3.4). 
Samples (40 µg of protein) were loaded onto a 1 mm 10-well 8% SDS-PAGE gel and separated for 
1h at 120V. The gel was stained with Coomassie Brilliant Blue (Sigma) in 50% methanol and 10% 
glacial acetic acid for 1h then destained overnight with 45% methanol, 5% acetic acid at room 
temperature. Neuroligin-1 and neuroligin-2 proteins bands, which separated at 110 and 95 kDa 
respectively, were manually excised from the gel, destained and dehydrated with acetonitrile, 
reduced and alkylated with 10 mM dithiothreitol at 60°C for 30 min and 50 mM iodoacetamide at 
room temperature for 30 min in the dark. Prior to enzymatic digestion, excess reagents were removed 
and the gel pieces washed twice with 50 mM NH4HCO3 and dehydrated with 100% acetonitrile. For 
protein digestion, gel samples were incubated with 10 µl of trypsin (10 ng/µl in 50 mM NH4HCO3) 
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for 15 min at 4°C. An additional 15 µl of 50 mM NH4HCO buffer was added and the incubation 
overnight at 37
o
C. Peptides were extracted from the gel by sonication twice for 10 min with 50 µl of 
50% acetonitrile/0.1% trifluoracetic acid. Samples were vacuum centrifuged to remove acetonitrile 
and ZipTipped before MS was performed. 
4.3.9.5 Sample analysis by mass spectrometry and chromatography 
Samples were analysed using an HPLC system connected to a TripleTof 5600 mass 
spectrometer (AB SCIEX). Samples were acquired in data dependent mode to obtain MS/MS spectra 
for the most abundant ions. 
4.3.9.6 Bioinformatics database search 
Mass spectrometer data were searched using the MASCOT server v2.3.02. Peak lists for 
MASCOT searches were produced by AB SCIEX MGF converter. MS/MS datasets were also 
analysed using ProteinPilot
TM
 software v4.5 (AB SCIEX), which uses the Paragon algorithm (Shilov 
et al., 2007) to search the SwissProt database. The settings for the search were as follows: cysteine 
alkylation, iodoacetamide; digestion, trypsin; fixed modification, carbamidomethylation; variable 
modification, methionine oxidation; detected protein P-value threshold 0.05. 
4.4 Results 
Three proteins were targeted for this study: neuroligin-1, neuroligin-2 and -neurexin-1. 
Proteotypic peptides (that uniquely represent these proteins) were chosen using MRM Pilot software 
(Fig. 4.5) and the best peptides with the highest mean intensity and best CV value were added from 
the peptide selection view (Fig. 4.6). Lists of all possible trypsin-digested peptides were produced for 
the three target proteins. To determine the true total protein abundance in the samples, peptides with 
methionine, cysteine, or amino acids with known chemical and/or post-translational modifications 
were excluded. Due to the susceptibility of methionine to oxidation and cysteine to alkylation, 
quantitative data attained from target peptides with these amino acids could produce errors. To 
produce a reliable MRM and to evaluate which is the most sensitive and reproducible, replicate 
samples are required. Fig. 4.7 is an example of results from running several replicates. 
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Different transitions were produced for these proteins. Several transitions were produced for 
each peptide (Table 4.2), and after MIDAS analysis on the QTRAP 5500, transitions that gave peak 
intensities below 700 cps, or different indistinct peaks, were removed from the list. To prevent false 
characterizations, MS/MS data produced from MIDAS analysis were searched against MASCOT to 
confirm protein identity. The MASCOT search failed to identify any peptides from neuroligin-1, 
neuroligin-2 or -neurexin-1. As none of the peptides matched the MASCOT search, manual 
sequencing of the MS/MS spectra from the MIDAS analysis were conducted to confirm their 
sequence using the fragment ion table for each peptide. B-, y- and a-ions between 100 and 999 m/z 
were searched within the spectra for all peptides. None of the peptides from the three proteins could 
be sequenced correctly (Figs 4.8, 4.9). The incorrect matching might result from highly abundant 
peptide/s with similar m/z values co-eluting with the peptides of interest and producing an error to 
the targeted transitions signal. 
 
Fig. 4.5. MRM peptide selection view. After importing proteins into MRM Pilot 
Software, MRM transitions are created. The best transitions for the best peptides for 
each protein were selected. The peptide fragment data is shown in the bottom pane for 
the selected peptide from neuroligin-1protein. 
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Fig. 4.6. MRM Table view. The table displays panes of data related to MRM for the 
selected protein. A table of all peptide MRM transitions is shown in the top pane for 
the selected protein. The top right pane displays a graph of MRM intensity vs 
variation (% CV) used to study the quality of the MRM transitions. This graph allows 
easy visualization of peptides with the highest intensity and reproducibility for 
quantitative purpose. The bottom pane has overlays of all extracted ion 
chromatograms (XIC) for the chosen MRM, spectra for the selected MRM, and full-
scan MS/MS data acquired using the MIDAS™ Workflow for confirmatory purposes. 
 
 
Fig. 4.7. MRM validation of the transitions. The summary graph in the top right of the 
MRM Table view shows the best MRM selected for optimization highlighted in blue 
and the remaining poor/failed MRM transitions highlighted in orange. 
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644.82 848.43 17.45 33 2+ / y7 QQPSPFSVDQR 5432 16.6 
642.33 827.44 14.03 33 2+ / y7 ELVDQDIQPAR 5263 13.3 
723.41 1111.68 15.61 37 2+ / y10 GNYGLLDLIQALR 3925 5.4 
817.45 946.5 20.3 44 4+ / y8 DYSTELSVTIAVGASL
LFLNILAFAALYYK 
3420 2.2 
698.84 784.42 16.59 36 2+ / y7 TGDPNQPVPQDTK 2260 14.8 
642.33 942.46 14.03 33 2+ / y8 ELVDQDIQPAR 2223 1.4 
699.37 1058.53 17.59 38 4+ / y10 ELNNEILGPVIQFLGV
PYAAPPTGER 
1466 2.1 
726.92 933.6 16.96 37 2+ / y8 DQLYLHIGLKPR 1147 19.6 
848.41 1192.61 20.21 42 2+ / y11 WTSENIGFFGGDPLR 1027 4.3 
826.91 957.48 16.27 41 2+ / y8 FQPPEPPSPWSDIR 960 10.9 
817.45 1059.59 20.3 44 4+ / y9 DYSTELSVTIAVGASL
LFLNILAFAALYYK 
908 13.6 
377.19 616.3 13.21 22 2+ / y5 HNPETR 769 17 
AAM46111 
Neuroligin-2 
981.98 1087.57 18.65 48 2+ / y11 GGGGPGGGAPGGPGL
GLGSLGEER 
30807 1.9 
707.7 1134.59 13.99 39 3+ / y9 AIAQSGTAISSWSVNY
QPLK 
2390 6.6 
718.4 1141.64 14.29 40 3+ / y11 TLLALFTDHQWVAPA
VATAK 
1061 12.2 
707.7 948.51 13.99 39 3+ / y8 AIAQSGTAISSWSVNY
QPLK 
1020 12.1 
769.89 1166.6 17.03 39 2+ / y11 FQPPEAPASWPGVR 729 8.4 





745.7 931.48 14.72 41 3+ / y9 FNVGTDDIAIEESNAII
NDGK 
996 2.6 
532.31 766.41 12.69 28 2+ / y7 LAIGFSTVQK 905 5.1 
532.31 709.39 12.69 28 2+ / y6 LAIGFSTVQK 762 23.9 
776.39 873.48 21.3 39 2+ / y9 NYISNSAQSNGAVVK 725 15.8 
914.96 1228.63 19.51 45 2+ / y10 SGGNATLQVDSWPVI
ER 
675 30.5 
596.83 831.51 13.32 31 2+ / y7 HHSVPIAIYR 637 9.5 
745.7 1189.57 14.72 41 3+ / y11 FNVGTDDIAIEESNAII
NDGK 
583 0.6 
596.83 732.44 13.32 31 2+ / y6 HHSVPIAIYR 488 4.6 
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532.31 879.49 12.69 28 2+ / y8 LAIGFSTVQK 456 6.4 
745.7 1060.53 14.72 41 3+ / y10 
FNVGTDDIAIEESNAII
NDGK 411 7.2 
613.31 845.42 16.37 32 2+ / y7 WPPNDRPSTR 342 1.4 
609.31 991.52 15.09 32 2+ / y9 EPYPGSAEVIR 313 6.6 
776.39 1074.55 21.3 39 2+ / y11 NYISNSAQSNGAVVK 227 29.9 
647.27 1049.46 17.37 33 2+ / y9 DEGSYHVDESR 203 39 
412.22 766.41 11.68 23 2+ / y7 GGGQITYK 195 60.9 
343.71 557.38 11.89 20 2+ / y5 EAVLVR 98 17.3 
282.15 332.16 9.82 17 2+ / b3 YPAGR 52 32.6 
309.17 471.22 17.94 19 2+ / b5 QPSSAK 35 30.7 
412.22 652.37 11.68 23 2+ / y5 GGGQITYK 34 87.3 
314.19 570.36 18.08 19 2+ / y5 GKPPTK 27 100 
315.68 456.25 10 19 2+ / b5 SPASLR 27 100 
282.15 400.23 9.82 17 2+ / y4 YPAGR 27 100 
287.13 444.21 4.91 18 2+ / y3 EYYV 20 49.5 
315.68 543.32 10 19 2+ / y5 SPASLR 20 49.5 
BAA87821.1 
-Neurexin-1 
515.25 784.4 12.72 28 2+ / y6 TGSISFDFR 5168 14.5 
516.3 918.5 15.67 28 2+ / y9 ITTQITAGAR 4064 10.1 
559.32 777.41 18.44 30 2+ / y7 NIIADPVTFK 2396 6.7 
380.24 545.34 12.36 22 2+ / y5 LTLASVR 1647 10.7 
623.29 869.43 15.58 32 2+ / y7 FNDNAWHDVK 1137 2.7 
500.75 742.41 17.76 27 2+ / y6 EEYIATFK 1062 20.1 
547.3 820.49 15.3 29 2+ / y7 SADYVNLALK 976 2.6 
547.3 935.52 15.3 29 2+ / y8 SADYVNLALK 777 15.4 
435.76 563.36 14.11 24 2+ / y5 IHGVVAFK 679 2.8 
559.32 706.38 18.44 30 2+ / y6 NIIADPVTFK 662 17.9 
516.3 716.4 15.67 28 2+ / y7 ITTQITAGAR 611 15.2 
507.76 899.49 14.75 27 2+ / y8 DTSNLHTVK 585 1.9 
511.76 794.4 13.18 28 2+ / y7 DLFIDGQSK 550 15.8 
387.21 660.33 12.58 22 2+ / y6 LELDAGR 516 1.5 
524.29 689.39 16.29 28 2+ / y6 SGTISVNTLR 457 12.4 
511.78 707.41 13.06 28 2+ / y7 SDLYIGGVAK 440 55 
778.37 1056.49 16.5 43 3+ / y8 
GPETLFAGYNLNDNE
WHTVR 438 5.7 
524.29 802.48 16.29 28 2+ / y7 SGTISVNTLR 431 0.8 
689.86 949.5 16.98 35 2+ / y8 NTTLFIDQVEAK 401 5.5 
387.21 599.3 12.58 22 2+ / b6 LELDAGR 344 1 
524.29 903.53 16.29 28 2+ / y8 SGTISVNTLR 294 11.8 
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500.75 871.46 17.76 27 2+ / y7 EEYIATFK 280 6.6 
263.64 379.21 20.13 17 2+ / y3 FGFR 273 32.6 
632 1161.63 17.82 36 3+ / y11 
GYLHYVFDLGNGAN
LIK 204 1.4 
260.64 391.23 17.38 16 2+ / y3 EPFK 123 48.3 
272.64 416.21 17.73 17 2+ / y4 QGDPK 80 100 
260.64 374.17 17.38 16 2+ / b3 EPFK 55 97.7 
263.64 352.17 20.13 17 2+ / b3 FGFR 40 100 
309.18 504.28 9.87 19 2+ / y4 LELSR 40 100 
259.16 343.2 7.23 16 2+ / b3 TLQR 40 100 
324.15 532.26 8.19 19 2+ / y4 DGWNR 27 100 
270.64 310.18 10.1 17 2+ / y2 ETYK 27 100 
266.16 474.28 7.46 17 2+ / y3 GWIR 13 100 
Notes: 
1
, RT, retention time detected for a peak matching the transitions listed that subsequently 
was found to not match the specific protein of interest; 
2
, CE, collision energy, V. 
 
Fig. 4.8. Validation of transitions by examination of the full MS/MS spectrum during 
MRM set-up. Example of manual sequencing for a peptide (ELVDQDIQPAR) that 
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could not be identified by MASCOT search. The fragment ion for the peptide was 
determined using the web-base fragment ion calculator 
http://db.systemsbiology.net:8080/proteomicsToolkit/FragIonServlet.html. The table 
at the top right shows the b/y ions obtained from the fragment ion calculator for the 
peptide. A peak that matched the calculated b- and y-ion masses was searched on a 
MS/MS spectrum. 
 
Fig. 4.9. Validation of the transitions by examination of the full MS/MS spectrum in 
the MRM set-up. Example of manual sequencing for a peptide (QQPSPFSVDQR) 
peptide that could not be identified using MASCOT search. Detail as for Fig. 4.8. 
The IDA results from in-solution samples were searched using both MASCOT and Protein 
Pilot software. This approach detected several hundred proteins that are listed in Supplementary 
Table 4.3 in the Appendix for this chapter. However, none of the proteins of interest (neuroligin-1, 
neuroligin-2 or -neurexin) was found in the search lists. This could be due to the complexity of the 
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sample or to the low abundance of these proteins. Hence, SCX fractionation was used prior to mass 
spectrometry. Data obtained were searched using both MASCOT and Protein Pilot. Again, more than 
200 proteins were identified that did not include the proteins of interest (Supplementary Table 4.4 in 
the Appendix for this chapter). 
A final approach used to find these proteins was SDS-PAGE separation and in-gel digestion. 
Sections of gel representing proteins around 100 kDa in size was excised and the protein extracted. 
MASCOT search identified all five neuroligin proteins (neuroligin-1, -2, -3, -4 and -4Y). However, 
each protein identification was based on only one or two peptides, with one peptide in common to all 
five proteins. This meant that no unique peptide was detected for any individual protein. Some of the 
scores of peptides matching to neuroligin proteins were very low, such as 6, 1 and 2 for neuroligin-1, 
neuroligin-2 and neuroligin-3 respectively, which is not reliable data for quantification (Table 4.5). 
Table 4.5. Neuroligin peptides obtained from in-gel digestion. 
Query Observed Mr(expt) Mr(calc) ppm Miss Score Expect Rank Unique Peptide 
NLGN1_HUMAN: Mass: 94574 Score: 74 Matches: 4(2) Sequences: 2(1) emPAI: 0.03 
6676 723.4040 1444.7934  1444.8038 –7.16 0 6 19 1 U K.GNYGLLDLIQALR.W 
6934 738.9209  1475.8272  1475.7984 19.5 0 49 0.00064 1 – R.LGVLGFLSTGDQAAK.G 
NLGN2_HUMAN: Mass: 91333 Score: 218 Matches: 7(5) Sequences: 3(2) emPAI: 0.07 
2802 562.3078  1122.6010  1122.5822  16.8 0 1 96 8 U R.FPVVNTAYGR.V 
6790 730.9128  1459.8110  1459.7783  22.4 0 90 5.110–8 1 – K.GNYGLLDQIQALR 
6934 738.9209  1475.8272  1475.7984  19.5 0 49 0.00064 1 – R.LGVLGFLSTGDQAAK 
NLGN3_HUMAN: Mass: 94463 Score: 168 Matches: 5(3) Sequences: 3(1) emPAI: 0.03 
6790 730.9128 1459.8110  1459.7783  22.4 0 90 5.110–8 1 – K.GNYGLLDQIQALR 
7434 766.9205  1531.8264 1531.8722  –29.87 1 20 0.59 2 U R.LTALPDYTLTLRR 
8480 846.9831 1691.9516 1691.9433  4.95 0 2 23 8 U R.SLCLTLWFLSLALR 
NLGN4_HUMAN Mass: 92427 Score: 213 Matches: 6(5) Sequences: 2(2) emPAI: 0.07 
6790  730.9128  1459.8110  1459.7783  22.4 0 90 5.110–8 1 – K.GNYGLLDQIQALR.W 
7090 745.9289  1489.8432  1489.8140  19.6 0 54 0.00016 1 U R.LGILGFLSTGDQAAK.G 
4.4.1 Identification of other synaptic proteins by these methods 
Several hundred membrane proteins as well as synaptic proteins were identified using 
quadrupole Triple TOF 5600 mass spectrometry and MASCOT search with the different approaches 
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utilized. Examples of these were synapsin-1, Vesicle-associated membrane protein 2, excitatory 
amino acid transporter 1 and 2, synapsin-2, synaptosomal-associated protein 25, septin-5 and -9, 
synaptic vesicle membrane protein, synaptic vesicle glycoprotein, synaptophysin, neural cell 
adhesion molecule, cadherin and vesicular glutamate transporter 3. These proteins were detected 
with sufficient number of unique peptides and a high score of identity. An example is shown below: 
Protein View: EAA2_HUMAN; Excitatory amino acid transporter 2 OS=Homo sapiens 
GN=SLC1A2 PE=1 SV=2; Database: SwissProt; Score: 58; Nominal mass (Mr): 62577; Calculated 
pI: 6.09; Taxonomy: Homo sapiens; Protein sequence coverage: 6% 
Matched peptides are shown in bold. 
1 MASTEGANNM PKQVEVRMHD SHLGSEEPKH RHLGLRLCDK LGKNLLLTLT 
51 VFGVILGAVC GGLLRLASPI HPDVVMLIAF PGDILMRMLK MLILPLIISS 
101 LITGLSGLDA KASGRLGTRA MVYYMSTTII AAVLGVILVL AIHPGNPKLK 
151 KQLGPGKKND EVSSLDAFLD LIRNLFPENL VQACFQQIQT VTKKVLVAPP 
201 PDEEANATSA VVSLLNETVT EVPEETKMVI KKGLEFKDGM NVLGLIGFFI 
251 AFGIAMGKMG DQAKLMVDFF NILNEIVMKL VIMIMWYSPL GIACLICGKI 
301 IAIKDLEVVA RQLGMYMVTV IIGLIIHGGI FLPLIYFVVT RKNPFSFFAG 
351 IFQAWITALG TASSAGTLPV TFRCLEENLG IDKRVTRFVL PVGATINMDG 
401 TALYEAVAAI FIAQMNGVVL DGGQIVTVSL TATLASVGAA SIPSAGLVTM 
451 LLILTAVGLP TEDISLLVAV DWLLDRMRTS VNVVGDSFGA GIVYHLSKSE 
501 LDTIDSQHRV HEDIEMTKTQ SIYDDMKNHR ESNSNQCVYA AHNSVIVDEC 
551 KVTLAANGKS ADCSVEEEPW KREK 
  
4.5 Discussion 
The purpose of the study in this chapter was to validate the quantifications of neuroligin, and 
neurexin proteins in human autopsy brain tissues from AD cases and controls performed in chapter 3. 
It is essential to use more accurate and sensitive techniques to validate the immunoblotting approach, 
due to the possibility of off-target antibody binding. The study aimed to demonstrate the feasibility 
of isolating the neurexin-neuroligin complex from autopsy specimens for quantitative mass 
spectrometric proteomic analysis. MRM was chosen for its advantages of capacity for high 
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throughput in quantification and ability to detect up to 100 proteins in complex mixtures (Picotti et 
al., 2009), and its good reproducibility across laboratories (Addona et al., 2009). 
Autopsy brain whole-membrane samples from hippocampus, occipital cortex and inferior 
temporal cortex were and trypsin-digested for mass spectrometry for MRM quantification of the 
proteins. Samples were run on the QTRAP 5600 for MIDAS analysis and various transitions from 
each protein were obtained. Due to the possibility of incorrect signals derived from other peptides 
with precursor/fragment ion pairs of similar m/z values for the specific transitions, validation of the 
transitions obtained were performed both by the parallel acquisition of multiple transitions approach 
and by scanning the full MS/MS spectra manually. Unfortunately, neither approach matched the 
transitions to the proteins of interest, which may suggest that these proteins are of very low 
abundance in brain samples. In consequence I could not use MRM for quantification. 
Although MRM is very powerful for proteomics and can detect scarce proteins, it has some 
limitations. For each protein, at least two peptides are required to confirm the identity of the protein 
of interest and determine its quantity. It is necessary to differentiate between correctly identified 
peptides and false positives: digested peptides can share considerable homology. MRM results can 
be degenerate if there are sequence similarities between the target peptide and any other peptide in 
the sample. In the current study, I could not obtain any transitions matching the protein of interests 
due to variations in the elution time of the same transitions. This was confirmed by full MS/MS 
spectra manual sequencing. As a result the technique could not be used. 
Alternatively, I attempted to use SWATH, which is a new technique introduced for targeted 
protein quantification to provide MRM-like reproducibility but with higher multiplexing. Samples of 
hippocampus, occipital cortex and inferior cortex from AD cases and controls were prepared in 
solution form (The preparation of these samples resemble that for MRM). To perform SWATH to 
quantify proteins of interest, samples should be run on an HPLC system connected to a quadrupole 
triple TOF mass spectrometer to obtain data using an information dependent acquisition mode to 
generate MS/MS spectra based on the precursor ions detected in the sample. These data were 
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subsequently analysed using Protein Pilot software and the MASCOT search algorithm to identify 
the proteins. Unfortunately, none of the proteins of interest was found in any of the samples run on 
the mass spectrometer. Nevertheless, several hundred proteins were identified in the sample mixture. 
Proteomics based on mass spectrometry can to detect and identify very small amounts of 
proteins in the femtomole to attomole range, but sample complexity can result in difficulties in 
detecting and quantifying proteins present at two to three orders of magnitude lower than the most 
abundant ones. Hence, extensive fractionation is crucial to reduce the concentration range and 
improve the coverage of the proteins in the sample mixture. SCX fractionation was used in the 
current study to overcome this problem. After fractionation the peptides were run on an HPLC 
system connected to a Triple TOF mass spectrometer. Data were analysed using both MASCOT 
search and Protein Pilot software. Many proteins were identified using this approach, but none of 
them was a protein of interest. 
Finally, an alternative approach was used to fractionate the sample mixture, in-gel digestion. 
This is a popular sample preparation method that offers a simple way of protein pre-fractionation 
based on size. Subsequent gel excision of the approximate range of the protein of interest means the 
removal of low- and high-molecular weight proteins irrelevant to the project. In-gel digestion was 
combined with a gel-staining protocol that does not interfere with protein digestion (Vasilj et al., 
2012, Piersma et al., 2013). After the extraction of proteins at the expected molecular weight from 
the gel, samples were run on an HPLC system connected to a Triple TOF mass spectrometer. Data 
were analysed using both MASCOT search and Protein Pilot software. This approach gave fewer 
proteins, but all neuroligin isoforms were found in Mascot search but not in ProteinPilot software. 
On closer inspection, only two peptides were obtained for neuroligin-1 and neuroligin-4 and three 
peptides for neuroligin-2 and neuroligin-3. As mentioned above, uniqueness of the peptides to the 
protein of interest is crucial to the assay. I found one peptide in common to all four proteins 
(GNYGLLDLIQALR), which left neuroligin-1 and neuroligin-4 with only one peptide and 
neuroligin-2 and neuroligin-3 with 2 peptides in total. The confidence in the identification scores for 
the remaining peptides was very low, and did not allow me to confirm that these peptides belong to 
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the proteins of interest. In consequence, I could not use SWATH to quantify neuroligins and 
neurexins in AD cases and controls. 
The inability to detect a sufficient number of peptides in neuroligin-1, neuroligin-2 and -
neurexin-1 could reflect their relatively low abundance in the synaptic membrane. It is also possible 
that some of these proteins migrate with more-abundant proteins and are thus difficult to detect by 
mass spectrometry. It is noteworthy that the low abundance of a protein in a membrane preparation 
does not necessarily indicate that it is absent from the synaptic terminal in vivo. It is more likely that 
the association of some proteins with other synaptic proteins is disrupted by extraction with the 
reagents used in the methodology. The inability to detect neurexins and neuroligins in the current 
study conforms to a previous report on the identification of proteins in the postsynaptic density 
fraction by mass spectrometry (Walikonis et al., 2000). Multiple synaptic proteins located at the post 
synaptic density could not be identified, such as SHANK, GKAP, PSD-95 and SAP102 (Müller et 
al., 1996), even though they have been reported to be enriched in PSD. This is interesting because 
neuroligin binds to PSD-95 via its PDZ domains, and PSD-95 in turn, interacts with GKAP and 
SHANK, which lie deep in the PSD. GKAP and SHANK also bind through their PDZ domain to the 
C terminus of PSD-95. All these proteins are located in the PSD and attached to each other, and their 
strong association to the synaptic membrane could prevent their extraction by the protocols used 
here. Additional methods, such as high-resolution immunolocalization, will be needed to ascertain 
the full protein composition of the synaptic proteome. Increasing the amount of starting material or 
modifying the fractionation strategy, such as immunoprecipitation followed by mass spectrometry, 
might be worth pursuing in the future. 
4.6 Supplementary material for Chapter 4 Appendix 
Table 4.3. Membrane proteins identified using in-solution detection. 
Table 4.4. Proteins identified by MASCOT search using SCX fractionation. 
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Chapter 5 
5  Quantification of neuroligin-1, neuroligin-2 and -neurexin-1 mRNA 
5.1 Aim of the research 
1. To assay NLGN-1, NLGN-2 and -NRXN-1 messenger RNA (mRNA) transcript expression in 
human autopsy brain tissue in AD cases and matched controls. 
2. To compare transcript expression across the three brain regions studied. 
3. To evaluate the impact of age, gender, and post-mortem delay on transcript expression 
4. To assess transcript expression according to severity of AD pathology and APOE genotype. 
5.2 Introduction 
To understand the biological machinery involved in neuronal survival and death, it is 
important to study gene expression to gain information about cellular pathways. Neuronal functions 
and behavioural alterations in an organism are modified by gene expression and the resulting 
functional consequences. The death of a neuron can be mediated by disorders in processes that are 
derived from altered gene expression, which can lead to functional changes. Cellular pathways in the 
brain are highly regulated, and minor alterations in mRNA expression can have strong effects. To 
understand AD ætiology and disease progression, and to aid the development of new therapeutics, 
the characterization of changes in cellular and molecular pathways responsible for neuronal survival 
will provide relevant information. Small changes in gene expression can have large impacts on 
cellular pathways. Alterations of many synaptic proteins involved in mechanisms of plasticity, 
memory, and learning have been studied at the level of gene transcription. These changes could play 
roles in synaptic damage. Nerve-endings require mRNA to express the proteins required for synaptic 
activity. Impairment of LTP occurs prior to neuronal loss in hippocampal neurons harvested from 
transgenic AD animal models; by analogy, altered gene expression could be implicated in cognitive 
impairment in AD. Comparisons of confirmed AD cases and controls using autopsy brain tissue have 
shown differences in the expression of genes involved in memory processing and learning. Most of 
these studies report down-regulation of these genes in the AD cases. 
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The structure of the human brain is complicated and heterogeneous. Advanced technologies 
can be used to quantify transcript expression, including high-throughput gene expression assays 
(microarrays). Microarray techniques allow researchers to analyse thousands of mRNA transcripts 
and portray patterns of differentially regulated genes in the disease state. The techniques produce a 
huge amount of information that highlights pathogenic pathways. A limitation of the microarray 
approach is the inability to distinguish between gene variants that arise by alternate RNA splicing. 
Techniques that can be used to validate high-throughput assays include Northern blot, quantitative 
real time reverse-transcription (RT)-PCR (Gutala and Reddy, 2004, Reddy et al., 2004, Therianos et 
al., 2004) and in situ hybridization (Mirnics et al., 2000, Yang et al., 1999). Each technique has 
advantages and limitations. Northern blotting, for example, uses electrophoresis to separate RNA 
transcripts by size, and the transcripts of interest are detected by probe hybridization. This technique 
can determine minor changes that RNA microarrays cannot, and can yield data about the size of the 
transcript, but has low sensitivity, is time consuming, and needs large amounts of RNA. The last-
mentioned is an issue with the limited amounts of starting material available from autopsy tissues. In 
situ hybridization can be used to determine the location and distribution of mRNA transcripts across 
tissues, but its facility for quantifying the transcript is low. End-point relative RT-PCR quantifies the 
transcript at the final stage of a PCR reaction on a DNA acrylamide gel. This technique has some 
limitations such as limited dynamic range and resolution, poor precision, and it requires post-PCR 
processing. 
Real time RT-PCR is considered the most sensitive quantitative gene transcription assay. It 
has a broad (10
7
) dynamic range and allows the measurement of both abundant and scarce transcripts 
(Higuchi et al., 1992). There are two RT-PCR chemistry strategies available: fluorescent probes such 
as TaqMan®, Molecular Beacons, or Scorpions®, and the SYBR® Green method. The SYBR® 
Green I method utilizes a DNA binding dye that intercalates into the minor groove of double-
stranded DNA as the fluorescent reporter. During amplification of the target sequence by PCR, 
SYBR® Green I attaches to the amplified sequence and then fluoresces, so that as the amplicon 
concentration increases following each PCR cycle, the fluorescence increases proportionally and can 
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be quantified. Although this method is cost effective it has the disadvantage that the probe binds to 
all double-stranded DNA, including primer-dimers and any non-specific products present, some of 
which cannot be effectively removed from the assay. 
RT-PCR quantification by the gene-specific TaqMan® probe and primer method has 
advantages for quantitative gene expression studies. The assay comprises an 6-carboxyfluorescein 
(FAM™) dye-labelled TaqMan® minor groove binder (MGB) probe and two PCR primers 
combined in one tube. As the specific target is amplified the probe gets cleaved, decoupling the 
fluorescent and quencher moiety and preventing fluorescence resonant energy transfer, so the total 
reaction fluorescence increases with each amplification cycle. The fluorescence increase takes place 
in proportion to the original concentration of target mRNA present, which can be accurately 
quantified. The assay is optimized to run under universal thermal cycling conditions with a final 
reaction concentration of 250 nM for the probe and 900 nM for each primer. The technique has 
several advantages over the SYBR Green method in that it is customized, fast, and easy to set up. It 
is specific and sensitive as well as cost effective compared with microarrays. The TaqMan® probe 
and primer RT-PCR assay was chosen for the study. 
RT-PCR quantification can be either relative or absolute. In relative qRT-PCR the level of 
the target gene is normalized to a housekeeper reference gene that is uniformly expressed across all 
samples. Unfortunately, the levels of many commonly used housekeeper genes, which are involved 
in energy metabolism, cell cycling, communication, and cytoarchitecture, differ between AD cases 
and controls (Gebhardt et al., 2010). Absolute qRT-PCR is more accurate because it utilizes a 
standard curve of known concentrations of either RNA or DNA to quantify the target gene. Most 
absolute quantification methods use known concentrations of recombinant plasmids that contain the 
transcript of interest to calculate the copy number of the transcript in each unknown sample. In the 
current study I chose this approach. An absolute TaqMan qRT-PCR assay was developed to quantify 
the levels of neuroligin-1, neuroligin-2 and -neurexin mRNA transcript in autopsy brain tissue from 
AD cases and controls. 
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5.3 Methods 
5.3.1 Tissue collection and storage 
See Chapter 3, Section 3.2.1. 
Table 5.1. Details of AD cases and controls. 
#  Age, y PMD, h Gender ApoE Pathological score 
     
Hipp ITC OCC 
AD cases 
 
AD1 65 34.83 M 3,4 3 3 1 
AD2 82 54.92 M 3,4 3 3 1 
AD3 79 26.33 M 4,4 3 3 1 
AD4 91 48.00 F 3,3 3 3 1 
AD5 86 35.50 F 3,3 2 2 1 
AD6 81 1.67 F 3,3 1 2 1 
AD7 82 41.25 F 3,4 3 3 3 
AD8 75 4.00 M 4,4 3 3 1 
AD9 82 15.38 F 3,3 2 1 1 
AD10 66 18.83 M 3,4 3 3 1 
AD11 78 7.50 F 2,3 3 3 0 
AD12 77 19.50 M 2,3 3 3 2 
AD13 84 25.40 M 4,4 3 2 3 
AD14 72 80.00 M 4,4 3 3 2 
Average  78.7 ± 7.1 29.67 ±21 8M, 6F     
Normal controls 
      
NC1 78 4.00 F 3,4 0 0 0 
NC2 87 21.50 F 2,3 1 0 0 
NC3 82 46.83 M 3,3 0 0 0 
NC4 85 24.50 M 2,3 0 0 0 
NC5 75 24.43 F 3,3 0 0 0 
NC6 68 43.66 F 3,4 0 0 0 
NC7 72 15.41 F 3,3 1 0 0 
NC8 71 7.75 F 3,4 0 0 0 
NC9 78 16.25 M 3,3 0 0 0 
NC10 68 28.16 M 2,2 0 0 0 
NC11 76 24.00 F 3,3 0 0 0 
NC12 73 85.15 M 2,3 1 0 0 
NC13 77 18.00 F 3,4 0 0 0 
NC14 80 47.15 M 3,3 0 0 0 
Average 76.6 ± 5.5 24.8 ± 12.8 6M, 8F     
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5.3.2 Case selection and neuropathological classification 
Fourteen AD cases and 14 controls were selected and matched as closely as possible for age, 
PMD and gender. The average age at death for AD cases was 78.7 years, for controls 76.6 years. The 
average post-mortem delay for the AD cases was 29.7h, for controls 24.8h. Tissue from the three 
different areas used in other Chapters was obtained from each brain, although some AD cases were 
replaced because of a lack of available tissue. Each area of each brain was given a neuropathological 
severity score from 0-3 based on AD hallmarks, which are the severity of neuronal loss and the 
abundance NFTs and A (Table 5.1). 
5.3.3 RNA extraction 
RNA was extracted from frozen tissue that had been stored in 0.32 M sucrose at –80°C. The 
TRIzol® (Invitrogen) extraction protocol was used according to the manufacturer’s instructions. 
Tissue pieces were rapidly thawed and homogenized on ice in 10 (w/v) of TRIzol® using a 
Polytron® homogenizer (Kinematica). The homogenate was incubated for 5 min at room temp., 0.2 
(v/v) of chloroform was added, the mixture incubated at room temp. for 2–3 min with shaking, then 
centrifuged for 20 min at 10 000  g at 4°C and the aqueous phase transferred to a new tube. A one-
tenth volume of isopropanol was added and the mixture incubated at room temp. for 10 min. To 
deposit the RNA, samples were centrifuged at 10 000  g for 15 min at 4°C. The pellet was 
resuspended in 1 ml of 75% ethanol and the mixture centrifuged at 10 000  g for 20 min at 4°C. The 
pellet was dried, resuspended in 50 µl of nuclease-free MilliQ H2O, and incubated for 10 min at 
60°C. 
5.3.4 RNA integrity 
The quality of the RNA was tested by electrophoresis on a 1.5% agarose/2.2 M formaldehyde 
gel. The integrity of the RNA was checked using an Agilent RNA 6000 Nano kit as per the 
manufacturer’s instructions. The Agilent software gives an RNA integrity number (RIN) between 1 
and 10, where 1 is the poorest quality and 10 is the best (Imbeaud et al., 2005). RNA samples with a 
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RIN below 2 were discarded. The quantity of RNA was measured by UV spectrometry at the 
absorbance wavelengths () 240, 280 and 320 nm. 
5.3.5 Reverse transcriptase 
To remove contaminating genomic DNA, DNase was added (1 µl of 10 DNase I reaction 
buffer, Fermentas) was added to each 3 µg of RNA and the mixture incubated with 40 U of RNase 
OUT (Fermentas) and 1 U of RNase-free DNase (Fermentas) for 30 min at –37°C. EDTA was added 
to a final concentration of 2.27 mM and the incubation continued for 5 min at 75°C. 
The synthesis of cDNA was conducted by adding 0.82 µg of DNase and 300 µM dNTPs 
(Promega), 1 µg of Oligo (dT) 12–18 primers (Promega) and 0.5 µg of random hexamers (Promega) 
to the RNA. The volume adjusted to 12 µl with nuclease-free MilliQ H2O and the mixture incubated 
for 5 min at 65°C. 5 first-strand buffer, 4.8 mM DTT, 40 U of RNaseOUT and 400 U of Superscript 
III Reverse Transcriptase® (Invitrogen) were added and the mixture incubated for 5 min at 25°C, 
then for 60 min at 50°C, then for 15 min at 70°C. To remove contamination 2 U of DNase-free 
ribonuclease H (Invitrogen) was added and the incubation continued for 20 min at 37°C. The cDNA 
was stored in –80°C. 
5.3.6 Standard preparation and dilution 
NLGN-1 and NLGN-2 standards were prepared by the method outlined in Chapter 2, Section 
2.2.1. QIAprep Spin Miniprep kits (QIAGEN) were used to purify high-copy plasmid DNA. The 
concentrations of the plasmids were measured by nanodrop and aliquots of the dilutions were kept at 
–80°C to prevent degradation and avoid experimental variation between RT-PCR assays 
(Dhanasekaran et al., 2010). A fresh aliquot of each standard was used for each RT-PCR assay. 
-NRXN-1 plasmid was obtained from GeneArt® Gene Synthesis (Life Technologies). The 
following is the sequence of the-NRXN-1 standard used: 
1 CCCCGCCATG TACCAGAGGA TGCTCCGGTG CGGCGCCGAG CTGGGCTCGC CCGGGGGCGG 
61 CGGCGGCGGC GGCGGCGGCG GCGGCGCAGG GGGGCGCCTG GCCCTGCTTT GGATAGTCCC 
121 GCTCACCCTC AGCGGCCTCC TAGGAGTGGC GTGGGGGGCA TCCAGTTTGG GAGCGCACCA 
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181 CATCCACCAT TTCCATGGCA GCAGCAAGCA TCATTCAGTG CCTATTGCAA TCTACAGGTC 
241 ACCGGCATCC TTGCGAGGCG GACACGCTGG GACGACATAT ATCTTTAGCA AAGGTGGTGG 
301 ACAAATCACG TATAAGTGGC CTCCTAATGA CCGACCCAGT ACACGAGCAG ACAGACTGGC 
361 CATAGGTTTT AGCACTGTTC AGAAAGAAGC CGTATTGGTG CGAGTGGACA GTTCTTCAGG 
421 CTTGGGTGAC TACCTAGAAC TGCATATACA CCAGGGAAAA ATTGGAGTTA AGTTTAATGT 
481 TGGGACAGAT GACATCGCCA TTGAAGAATC CAATGCAATC ATTAATGATG GGAAATACCA 
541 TGTAGTTCGT TTCACGAGGA GTGGTGGCAA TGCCACGTTG CAGGTGGACA GCTGGCCAGT 
601 GATCGAGCGC TACCCTGCAG GGCGTCAGCT CACAATCTTC AATAGCCAAG CAACCATAAT 
661 AATTGGCGGG AAAGAGCAGG GCCAGCCCTT CCAGGGCCAG CTCTCTGGGC TGTACTACAA 
721 TGGCTTGAAA GTTCTGAATA TGGCAGCCGA AAACGATGCC AACATCGCCA TAGTGGGAAA 
781 TGTGAGACTG GTTGGTGAAG TGCCTTCCTC TATGACAACT GAGTCAACAG CCACTGCCAT 
841 GCAATCAGAG ATGTCCACAT CAATTATGGA GACTACCACG ACCCTGGCTA CTAGCACAGC 
901 CAGAAGAGGA AAGCCCCCGA CAAAAGAACC CATTAGCCAG ACCACAGATG ACATCCTTGT 
961 GGCCTCAGCA GAGTGTCCCA GCGATGATGA GGACATTGAC CCCTGTGAGC CGAGCTCAGG 
1021TGGGTTAGCC AACCCAACCC GAGCAGGCGG CAGAGAGCCG TATCCAGGCT CAGCAGAAGT 
1081 GATCCGGGAG TCCAGCAGCA CCACGGGTAT GGTCGTTGGG ATAGTAGCCG CTGCCGCCCT 
1141 GTGC 
5.3.7 Taqman PCR assay 
Assays were carried out in duplicate on MicroAmp® optical 384-well reaction plates 
(Applied Biosystems) on an ABI Prism® 7900HT Sequence Detection System. cDNA was diluted 
1:8; 2 µl was added to each 10 µl reaction mix containing 5 µl PCR universal master mix (Applied 
Biosystems), 0.5 µl of primer probes (NLGN1: Hs00208784_m1; NLGN2: Hs00395803_ml; 
NRXN1: Hs00373346_m1; and RPL13; Life Technologies). An EpMotion 5075 robotics system 
(Eppendorf South Pacific P/L, North Ryde, NSW, Australia) was used to ensure accurate pipetting. 
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5.3.8 Data Analysis 
Multiple comparisons were evaluated by ANCOVA and ANOVA using the SPSS (Chicago, 
IL, USA) and Statistica (Tulsa, OK, USA) software packages with appropriate post-hoc tests. 
Differences were considered statistically significant at P < 0.05. 
5.4 Results 
RT-PCR assays were utilized to measure the absolute expression of NLGN1, NLGN1 and 
NRXN1 transcxripts in RNA extracted from samples of hippocampus, inferior temporal cortex and 
occipital cortex from AD and control subjects. The absolute quantities of the three trancripts were 
calculated by interpolation from their respective known plasmid copy-number standard curves based 
on their observed Ct value (Fig. 5.1). 
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Fig. 5.1. Standard curves for absolute quantification. Standards, black squares, 
unknowns, red crosses; A, neuroligin-1, B, neuroligin-2, C, -neurexin-1. 
5.4.1 Data distribution 
Normal probability plots of non-adjusted levels of NLGN1, NLGN2 and NRXN1 showed 
positively skewed distributions that deviated significantly from normal (Fig. 5.2). 
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Fig. 5.2. Normal probability plots of transcript expression. A, NLGN1, B, NLGN2, C, 
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NRXN1 across the three areas. Shapiro-Wilks testing showed that all traces deviated 
significantly from the normal distribution, as shown in the in-graph boxes. 
Transforming the values using the Box-Cox algorithm, available in the Statistica package, 
stabilized the variances and corrected the distributions (Fig. 5.3). This permitted parametric statistics 
to be used for the rest of the analyses, which was critical because the aim of the study was to 
undertake a quantitatve assessment of expression in AD cases and controls. 
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Fig. 5.3. Normal probability plots of Box-Cox transformed data. A, NLGN1, B, 
NLGN2, C, NRXN1. Details as for Fig. 5.1. Shapiro-Wilks tests showed that no trace 
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deviated significantly from the normal distribution, as shown in the in-graph boxes. 
Table 5.2. RNA integrity number 
 AD Cases 
 
 Controls 
 HP OC ITC  HP OC ITC 
AD1 3.3 4.8 4.5 NC1 6.3 6.4 7 
AD2 4.7 5 4.8 NC2 4.8 2.3 4.8 
AD3 4.7 5.3 4.6 NC3 6 5.9 6.6 
AD4 4.9 5 5.3 NC4 3.4 5.1 4.1 
AD5 5 5.9 5 NC5 6.1 6.8 7 
AD6 5.3 4.8 5 NC6 3.9 3.4 4.5 
AD7 5 5 3.2 NC7 6.2 7 5.8 
AD8 4.7 3.6 4.8 NC8 2.2 3.8 3.2 
AD9 5.1 5.5 5.7 NC9 5.1 4.6 5.4 
AD10 3.2 2.5 2.7 NC10 4.4 3 4.3 
AD11 2.9 2.6 3.4 NC11 5.9 6.8 6.2 
AD12 2.6 3.8 2.7 NC12 4.9 3 4 
AD13 3.5 3.3 2.9 NC13 5.3 4.6 5.3 
AD14 4.3 4.2 3.5 NC14 5.5 4.8 4.5 
5.4.2 RNA integrity 
RNA integrity was estimated in each sample to check whether the quality of the RNA would 
impact the concentration of transcripts measured (Table 5.2). A number of studies have reported on 
the impact of age at death and PMD on the quality of the mRNA, and shown that neither has a 
marked effect (Chevyreva et al., 2008, Harrison et al., 1991). RNA in autopsy tissue is stable for up 
to 120h post-mortem (Hynd et al., 2003). In this study regression analyses showed that post-mortem 
delay had no effect on the integrity of RNA (F1,82 = 0.146, P = 0.70), while age showed a just-
significant effect on RIN (F1,82 = 3.757, P = 0.056; Fig. 5.4). RIN was normally distributed (Fig. 5.5) 
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Fig. 5.4. Scatterplots of RIN against A, age, B, PMD. 
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Normal Probability Plot of RIN

























 RIN:  SW-W = 0.974, p = 0.0863  
Fig. 5.5. Normal probability plot of RIN. Data did not deviate significantly from the 
normal distribution by Shapiro-Wilks testing as shown in the in-graph box. 
5.4.3 Reference gene (RPL13 expression) 
There are several housekeeper genes that are uniformly expressed across many tissue and cell 
types, such as glyceraldehyde-3-phosphate dehydrogenase (GAPDH), HSP90, CYC1, EIF4A2 and -
actin. However, the expression of these genes may vary depending on experimental and pathological 
conditions. In the RT-PCR assay, there is no universal reference gene suitable for all experimental 
conditions. Careful validation of housekeepers should be performed to choose the most appropriate. 
Differences in the expression of the reference gene between study samples and controls can 
profoundly compromise interpretation. Most RT-PCR studies in the literature use GAPDH 
(NM_002046.3) as the reference gene for normalization. In AD, reduced synthesis of GAPDH 
mRNA, abnormal aggregation of GAPDH protein in the nucleus of, and increased activity of the 
enzyme cells have been observed in diseased tissues, suggesting a direct or indirect relationship of 
GAPDH with the neurodegenerative process. This makes GAPDH unsuitable as a reference gene in 
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this study. The housekeeping gene that showed the most constant expression in AD cases and 
controls in autopsy tissues was RPL13, which is a component of the 60S ribosomal subunit 
(Gebhardt et al., 2010). In this study RPL13 was used as a housekeeper. Its expression across 
samples showed no overall difference between AD cases and controls (F1,80 = 0.078, P = 0.78; Fig. 
5.6). No variation in RPL13 expression was observed between cases and controls in any brain area 
(F2,50 = 0.092, P = 0.91; Fig. 5.7). 
 
Fig. 5.6. RPL13 expression by case-group. 
 
Fig. 5.7. RPL13 by case-group across brain regions. 
5.4.4 Age at death and post-mortem delay with RPL13 transcript expression 
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(F1,82 = 0.010, P = 0.92; F1,82 = 3.921, P = 0.051 respectively; Fig. 5.8). 
 
 
Fig. 5.8. Regression of RPL13 CT value on A, PMD and B, Age. 
P a g e  | 138 
No significant association was observed between PMD and the expression of NLGN1 (F1,82 = 
0.004, P = 0.94), NLGN2 (F1,82 = 0.261, P = 0.61) or NRXN1 (F1,82 = 0.011, P = 0.91). NLGN1 
showed a near-significant relation with age (F1,82 = 3.836, P = 0.053), although NLGN2 (F1,82 = 
0.042, P = 0.83) and NRXN1 (F1,82 = 1.375, P = 0.24) did not (Fig. 5.9). As a result age was used as 
a covariant in subsequent analyses for all transcripts. 
5.4.5 Neuroligin-1 transcript expression between cases and controls 
The copy number of NLGN1 transcript was quantified by RT-PCR assay using a standard 
curve with known copy numbers of recombinant plasmid and adjusted for RIN. There was 
significant difference in expression levels averaged across all areas between AD cases and controls 
(F1,82 = 8.978, P = 0.004). The transcript copy number of neuroligin-1 mRNA was lower in AD cases 
and controls (Fig. 5.10). The Group  Area interaction was significant (F2,52 = 4.780, P = 0.012), and 
was probed further by post-hoc testing (Fig. 5.11). The level of neuroligin-1 transcripts measured 
was lowest in the occipital cortex and highest in inferior temporal cortex. 
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Scatterplot of Age against log cn
Beta neurexin-copy number 9v*84c
Age = 71.293+0.6093*x
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Scatterplot of PMD against log cn
Beta neurexin-copy number 9v*84c
PMD = 25.7266+0.1436*x
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Fig. 5.9. Regression of NLGN1, NLGN2 and NRXN1 transforms on age at death and 
PMD. See text for details. 
 
Fig. 5.10. NLGN1 transcript level by case-group averaged across the three areas. *, 
Significantly different from controls, see text. Bars show mean copy number  103 per 
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Fig. 5.11. NLGN1 mRNA copy numbers by case-group and area. Details as for Fig. 
5.10; *, significantly different from controls in the same area, P < 0.05 by Newman-
Keuls post-hoc test. 
5.4.6 Neuroligin-1 transcript expression and gender 
Gender is a significant factor in disease progression, and medications targeting proteins that 
are differentially expressed between males and females may significantly impact treatment (Vina and 
Lloret, 2010). Some genes that shown similar expression levels in both sexes in normal healthy 
controls could be differentially expressed between genders in disease (Vawter et al., 2004). Gender 
may be important in disease progression (Hynd et al., 2003). In this study the main effect for Gender 
was significant (F1,82 = 8.909, P = 0.003) because NLGN1 expression was expression was lower 
overall in males than in females. This pattern was similar in both case-groups: the Group  Sex 
interaction on NLGN1 was not significant (F1,80 = 0.024, P = 0.87), in essence because expression 
was higher in females in both groups, as revealed by post-hoc testing (Fig. 5.12). When samples 
were further divided by area, the NLGN1 copy number was higher in females than in males in all 
three areas and in both groups. This resulted in a non-significant Group  Gender  Area interaction 
(F2,48 = 0.692, P = 0.50), but post-hoc testing showed that regional differences reached significance 
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Fig. 5.12. NLGN1 mRNA expression by case-group and sex. Details as for Fig. 5.11; 
*, significantly higher than expression in males in the same case-group, P < 0.05 by 
Newman-Keuls post-hoc test. 
 
Fig. 5.13. NLGN1 expression by case-group, sex, and area. Details as for Fig. 5.11; *, 
significantly different from same-sex controls, and †, opposite-sex AD cases, in the same 
area, P < 0.01 by Newman-Keuls post-hoc testing. 
5.4.7 NLGN1 transcript expression and APOE genotype 
As noted in Chapter 3, not all APOE genotypes were present in the dataset. For statistical 
analysis subjects were divided into two groups: 4 allele carriers and 4 non-carriers. These two 
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of the 4 allele and finally cases with two copies of the 4 allele. Because 2 allele is known to be 
neuroprotective, it was decided that 2,4 carriers resembled 3,3 cases, and as a result these two 
genotypes were combined in the same class. 
NLGN1 expression was significantly lower overall in APOE 4 carriers than in those without 
an 4 allele (F1,82 = 6.203, P = 0.014; Fig. 5.14). The patterns were parallel in AD cases and controls, 
hence the Group  Nº of 4 alleles interaction was not significant (F1,80 = 0.767, P = 0.384) but the 
differences remained significant in AD cases under post-hoc testing (Fig. 5.15). There was no 
significant regional variation in NLGN1 expression pattern (F2,52 = 0.149, P = 0.86; Fig. 5.16), and 
the statistics had insufficient power to find differences between the genotypes within case-groups at 
this level by post-hoc testing. However, there were differences in NLGN1 expression between AD 
cases and matched controls in both hippocampus and inferior temporal cortex in subjects that did not 
carry any 4 allele. 
 
Fig. 5.14. NLGN1 transcript expression by APOE genotype. Display details as for Fig. 
5.10. Subjects were combined across case-groups and divided into those who had no 
(APOE1) or at least one (APOE2) APOE 4 allele; *, significantly different from 
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Fig. 5.15. NLGN1 expression by case-group and Nº of APOE 4 alleles. Details as for 
Fig. 5.14; *, significantly different from AD cases with no 4 allele, P < 0.05 by 
Newman-Keuls post-hoc test. 
 
Fig. 5.16. NLGN1 expression by case-group, area, and Nº of APOE 4 alleles. Details 
as for Fig. 5.14; *, significantly different from controls with the same genotype, 
P < 0.02 by Newman-Keuls post-hoc tests. 
5.4.8 NLGN1 expression and disease severity 
AS explained in Chapter 3, only AD cases were analysed by pathological score. Overall, the 
effect of disease severity on NLGN1 expression only trended toward significance (F2,39 =2.973, 
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other two areas (Fig. 5.17). In conformity with this regional difference in patter, the PS  Area 
interaction was significant (F4,33 = 3.016, P = 0.031).The level of NLGN1 transcript in inferior 
temporal cortex samples from AD cases at a moderate stage of disease were significantly lower than 
from those with mild disease, and significantly lower again in cases that showed severe disease 
features. Only the latter comparison reached significance in hippocampus (Fig. 5.17). 
 
Fig. 5.17. NLGN1 transcript expression by disease severity. Tissue samples from AD 
cases were divided according to the index of pathological severity as described in the 
text. Newman-Keuls post-hoc testing showed that expression in hippocampus at the 
severe stage was significantly lower than at the moderate stage (P = 0.006). In inferior 
temporal cortex expression was significantly lower at the moderate stage than at the 
mild stage (P = 0.001) and significantly lower again at the severe stage (P = 0.013). 
Expression did not vary significantly with disease severity in AD occipital cortex. 
5.4.9 Neuroligin-2 transcript expression by case-group 
The copy number of neuroligin-2 transcript was quantified by RT-PCR assay as described in 
Methods. Statistical tests were performed on Box-Cox transforms of the values as outlined in Section 
5.4.1 and the means converted to the original scale for presentation. The transcript copy number of 
neuroligin-2 was averaged and quantified across all three areas. Overall, NLGN2 expression was 
significantly lower in AD cases than in controls (F1,82 =23.515, P < 0.001; Fig. 5.18). The Group  
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Area interaction also reached significance (F2,52 =4.345, P =017); although expression was lower in 
AD cases than controls in all areas, it was more marked, and significant, in the two areas most 
affected by disease pathology (Fig. 5.19). 
 
Fig. 5.18. NLGN2 transcript expression by case-group averaged across the three areas. 
Details as for Fig. 5.10; *, significantly different from controls, see text. 
 
Fig. 5.19. NLGN2 mRNA copy numbers by case-group and area. Details as for Fig. 
5.11; *, significantly different from controls in the same area. Post-hoc Newman-
Keuls testing showed significantly lower expression in AD cases than controls in 
hippocampus (P = 0.002) and inferior temporal cortex (P = 0.001). No significant 
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5.4.10 Neuroligin-2 transcript expression and gender 
The influence of gender on the expression of NLGN2 transcripts was studied no significant 
difference was found (F1,80 = 0.175, P =0.67). Post-hoc testing showed there were significantly lower 
NLGN2 mRNA levels in in both male and female AD cases than in same-sex controls (Fig. 5.20). 
The Group  Gender  Area interaction was not significant (F2,48 =0.015, P = 0.98) because patterns 
were similar in the three regions, as portrayed by post-hoc testing (Fig. 5.21). 
 
Fig. 5.20. NLGN2 copy numbers by case-group and sex. Details as for Fig. 5.11; *, 
significantly lower than expression in same-sex controls, P < 0.05 by Newman-Keuls 
post-hoc test. 
5.4.11 Neuroligin-2 transcript expression and APOE genotype 
Expression trended lower in AD cases carrying the APOE 4 allele than in non-carrier 
AD cases, but did not reach significance (F1,82 = 3.028, P = 0.08; Fig. 5.22). The Group  Nº 
of APOE alleles interaction was not significant (F1,80 = 0.160, P = 0.68), in essence because 
the same pattern was seen in subjects with the same genotype (Fig. 5.23). The further 
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Fig. 5.21. NLGN2 copy numbers by case-group, area, and sex. Details as for Fig. 
5.11; *, significantly lower in AD cases than in same-sex controls by Newman-Keuls 
post-hoc testing, P < 0.001. No other comparison was statistically significant. 
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Fig. 5.23. NLGN2 transcript expression by case-group and the Nº of APOE 4 alleles. 
AD cases and controls were separated by APOE genotype as set out in Fig. 5.14 
legend; *, there was significantly lower expression in AD cases than controls both in 
subjects without an 4 allele (P = 0.014) and those with at least one (P = 0.002) by 
Newman-Keuls post-hoc test. 
 
Fig. 5.24. NLGN2 mRNA copy numbers by case-group, APOE genotype and area. 
Details as for Fig. 5.14; *, in hippocampus, expression was significantly lower in AD 
cases with no 4 alleles than in matched controls, while in inferior temporal cortex 
AD cases with at least one 4 allele showed lower expression than the corresponding 
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5.4.12 Neuroligin-2 transcript expression and pathological score 
The PS main effect on NLGN2 expression was not significant (F2,39 = 1.858, P = 0.16), but 
the PS  Area interaction was (F4,33 = 3.097, P = 0.02). There was a graded reduction in NLGN2 
copy number with disease stage in hippocampus. In occipital cortex the copy number did not vary. In 
inferior temporal cortex, there was no significant difference between mild and moderate stages but 
expression was markedly attenuated at the severe stage of the disease (Fig. 5.25). 
 
Fig. 5.25. NLGN2 copy number and pathological score. Details as for Fig. 5.17. 
Expression was significantly lower in hippocampus at the moderate stage than the 
mild stage (P < 0.001) and lower again at the severe stage (P < 0.001). Inferior 
temporal cortex showed significantly lower expression at the severe stage than at 
either earlier stage (P < 0.001). Newman-Keuls post-hoc tests. 
5.4.13 -Neurexin-1 transcript expression by case-group 
The copy number of NRXN1 transcripts was quantified as described in Methods, Section 
5.3. NRXN1 mRNA expression was significantly lower overall in AD cases than in controls 
(F1,82 = 5.303, P = 0.02; Fig. 5.26). The Group  Area interaction was not significant (F2,52 =0.777, 
P = 0.46), in essence because the same general pattern was seen in all three areas (Fig. 5.27). None of 
the within-area differences between cases and controls reached significance on post-hoc testing, but 
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within AD cases the expression in hippocampus was significantly lower than in the other two areas 
(Fig. 5.27). 
 
Fig. 5.26. NRXN1 transcript level by case-group averaged across the three areas. 
Details as for Fig. 5.10; *, significantly different from controls, see text. 
 
Fig. 5.27. NRXN1 mRNA copy numbers by case-group and area. Details as for Fig. 
5.11; †, significantly different from occipital cortex and inferior temporal cortex in the 
same cases, P < 0.001 by Newman-Keuls post-hoc test. The differences between AD 
cases and controls showed a strong trend in inferior temporal cortex (P = 0.06), and a 
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5.4.14 -Neurexin-1 transcript expression by gender 
Overall NRXN1 expression was significantly lower in males than in females (F1, 40 = 6.192, 
P = 0.017, and because the same pattern was seen in both case-groups the Group  Sex interaction 
was not significant (F1,80 = 1.457, P =0.23). Post-hoc testing confirmed the differences between cases 
and controls in each sex/between sexes in each case-group (Fig. 5.28). 
 
Fig. 5.28. NRXN1 copy numbers by case-group and sex. Details as for Fig. 5.11; *, 
significantly lower than expression in same-sex controls, and †, significantly different 
from opposite-sex subjects in the same case-group, P < 0.05 by Newman-Keuls post-
hoc test. 
The Group  Sex  Area interaction was not significant (F2,48 = 0.839, P = 0.43), in part 
because the pattern seen in Fig. 5.28 was repeated across the three areas (Fig. 5.29), and in part 
because the statistics for such a deep-level interaction were underpowered. Post-hoc testing revealed 
that the between-group difference only reached significance in occipital cortex in females, though 
there was a trend in inferior temporal cortex (Fig. 5.29). Within-subject expression was significantly 
lower in occipital cortex, a pathologically spared area, than in inferior temporal cortex, a strongly 
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Fig. 5.29. NRXN1 copy numbers by case-group, area, and sex. Details as for Fig. 
5.11; *, significantly lower in female AD cases than in female controls, P < 0.001, and 
†, significantly higher than in occipital cortex in AD males, P = 0.013, by Newman-
Keuls post-hoc testing. No other comparison was statistically significant. 
5.4.15 -Neurexin-1 transcript expression by APOE genotype 
When not divided by diagnosis, the overall level of NRXN1 transcript was lower in subjects 
with at least one 4 allele (F1,82 =6.612, P = 0.01; Fig. 5.30). The level of NRXN1transcript trended 
lower for both genotypes in AD cases than in matched controls, but the Group  Nº of 4 alleles was 
not significant (F1,80 =0.430, P =0.51; Fig. 5.31). There was a trend toward significance in the Group 
 Area  Nº of 4 alleles interaction but it was not significant (F1,80 = 1.770, P = 0.181). Post-hoc 
testing showed no significant difference in expression between AD cases and controls matched for 
APOE genotype in any area of the brain (Fig. 5.32). 
5.4.16 -Neurexin-1 transcript expression and pathological score 
There was a graded reduction in -neurexin-1 copy number with pathological score in all 
three areas of the AD cases, and the Area  Disease severity interaction was significant (F2,39 =8.255, 
P = 0.001). The pattern varied from region to region, and was most pronounced in inferior temporal 
cortex (Fig. 5.33), but all area showed markedly lower NLGN1 mRNA levels by the severe stage of 
the disease. 
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Fig. 5.30. NRXN1 transcript expression by APOE genotype. Details as for Fig. 5.14; 
*, significantly lower in subjects with at least one APOE 4 allele, see text. 
 
Fig. 5.31. NRXN1 transcript expression by case-group and the Nº of APOE 4 
alleles. Subjects were separated by APOE genotype as set out in Fig. 5.14 legend; 
there was a trend toward significantly lower expression in AD cases with at least one 
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Fig. 5.32. NRXN1 mRNA copy numbers by case-group, APOE genotype and area. 
Details as for Fig. 5.14; *, in hippocampus, expression was significantly lower in AD 
cases with no 4 alleles than in matched controls, while in inferior temporal cortex 
AD cases with at least one 4 allele showed lower expression than the corresponding 
controls, P = 0.001 by Newman-Keuls post-hoc testing. 
 
Fig. 5.33. NRXN1 copy number and pathological score. Details as for Fig. 5.17. 
Expression was significantly lower in hippocampus at the severe stage than at either 
earlier stage (P = 0.01 and P = 0.001). In occipital cortex, expression was lower at 
both moderate (P = 0.03) and severe (P = 0.001) stages than at the mild stage. 
Expression trended lower in inferior temporal cortex at the moderate stage than at the 
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mild stage, (P = 0.063) and was significantly lower at the severe stage than at the mild 
stage (P < 0.001). Newman-Keuls post-hoc tests. 
5.5 Discussion 
Loss of memory and cognitive dysfunction are associated with the regional impairment of 
specific synapses, which precedes neuron loss, in the AD brain. Synaptic impairment occurs at early 
in AD stages and may result from a loss in the amounts and activities of key synaptic proteins, 
enzymes and receptors. Alterations in the quantities of synaptic proteins that mediate memory, 
learning, synaptic strength, and plasticity have been reported in the early stages of AD, and underpin 
the changes in LTP and LTD in animal cell culture models of AD and other diseases. Most changes 
in synaptic protein expression in many neurological diseases take place at the level of transcription. 
In the current study, methods were developed to quantify the mRNA levels of the post-synaptic 
proteins neuroligin-1 and -2 and the pre-synaptic protein -neurexin-1 by absolute qRT-PCR assays. 
Expression of the three transcripts was assessed using human autopsy brain tissue from AD cases 
and gender- and age-matched controls. Two of the areas studied are the most affected areas in AD: 
hippocampus and inferior temporal cortex, while the relatively spread occipital cortex was used as a 
regional control. Expression of the three transcripts was also evaluated with respect to gender, APOE 
genotype and pathological severity. 
5.5.1 Neuroligin-1 mRNA expression 
Neuroligin-1 is a post-synaptic protein located in the excitatory synapse that has been 
primarily implicated in autism spectrum disorders (ASD) as mutations in gene encoding neuroligin-1 
has been linked with some rare cases of inherited ASD (Jamain et al., 2003, 2008, Hines et al., 2008, 
Lawson-Yuen et al., 2008, Talebizadeh et al., 2005, Yan et al., 2005, Ylisaukko-Oja et al., 2005b). 
The involvement of neuroligins in synapse formation has been addressed in several studies (Lisé and 
El-Husseini, 2006, Craig and Kang, 2007). The role of neuroligin-1 in LTP in the amygdala and the 
development of associative fear memory in adult animals has been established (Kim et al., 2008). 
Neuroinflammation activated by amyloid deposition results in epigenetic suppression of neuroligin-1 
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expression and consequent damage of synaptic function and memory (Malkki, 2014). These data 
help to explain the pathogenic effects of amyloid deposition at the molecular level. The reduction of 
neuroligin-1 expression lowers synaptic efficacy, impairs synaptic plasticity, and disrupts memory. 
In line with these ﬁndings, the data presented here showed that NLGN1 mRNA copy numbers were 
lower in AD cases than in controls. This finding was surprising because it conflicts with data on 
neuroligin-1 protein level presented in Chapter 3, which were high in AD cases than in controls. 
Significant differences were observed in NLGN1 transcript level between AD cases and controls in 
both hippocampus and inferior temporal cortex. 
The highest level of NLGN1 transcript expression was found in occipital cortex, which is 
relatively spared in AD. Both hippocampus and inferior temporal cortex showed lower transcript 
levels. Also noteworthy was the significant, graded decrease in NLGN1 transcript levels with 
increasing severity of disease in both hippocampus and inferior temporal cortex. In occipital cortex, 
NLGN1 transcript copy number was lower at the moderate stage of disease than at the mild stage, but 
higher again at the severe stage. The latter could portray attempts by neurons to form new contacts in 
this region that is resistant to AD pathology, as neuroligin is critical in this process. NLGN1 
transcript copy number was significantly lower in AD males than in AD females, especially in 
hippocampus and inferior temporal cortex, and lower in AD males than in male controls. 
5.5.2 Neuroligin-2 mRNA expression 
Neuroligin-2 and its presynaptic binding partner, neurexin, form a complex in the synapse 
that has an important role in synaptogenesis (Huang and Scheiffele, 2008, Südhof, 2008). NLGN2 
gene knockout in vivo and acute NLGN2 transcript knockdown by shRNAs in vitro both generate 
significant deficits in synaptic transmission (Varoqueaux et al., 2006, Chih et al., 2005). 
Overexpression of NLGN2 with GABAA receptors in HEK cells can induce functional GABAergic 
innervation from surrounding neurons (Dong et al., 2007), whereas knockdown of NLGN2 markedly 
reduces GABAergic synaptogenesis (Sun et al., 2013, Poulopoulos et al., 2009). Transgenic mice 
overexpressing NLGN2 display improved GABAergic transmission (Hines et al., 2008), which is 
impaired in NLGN2 knockout mice (Blundell et al., 2009). 
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In the current study, the expression of NLGN2 transcripts was significantly lower in AD cases 
than in age- and gender-matched controls. Regionally, NLGN2 expression in both AD cases and 
controls was lowest in occipital cortex and highest in inferior temporal cortex and hippocampus. The 
high level in hippocampus could relate to the critical function of this molecule in regulating 
contextually appropriate emotional behaviour (Jackson et al., 2012, Belichenko et al., 2009). 
The level of NLGN2 transcript varied with pathological score in AD cases. In hippocampus, 
NLGN2 expression decreased with increasing severity of disease. For occipital cortex and inferior 
temporal cortex, the transcript level was higher at moderate stages but lower again at late stages of 
the disease. However, dividing the data by transcript, area and pathological score gave a limited 
number of data points with some of the pathological scores in this higher-order analysis, and adding 
more cases to the study would help detect trends. NLGN2 transcript expression was lower in male 
AD cases than in male controls. The variations in NLGN2 transcript levels in AD cases and controls 
were compatible with neuroligin-2 protein expression, which showed the same trends. 
5.5.3 -Neurexin-1 transcript expression 
In the current study, NRXN1 mRNA copy number was significantly lower in AD cases than 
in age- and gender-matched controls. The highest transcript expression was found the occipital 
cortex area, which is the area least affected by AD of the three studied, while the lowest expression 
was observed in the hippocampus, which is the most-affected area in the AD brain. NRXN1 
expression was lower in male AD cases than in male controls. The variations in NRXN1 level in 
males were compatible with NLGN1 and NLGN2 transcript levels in AD cases and controls. This 
may indicate that the male cases included in the current study had more-severe Alzheimer’s disease 
than the females. From Table 5.1 it may be seen that the males were on average younger (75 ± 2.5y) 
than the females (83 ± 2y), and this was statistically significant (t12 = 2.367, P = 0.036); earlier age at 
death can been argued to be an inverse index of severity (Hynd et al., 2001). 
NRXN1 mRNA copy number was lower in AD cases carrying APOE 4 alleles than in non-
carriers. Note, however, that most AD cases in the current study carried at least on APOE 4 allele 
P a g e  | 160 
(9/14), so this finding must be treated with caution. NRXN1 transcript expression decreased with 
increasing pathological severity of disease, both overall and in all three areas, which may stem from 
the reduction in total synaptic number. However, additional cases are needed to validate this. 
5.5.4 APOE genotype and transcript expression 
APOE genotype adds more complexity to the pathophysiology of AD. The APOE 4 allele 
influences the prevalence of AD and lowers the age of onset in sporadic cases (Ashford, 2004). It is 
noteworthy that in this study, two of the AD cases possessed a copy of the “protective” 2 allele, 
and, as in the Chapter 3 study, several of the controls had the “deleterious” 4 allele, clearly 
demonstrating that these factors influence risk rather than exhibiting classical Mendelian genetics. 
It was predicted that the 4 allele might impact the pathological severity of brain samples 
from AD cases. In this study, the quality of RNA was poorer in AD cases than in controls, as 
assessed by RIN. Nevertheless, no differences were observed in the expression of any of the three 
transcripts with respect to APOE 4 genotype by group. The current study used AD cases and 
controls in whom both diagnoses were pathologically confirmed by detailed examination at autopsy. 
The brain tissue was mostly from late-onset patients, and the transcripts detected reflect the impact of 
end-stage AD. The conclusions from these mRNA studies give a range of insights and add new data 
to assist in understanding AD progression and pathology. 
5.5.5 Limitations of the study 
Overall, the data presented here on NLGN1, NLGN2 and NRXN1 transcript expression by 
qRT-PCR in AD cases and controls show complex variations in gene expression patterns that suggest 
the involvement of multiple cellular pathways in AD progression. Studies of expression in human 
autopsy brain are restricted by various factors such as mRNA variability between patient–patient and 
control–control groups, which can occur due to differences in genetic makeup and lifestyle. These 
may make gene expression patterns complex in ways are not faced in animal studies (Mirnics and 
Pevsner, 2004). The most important lifestyle factors to be considered include smoking, alcohol 
consumption, physical exercise, and diet, which have significant effect on gene expression in the 
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brain (Dodd et al., 2006, Cotman and Berchtold, 2002). Additional factors like education and 
exposure to environmental contaminants could also have impacts (Thiriet et al., 2008, Miller et al., 
2009, Andin et al., 2007). 
The medical history of the subjects is an important potential confound for consideration, 
because medication can change mRNA expression, but in the current study medical histories were 
not available. To fully explore AD pathogenesis, it would be ideal to examine brain tissues from 
unmedicated subjects, but this is unlikely for both AD cases and controls in this age-group. The 
results from this study might be aided by comparisons with mRNA expression in AD post-mortem 
brains by conventional methods such as Northern blots and microarrays, but the methodology used is 
currently considered to be the gold standard for quantification. An important consideration is th the 
in AD that neuropathology of AD does not affect all brain regions to the same extent; this was 
exploited here by comparing several regions from each brain, such the subjects acted as their own 
controls. This is particularly important to help reduce the impacts of some of the factors discussed 
above. 
Correlating synaptic protein transcript levels at autopsy with clinical changes observed ante-
mortem an important goal for future work, to obtain a more complete picture of the cases included in 
the study. Clinical data such as the Mini-Mental State Examination (MMSE) and ADAScog for each 
subject was not available for most cases used here, which come mainly from community donors. 
Thus, clinical correlates could not be studied. For autopsies that have been in the brain bank for a 
long time, there are legal aspects of privacy and ethics which made it difficult to recover data, if 
permission was not explicitly gained from the next of kin at the time of autopsy. Many subjects now 
being collected have a much higher level of clinical and other data available. 
The method used to determine the pathological score of disease severity is not the same as 
Braak staging, which is based on measuring the spread of NFTs and A across all areas in a brain 
and gives an accurate representation of actual AD severity. The method used to check the severity of 
the disease in separate tissue samples here was based on the A plaque and NFT load, neuronal loss 
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and gliosis. This gave a score from 0 to 3 corresponding to the stages of none, mild, moderate and 
severe AD in the particular tissues from different brain areas. Both methods have the disadvantage of 
being semi-quantitative observations of histology markers, and require experienced pathologists who 
are blinded to diagnosis. 
Giving a pathological severity score for each area used can overcome problems related to 
determining the significance of more-complex, localized interactions, but in the current study it was 
difficult to obtain sufficiently large numbers of samples with some scores. For instance, there were 
relatively few samples with pathology scores of 1 or 2 available for hippocampus and inferior 
temporal cortex, while the opposite was true for occipital cortex. Therefore, it was difficult to obtain 
statistically significant differences with the number of AD cases available. This problem impacts the 
transcript level by area, APOE, and pathological score interactions. 
It has been widely noted that transcript expression often does not relate to protein expression 
for the products of the same gene, but it can predict overall protein expression. That can be due to 
different post-translational factors that might impact overall protein isoforms, trafficking, recycling 
and degradation. These processes may be badly disrupted in neurodegenerative disease. As a result, 
some differences were not detected in the expression of neuroligin and neurexin transcripts between 
AD cases and controls, even though marked differences were found at the level of protein expression 
of these synaptic adhesion molecules. 
It’s hard to correlate the RNA and protein data because the scales are so different. We applied 
different Box-Cox transforms to the protein and RNA data, which makes regression analysis very 
problematic. In preparing the protein-RNA comparison data for publication we will seek the advice 
of a professional statistician on this point. It is noteworthy that all possible variations can be found in 
the literature: RNA concentrations can show differences between disease cases and controls that are 
not reflected in protein levels; or the two moieties can be congruent; or protein levels can differ 
where no differences in RNA concentrations can be found. The present work is based on a single 
time-point in the subject’s life – i.e., death – and the abundance of transcripts and proteins measured 
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reflect the difference in the synthesis and degradation of each as well as possible differences in 
location, compartmentalization, and trafficking. 
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Chapter 6 
6 Genetic association of neuroligins and neurexins with AD 
6.1 Aim of the research 
The aim of this chapter was to use a case-control association approach in an Australian 
Caucasian population to confirm the association between AD and the single nucleotide 
polymorphism (SNP) rs17757879 in NRXN3, previously reported in a Spanish cohort. A meta-
analysis of genome-wide association studies (GWAS) had shown that this SNP had a consistent 
protective effect. 
6.2 Introduction 
AD genetics can be divided into two types. The first leads to early appearance of the disease, 
at around 50 to 65 years, and has a strong familial clustering and dominant Mendelian transmission 
linked to one of three genes, APP, PSEN1 and PSEN2. Mutations in any of these lead to 
modifications in the production of A (Tanzi and Bertram, 2005). However, only 5% of AD cases 
appear have these familial forms of the disease (Janssen et al., 2003). The second type is by far the 
more common; cases show later-onset, around 65 years of age, and there is no significant familial 
aggregation. The genetic underpinning of this form comprises a number of low-penetrance, common 
risk alleles at different genomic loci that may have impact on various pathways in the production and 
accumulation of A. Several lines of evidences suggest that combinations of these risk-factor genes 
have significant effects on disease susceptibility and age of onset (Bertram and Tanzi, 2008). Over 
the last three decades several very large candidate-gene association studies have been conducted on 
500 genes identified as a possible risk factors for late-onset AD (Bertram et al., 2007). Recently, new 
markers, which are found near or within the following genes: CLU, PICALM, CR1, BIN1, MS4A, 
CD2AP, ABCA7, EPHA1, and CD33, have been linked with AD in GWAS (Seshadri et al., 2010, 
Lambert et al., 2009). However, the 4 allele of APOE still shows the strongest association with late-
onset AD (Saunders et al., 1993). 
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AD is considered to be a polygenic disorder (Pedersen, 2010) and its complex genetic 
architecture makes genetic analysis difﬁcult. A pathway-based method has been applied to the 
available GWAS datasets to explore biological mechanisms underlying AD susceptibility. 
Significant pathways related to the immune system have been identified using KEGG analysis (Hong 
et al., 2010, Jones et al., 2010, Lambert et al., 2010). (Lambert et al., 2009) performed a GenGen 
pathway-based analysis of a French AD GWAS dataset and found several signiﬁcant pathways 
related to autophagy and the immune system. These pathway-based approaches complement standard 
single-marker analysis by extracting more biological information from the GWAS datasets. Another 
recent study consistently found an association between the CAM pathway and AD susceptibility in 
two GWAS datasets (Liu et al., 2012). 
The role of CAM in cognitive decline in AD and the involvement of genes such as PS1 in 
regulating the processing of neuroligins and neurexins, as set out in Section 1.4.4.1, have led to the 
suggestion that mutations in NLGN or NRXN genes might have roles in sporadic AD. Five GWAS 
included 1,256 SNPs in the NRXN1, NRXN2, NRXN3, and NLGN1 genes (3,009 AD cases and 3,006 
controls). Meta-analysis identified one SNP in the NRXN3 gene (rs17757879) that showed a 
consistent protective effect in all the GWAS, although the differences between AD cases and 
controls did not reach statistical significance (Martinez-Mir et al., 2013). Dividing the cases by 
gender showed that the protective effect was limited to males. A replication study conducted in a 
Spanish cohort of 1,785 AD cases and 1,634 controls confirmed the protective effect in males. These 
data suggest a possible role for NRXN in AD. I undertook to validate the results in this chapter by 
genotyping the NRXN3 marker in genomic DNA (gDNA) from Queensland Brian Bank. 
6.3 Methods 
6.3.1 gDNA preparation from autopsy brain tissue 
Autopsy brain tissue samples stored at –80°C in 0.32M sucrose according to the Dodd et al. 
(1986) protocol were obtained from Queensland Brain Bank. The phenol-chloroform method was 
used for gDNA extraction. Small pieces from each brain were thawed and incubated overnight in 
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1 ml lysis buffer (2% SDS, 200 mM NaCl, 50 mM EDTA, 50 mM Tris-HCl, pH 8) and 0.4 mg 
protease K at 37°C. Next day, 1 ml of phenol:chloroform:isoamyl alcohol (Sigma-Aldrich) was 
added and the mixture vortexed and centrifuged at 13,000  g for 15 min at room temperature. The 
top aqueous layer was transferred to a new tube, 1 ml of phenol:chloroform:isoamyl alcohol was 
again added, and mixture vortexed and centrifuged at 3,000  g for 10 min. The top layer was 
transferred to new tube, 100 µl of 3 M sodium acetate and 2 ml ethanol were added and the mixture 
centrifuged at 3,000  g for 10 min at 4°C. The supernatant was discarded, 1 ml of 70% cold ethanol 
was added to the pellet and the mixture centrifuged at 3,000  g for 10 min at 4°C. The pellet was 
dried and resuspended in 0.5 ml TE buffer (10 mM Tris-HCl, 1 mM EDTA, pH 8.0). 
6.3.2 DNA quantification and quality Control 
DNA was quantified on a NanoDrop 1000 Spectrophotometer (Thermo Scientific, Scoresby, 
Vic, Australia). Samples with higher concentrations were diluted to 10 ng/µl and stored at –20°C 
until genotyped. 
6.3.3 DNA genotyping 
Genotypes for 162 AD cases and 119 controls for rs17757879 gene were obtained using 
Taqman SNP Genotyping Assay (Life Technologies; assay Nº C__34498830_10). This technique 
was performed in the ABI-ViiA7 RT-PCR facility located at the School of Chemistry and Molecular 
Biosciences. Assays were prepared by mixing 2.5 µl of 2 TaqMan® Genotyping Master Mix 
(Applied Biosystems; AmpliTaq Gold® DNA Polymerase ultrapure, buffer, dNTPs, ROX™ dye) 
with 0.25 µl of TaqMan® SNP Genotyping Assay containing sequence-specific forward and reverse 
primers and two TaqMan® MGB probes labelled with VIC and 6-carboxy-fluorescein (FAM; 
Applied Biosystems). 0.25 µl of MilliQ H20 was added and 2.5 µl of 10 ng/µl gDNA. Total reaction 
was 5 µl, performed in 384-well plates. PCR conditions were as follows: an initial denaturation step 
of 95°C for 10 min, followed by 40 cycles of 95°C for 15s and 60°C for 1 min and a final extension 
step of 60°C for 30s. 
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6.3.4 Genotyping quality control and validation 
 Chosen samples were sequenced as a positive control to validate genotyping methods. To 
confirm the reproducibility of the genotyping results, about 30% of samples were randomly chosen 
for re-genotyping. The consensus rate ranged from 97% to 100%. 
6.3.5 Data quality control 
 Before performing genetic association analysis, data quality control was applied to check 
samples and gene polymorphisms with high rates of missing data, which could be caused by poor 
DNA quality and assay inefficiency. A Hardy-Weinberg equilibrium (HWE) test was performed to 
detect bias in dominant/recessive models of tri-allelic genotype for both AD cases and controls. 
6.3.6 Genetic association 
Genetic association of tri-allelic polymorphisms were detected by the 2 test of association 
for allelic (D vs d), genotypic (DD vs Dd vs dd), dominant (DD+Dd vs dd) and recessive (DD vs 
Dd+dd) models. 
6.3.7 Sample size and power 
Statistical power estimated by the Genetic Power Calculator (Purcell et al., 2003) showed that 
96 cases and 115 controls were required to attain 80% power at  = 0.05 for allelic comparison 
(relative risk increases by 2 in the presence of one copy of the risk allele). The prevalence of AD is 
13% according to Thies and Bleiler (2013). 
6.4 Results 
Genotyping missing data rates were less than 3% for all polymorphisms. The sample size was 
162 AD cases and 119 controls. The genotype distribution did not deviate significantly from HWE in 
cases or controls (Table 6.1). Data were re-classified as a bi-allelic model before analysis. Genotype 
distributions were analysed separately in SPSS v.17. 
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6.4.1 Genotypic and allelic associations 
 No significant difference was observed between AD cases and controls in general (2 = 
2.069, df = 2, P = 0.36). To check if there is any significant association with gender SNP, a 2 test 
was performed between AD cases and control for each gender separately. No significant differences 
were observed in females, but males trended toward significance in CC allele frequency (Table 6.2). 
To maximize the statistical power and to make a valid summary, CT and TT alleles combined were 
against the CC allele. This gave near-significant association in males but not in females (Table 6.3). 
Table 6.1. Genotype and allele distributions of rs17757879. 
 Alleles AD Cases HWE 2 Controls HWE 2 P 
-NRXN-3 
rs17757879 
CC 116 1.14 77 0.45 0.355 
CT 40 38 
TT 6 3 






AD Cases Controls 2 AD Cases Controls 2 
-NRXN-3 
rs17757879 
n = 83 n = 79 3.872; 
P = 0.144 
n = 79 n = 39 0.142; 
P = 0.931 
CC/CT/TT 63/17/3 50/27/2  53/23/3 27/11/1  
6.5 Discussion 
GWAS in AD was performed by Harold et al. (2009) and two SNPs in NRXN-3 were listed 
as possibly associated with AD. However, the same group perform larger follow-up work and the 
association with these two SNPs disappeared (Hollingworth et al., 2011). 
Considering the recent studies about the molecular interaction between -secretase and the 
neurexins and neuroligins (Suzuki et al., 2012, Saura et al., 2011, Martinez-Mir et al., 2013, Bot et 
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al., 2011) and the physical interaction of neurexin-neuroligin complex (Chih et al., 2006, Boucard et 
al., 2005), attention was given to these molecules and their genetic association with AD. A meta-
analysis utilizing five GWAS datasets was performed by including previous work conducted by the 
same group (Antunez et al., 2011). Antunez et al. (2011) found no association of NRXN or NLGN 
with sporadic AD; these data were similar to the result obtained from previous GWAS. By limiting 
the study to localized regions of the selected genes, an interesting and consistent association was 
observed — although not statistically significant — with the rs17757879 SNP within the NRXN3 
gene across the five GWAS analysed (Martinez-Mir et al., 2013). Remarkably, the effect observed 
with -NRXN-3 SNP was found only in males but not in females. 





AD Cases Controls 2 AD Cases Controls 2 
-NRXN-3 
rs17757879 
n = 83 n = 79 3.052; 
P = 0.057 
n = 79 n = 39 0.55; 
P = 0.49 
CC+CT/TT 63/20 50/29  53/26 27/12  
In this chapter I performed a genotyping study on the rs17757879 SNP with the available 
population from the Queensland Brain Bank. Tissue samples were taken from 162 AD cases and 119 
controls. The genotyping showed no significant association overall between the SNP and the disease. 
However, by divinding the subjects by gender, I found a trend toward significance between 
rs17757879 and AD. The most interesting finding was obtained by comparing subjects with at least 
one T allele (CT and TT) against CC homozygotes. This gave a near-significant result, which 
indicated that the T allele was protective against AD in males. Since the study was based on a 
prediction from earlier work, it may be justified to use 1-tailed statistics, in which case the P value 
would be significant, at 0.028. The data indicate that the effect size for the NRXN-3 SNP in AD is 
quite small, which would be consistent with it not being associated to AD in previous GWAS, 
although it should be noted that the sample was quite small for genetic work. A repetition with a 
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larger sample is clearly necessary. Considering the dimorphism observed in the current and previous 
studies will be important to elucidate the role of NRXN-3 in AD susceptibility. 
Various studies have shown differential expression of genes in the brain according to sex 
(Cahill, 2006). Previous evidence of morphological and functional brain dimorphisms have raised the 
awareness of the importance of sex in molecular neuroscience. Differences between males and 
females are ultimately controlled by the gonadal sex determination systems (Carruth et al., 2002). 
Due to factors controlled by the sex chromosomes, the impact of hormones is central, especially the 
gonadal hormones and their actions in the CNS (Flerko, 1971). The main male hormone testosterone 
is produced by the testes during late gestational and neonatal periods, where it mediates brain sexual 
dimorphism. Sexual dimorphism could mediate male-female differences in the ætiology, incidence, 
and development course of different neurological disorders, including AD. 
Several lines of evidences support the hypothesis of sexual dimorphism in AD, such as the 
higher incidence of AD in females than in males (Mielke et al., 2014). There are differences in the 
expression of synaptic proteins in between female and male AD cases (Proctor et al., 2010, Agarwal 
et al., 2008). Differential expression of protein and mRNA transcripts of the neuroligin–neurexin 
complex between male and females was also observed in the current study (Chapters 3 and 5). 
Sexual dimorphism for ESR1and APOE in AD was also observed in some studies (Monastero et al., 
2006). These data indicate that stratification by sex in GWAS analysis could be a strategy to detect 
novel genetic alterations linked to AD susceptibility. NRXN-3 has not previously been reported to 
show sexual dimorphism in human subjects. However, in -NRXN-1 heterozygous KO mice only 
male and show increased locomotor activity in a new environment and improved habituation upon 
subsequent exposures to this environment (Laarakker et al., 2012). 
The results from the current chapter indicate that the -NRXN-3 gene could mediate AD 
susceptibility in males, and that the differences between genders observed could explain the lack of 
association of -NRXN3 with AD in published GWAS. Additional replication studies in bigger 
samples are required to confirm these results. 
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6.5.1 Limitation of the study 
Some DNA samples for both cases and controls were obtained from different sources that 
produce characteristic that should be considered. The geographical origin, and as a result the 
ethnicity, of the subjects, was not 100% confirmed as Caucasian. As noted, the sample size was very 
small, and must it be considered to be a pilot. Increasing the number of subjects will provide more 
reliable results. 
The choice of the technique use for genotyping here was based on many factors, including 
accuracy of the assay, sensitivity, robustness, reproducibility, cost, and reliability. A SNP detection 
assay is capable of detecting mixed alleles and it is crucial to note that the TaqMan genotyping assay 
is a PCR-based protocol that discriminates the presence of either allele based on the affinity of one 
probe to the SNP sequences of the allele present as opposed to the one not present. Allele detection 
relies on the chemistry of each set of probes, which should provide accurate results so long as the 
samples are subjected to a low number of freeze-thaw cycles (ideally, none) and are stored at the 
right temperature. Care was taken here to only thaw samples once, at the time of homogenization; as 
noted, they had been stored at –80°C since autopsy. 
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Chapter 7 
7 Final discussion, conclusions and future direction 
7.1 General findings and implications of the project 
Alzheimer’s disease was first described in 1906, but no cure has been found nor any drug 
with significant impact developed. The characterization and sequencing of the main constituents of 
A and NFTs has helped established links between these pathological markers and AD. Although 
this was an important advance in knowledge of the basic roles of these proteins and their critical 
function in neurotoxic pathways in AD, it has not led to significant attenuation of the disease. Most 
researchers agree that A and NFTs have a significant function in the overall pathophysiology of 
AD; these deposits are pathological alterations that take place quite early in the disease timeline. 
Much evidence supports the idea that synaptic loss and dysfunction are better correlates with early 
cognitive decline in AD. A significant outcome of synaptic failure is the disruption of plasticity and 
LTP at early stages in AD animal models (Rowan et al., 2003). These functionalities are major 
mediators of memory and learning processes, so it is likely that such alterations play roles in the 
early in cognitive problems experienced by AD sufferers as the disease develops. The mechanisms 
that underlie synaptic dysfunction and neuronal loss are still unknown. Nevertheless, results from 
different studies have detected common changes in systems and pathways, which provide indications 
of the proteins or receptors that are most likely altered in the disease. The aim to detect these 
synaptic protein alterations was the basis of the studies in this thesis. 
7.2 The expression of neuroligin and neurexins proteins and transcripts in AD 
Presented here is the first study to quantify neurexins and neuroligins at both the transcript 
and protein level in AD. In Chapter 2, a quantitative immnodetection method was developed. First, 
recombinant truncate neuroligin-1 and neuroligin-2 proteins were cloned, expressed, and purified. 
These were used as standards to precisely quantify endogenous neuroligin-1 and neuroligin-2 in two 
of the most affected area in the brain, hippocampus and inferior temporal cortex, and the relatively 
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spared occipital cortex. -Neurexin-1 protein level was quantified in the same area by the same 
approach, using a commercial sample of neurexin recombinant protein. A major novel finding was 
the differing regional patterns of these proteins in AD cases and controls. Notably, the level of 
neuroligin-1 protein was significantly higher in AD cases than in controls. This difference was 
restricted to hippocampus and occipital cortex; the lack of difference in inferior temporal cortex was 
unexpected, since it is one of the most affected areas in the AD brain. In contrast, the opposite 
pattern was found for neuroligin-2 in the same AD cases and controls. Neuroligin-2 protein 
expression was lower in AD cases than control in all areas, but the most marked reduction was in 
inferior temporal cortex. The contrasting patterns of neuroligin-1 and neuroligin-2 expression in AD 
may reflect the complementary functions of these proteins at the synapse. Both molecules are 
localized to the post-synaptic density, but neuroligin-1 is specific for excitatory synapses while 
neuroligin-2 is specific for inhibitory synapses. It has been reported, in studies conducted in vitro 
using biochemical and physicochemical techniques, that neuroligin-1 binds to A oligomers and that 
this binding takes place via the extracellular domain of neuroligin-1. This signifies that neuroligin-1 
is a putative target for A oligomers at excitatory synapses. On the other hand, A reportedly does 
not bind to neuroligin-2, which is specific for inhibitory synapses. A binding may explain the 
higher level of neuroligin-1 in AD cases found here. A facilitates glutamate-mediated synaptic 
transmission in animal models, which could lead to alterations in the homeostasis of neuronal 
networks, a phenomenon that has been widely documented in AD (Palop et al., 2007, Cuevas et al., 
2011). Neuroligin-1 performs a significant function as an adhesion protein on the post- synaptic 
membrane, where it stabilizes and maintains synaptic transmission; the binding of A oligomers in 
AD would thus have a significant impact (Dinamarca et al., 2011). 
In the current study the level of -neurexin-1 was higher in AD cases than in controls, but 
this difference was not significant. This slight increase could reflect neurotoxicity arising from the 
binding of A to neuroligin-1, given that -neurexin-1 is located on pre-synaptic terminals. At these 
synapses it binds to neuroligin-1 and forms heterophilic adhesion complexes. Any disturbance of this 
binding could have an impact on the integrity of excitatory synaptic contacts in AD. 
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To further understand the roles of these molecules in AD, the levels of neuroligin-1, 
neuroligin-2 and -neurexin-1 transcripts in hippocampus, occipital cortex and inferior temporal 
cortex in AD cases and controls were measured using absolute quantification RT-PCR TaqMan 
assays (Chapter 5). The data obtained were in contradistinction to the protein data in Chapter 3. The 
expression of all three transcripts was significantly lower in AD cases than in controls. It was found 
that the mRNA copy number for all transcripts was negatively correlated with increasing the severity 
of disease. That is, the observed down-regulation of the transcripts could follow the progression of 
disease. The contrary results obtained for protein levels for neuroligin-1 and -neurexin-1 may 
suggest that the higher protein levels arise from the binding of these proteins to A which induce the 
neurotoxicity at the protein level. 
7.3 Conclusion and Future directions 
No specific, single molecule is essential for synaptic assembly or function. Nevertheless, the 
neuroligin–neurexin complex is a major organizer of synaptic connections and a stabilizer of the 
networks of pre- and post-synaptic proteins across the synaptic junction. The ability of neuroligins 
and neurexins to determine and maintain excitatory and inhibitory synapses provides a basis for their 
potential roles in neurological disorders such as AD. Changes in groups of synapses in a neural 
circuit, as opposed to a general impairment of all synapses in all circuits, makes it very difficult to 
compare single-protein complexes across brain disorders. Identical molecular changes could lead to 
varying neurological outcomes in different brain diseases. 
Data presented in this thesis indicate that neuroligins and neurexins are implicated, at least in 
part, in synaptic loss in AD. Further understanding of the association between fluctuations in the 
levels of neuroligin–neurexin complexes could open up a new understanding of synaptic 
pathogenesis in AD. 
The proteolytic regulation of neuroligins and neurexins may be a key pathophysiological 
mechanism in AD, as well as playing a general role in trans-synaptic signalling in diverse neural 
circuits. Therapeutic strategies for preventing or ameliorating synaptic dysfunction in AD might 
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fruitfully explore whether, and how, this process can be modified. The pathological disturbance of 
synapses through disruption of the metalloprotease and -secretase cleavage pathways may be 
critical to synaptic deficits in mild cognitive impairment and early-stage AD, which then lead to 
cognitive dysfunction and neurotoxicity in late-stage AD. Impairments in the processing of the 
neuroligin–neurexin complex due to a loss of PS1/-secretase activity could contribute to neuronal 
disruption. Neurexins have the LNS domain responsible for interaction with the CLD of neuroligin 
across the synaptic cleft. The transmembrane domain and C-terminal cytoplasmic tail of neuroligins 
comprise a PDZ II binding motif crucial for targeting presynaptic proteins such as CASK, VELI and 
MINT that play roles in vesicle clustering (Tabuchi and Südhof, 2002). The physical interactions of 
neurexins with neuroligins on the extracellular side of the membrane, and with scaffolding proteins 
on the cytoplasmic side, underpin the assembly of synapses. Impaired processing of full-length -
neurexin-3 by - and -secretases could alter the activity of synapses in AD. As discussed earlier in 
the thesis, mutations in the catalytic core of -secretase that lead to early-onset forms of AD also 
impair the processing of -neurexin-3. 
Studies on the relationship between this complex and AD should attempt to answer the 
following questions: 1. Do neurexins and neuroligins function only by binding to each other, or 
through binding with other molecules? 2. Do different isoforms or splice variants of neurexins and 
neuroligins perform different functions? 3. Do these complexes have an effect on A accumulation? 
4. Does the impairment of neuroligin and neurexin processing and production play a role in the 
neuronal defects associated with a loss of PS/-secretase function in familial AD? 
The answers to these questions will provide insight into the mechanisms of synaptic adhesion 
in AD and other cognitive diseases. If the involvement of this complex in AD is confirmed, new 
diagnostic and therapeutic approaches might emerge, such as manipulating the neuroligin–neurexin 
interaction to prevent A accumulation in the brain, or perhaps preventing A from disrupting 
neuroligin–neurexin complexes. 
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9 Appendix 
9.1 Appendix for Chapter 2 
Human NLGN1 and NLGN2 wild-type sequences were gained from the NCBI database 
(Accession No: NP_055747 and NP_065846 respectively). 
9.1.1.1 NLGN1 
 1 ccaccgactc ctgcccgcct caacacaatg ccttacctgt gaagcttgag gccactcaag 
 61 ttccaaattt gtgacaaatc ccccagggct cactggagtg gcagatatag acctgcagct 
 121 aactggattt gatttataag agagaaatct gcagtcaatg cccactcttg ccacactgct 
 181 aatatggaaa acagaatgtt caataggata tggtctgata aatagtgatg attgaagatg 
 241 ctgctccaat acatgtgaaa tcaatgggag atatctgctg tctgaagatc tttcagagct 
 301 tttctcgaca agctcccctg taagaaatcg gaggtatatt ctaccattat acagtctttc 
 361 tcaagtggat ataaatacgt ttgcctcact gtaaccagac aactagacaa ctaatgtggg 
 421 accatggcac tgcccagatg cacgtggcca aattatgttt ggagagcagt gatggcatgc 
 481 ttggtacacc ggggattggg tgccccattg actctctgta tgttgggatg tttgcttcag 
 541 gctggccatg tgctatcaca aaaattggat gatgtggacc cactggtggc taccaacttt 
 601 ggaaagataa gagggattaa gaaggaactc aataatgaaa ttttggggcc tgttattcaa 
 661 tttcttgggg ttccatatgc agccccacca acaggggaac gtcgttttca gcctccagaa 
 721 ccaccatctc cctggtcaga tatcagaaat gccactcaat ttgctcctgt gtgtccccag 
 781 aatatcattg atggcagatt gccagaagtc atgcttcctg tgtggtttac taataacttg 
 841 gatgtggttt catcatatgt gcaagaccag agcgaagact gcctatattt aaatatatat 
 901 gtcccgactg aggatgatat tcgggacagt gggggtccca aaccagtgat ggtgtatatc 
 961 catggtggct catatatgga aggtactgga aatttatatg atggaagtgt cttggcaagt 
 1021 tatggcaatg tgatcgtcat cacagtcaac tatcgacttg gagtactcgg tttcttgagt 
 1081 acaggcgatc aggctgcaaa ggggaactat ggactccttg atctcataca agctttaaga 
 1141 tggactagtg aaaacattgg attctttggt ggtgacccct taagaatcac tgtttttgga 
 1201 tctggtgctg ggggttcatg tgtcaacctg ctgactttat cccattattc tgaaggtaac 
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 1261 cgttggagca attcaaccaa aggacttttt caacgagcaa tagctcaaag tggaacagcc 
 1321 ctttccagct gggctgttag ttttcaacct gcaaaatatg ctagaatgtt ggccacaaaa 
 1381 gttggttgca atgtttcaga tacagtagag ttagtggaat gcctacagaa gaagccttac 
 1441 aaagaacttg ttgaccaaga tattcaacca gctcgatacc acatagcctt tggacctgtg 
 1501 attgatggtg atgtaatacc agacgacccc cagatattga tggagcaagg agagtttctc 
 1561 aactatgata taatgttagg agtgaaccaa ggggaagggt taaaatttgt tgaaaatata 
 1621 gtagatagcg atgatggtat atcagctagt gattttgact ttgctgtttc aaattttgtt 
 1681 gataatttat atggatatcc tgaaggcaaa gatgttttga gagaaaccat taagttcatg 
 1741 tatactgact gggctgaccg tcataaccct gaaaccagaa gaaagacatt actggctttg 
 1801 tttacggacc atcagtgggt ggcaccagct gtagccacag cggatcttca ctcaaacttt 
 1861 ggttcaccta cgtacttcta tgccttttac catcattgcc aaacagatca ggttccagct 
 1921 tgggctgatg cagcccacgg agacgaggtt ccctatgtac tgggaatccc catgattggc 
 1981 cctacagagt tatttccttg caatttctcc aaaaatgatg tgatgctgag tgcagttgta 
 2041 atgacatact ggacaaattt tgctaaaact ggtgacccaa atcaaccagt ccctcaagac 
 2101 acgaaattca ttcataccaa acccaaccgt tttgaagaag tagcatggac cagatattcc 
 2161 cagaaagacc aactttatct ccatattgga ttaaaaccaa gagttaaaga acattacaga 
 2221 gccaataagg tgaacctctg gttggagttg gtacctcatc tgcataatct caatgacatt 
 2281 tctcagtata cctctacaac aactaaagtg ccatcaactg acatcacttt cagacctacg 
 2341 agaaaaaatt ctgtacctgt cacgtcagcc tttcccactg ccaagcagga tgatcccaaa 
 2401 caacaaccaa gtccattttc agtggatcaa agggactact caacagagct gagtgtcact 
 2461 attgcagttg gagcatcact gctgtttctg aacatcttgg cctttgcagc cctgtactac 
 2521 aaaaaggata agaggagaca tgatgttcac aggagatgca gccctcagcg cactactacc 
 2581 aatgatctaa cccatgcaca agaagaggaa atcatgtccc tccaaatgaa gcacactgat 
 2641 ttggatcatg aatgtgagtc cattcatcca catgaggtgg ttcttcggac cgcctgtccc 
 2701 ccagattaca cactagctat gaggaggtca cctgatgatg ttcccttaat gacacccaac 
 2761 accattacaa tgattcccaa cactatacca gggattcagc ccttacacac attcaataca 
 2821 tttactggag gacagaacaa tactctgccc catccccatc cccaccccca ttcacattca 
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 2881 acaaccaggg tatagccaga taagagaaac aaactatttt ttttgatgga ttgcagtaaa 
 2941 cgatcactga agattccttg gctttcaacc tacaagactt actatttaaa taaggaggaa 
 3001 tattatgtga atatacatat caagaacttt gggggttttg aaaaaaatga attgtatata 
 3061 tacaaatcaa ctttaaaaac aaatttcaat tgcttgaagc aattgttctg aatgatactt 
 3121 tttcattcac attcaagaat taattttttg aagatttaag ttacataatg gaattaggca 
 3181 tgtggaacac caaacaggaa agaactatgt ctgaaatata aaaaataaaa ataaaaaaac 
 3241 aactatgaat atgcacaagg gacacaccag tggaatgtca gataattttc accagttttt 
 3301 atttggagcc gttttattgt gtagaccata tttacatatt tggataagta cacaaagcgt 
 3361 caatgctgtt aatggcctta gcaaaggctc atgctgaaat ttgccagtaa aacaaagaag 
 3421 tttaaagact ggcaggtaca ccattatcac ataagtgctg tcagtataaa gttgtgggga 
 3481 taaaggaaac tggatatttt tagcacgatg tgcatgataa tttatatgct tggtggctgt 
 3541 gctgctgatt aagccgtaat taaaattctt ctcatcccat tggagttttt aatagaagct 
 3601 tcctccatca attggcagaa cctaaagaag attttaaggg gcaaaagtaa ttacaataaa 
 3661 ataattcaca gtagtttcaa tatagaagga attagctatt aaaggtattt gaagaaacta 
 3721 taggtatagt ggtgaatact cgctgatatg aatcccagaa aaaaatttcc tgtttttaat 
 3781 gttcttttca atcccatcta gataatttat agaaatataa ccctaattgg acatgtggta 
 3841 caggatctat aagttgctgt gtttttttgt tactctgtat tttgttcctt ttggtaaggt 
 3901 gaagtgtgtc caaagagtta cttgcaacag tctttcatga tatgaggatg cccccgtatt 
 3961 accactctga ttatagttct gagttctttg atttactcat gctgcatgac aaaatgttta 
 4021 ctaataacaa ttcattataa agttatatcc ctctttacat cacttatctt tctcactgag 
 4081 gttcattcac tggaatttac tcacgcaatc tcagtagagt acaacgtaga tacagaacct 
 4141 aggagagtca acatctggag gattttagtc tttcttacac atatgtgtga ttttaaacga 
 4201 atattctcag accacaggaa actcttcatc cccctgttgt ttaccagtaa cagtatatca 
 4261 cagacctttc caaatgtttg tatatgtaat cagatgtaca tttatattga aaaacaaatg 
 4321 agatggactt aaagagcaca tcctgataaa tactttctct ctcacctgta ctatatttct 
 4381 attagactaa agttatgtga tttttttttt acattttttc agatgactag caattttgat 
 4441 agtttataag ataatgcaaa gaactttctc tgacaaacta actgcagtaa cagaaacctt 
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 4501 tcttttcagt tactcttttt caagaatgaa agattattat acaaaaaatt gtatactact 
 4561 tgatggaacc aactttgtac atcttggcca tgtcactggt cattgtgtga aataaagata 
 4621 atctggataa tgactattag tccaatgcta agaaacatga tctttgctca ttaaagagct 
 4681 aaaatgttta ttgctgtttt gtctttcttt tttctaaaaa aagaaaaaaa agaaaaaaag 
 4741 gaaaagaaga acaaagaaac atgactgtct caaagagtaa tttttctaga ttagaccagt 
 4801 caggtttttg aagacatata ggtaacttcc acagaaaaca caaacatgta tttaaaggca 
 4861 agtctcatct aagatgaaac tcataaaaat tatttaatgt ttgttatgaa tttaaaag 
9.1.1.2 Compute pI/Mw 
Theoretical pI/Mw (average) for the user-entered sequence 
 10 20 30 40 50 60 
TMALPRCTWP NYVWRAVMAC LVHRGLGAPL TLCMLGCLLQ AGHVLSQKLD DVDPLVATNF 
 70 80 90 100 110 120 
GKIRGIKKEL NNEILGPVIQ FLGVPYAAPP TGERRFQPPE PPSPWSDIRN ATQFAPVCPQ 
 130 140 150 160 170 180 
NIIDGRLPEV MLPVWFTNNL DVVSSYVQDQ SEDCLYLNIY VPTEDDIRDS GGPKPVMVYI 
 190 200 210 220 230 240 
HGGSYMEGTG NLYDGSVLAS YGNVIVITVN YRLGVLGFLS TGDQAAKGNY GLLDLIQALR 
 250 260 270 280 290 300 
WTSENIGFFG GDPLRITVFG SGAGGSCVNL LTLSHYSEGN RWSNSTKGLF QRAIAQSGTA 
 310 320 330 340 350 356 
LSSWAVSFQP AKYARMLATK VGCNVSDTVE LVECLQKKPY KELVDQDIQP ARYHIA 
Theoretical pI/Mw: 5.97 / 38921.59 
9.1.1.3 NLGN2 
 1 tccctctccc ccccttctct ctctctccga gggggggggg tcccagggag ggaggggggg 
 61 tcccccgatc agcatgtggc tcctggcgct gtgtctggtg gggctggcgg gggctcaacg 
 121 cgggggaggg ggtcccggcg gcggcgcccc gggcggcccc ggcctgggcc tcggcagcct 
 181 cggcgaggag cgcttcccgg tggtgaacac ggcctacggg cgagtgcgcg gtgtgcggcg 
 241 cgagctcaac aacgagatcc tgggccccgt cgtgcagttc ttgggcgtgc cctacgccac 
 301 gccgcccctg ggcgcccgcc gcttccagcc gcctgaggcg cccgcctcgt ggcccggcgt 
 361 gcgcaacgcc accaccctgc cgcccgcctg cccgcagaac ctgcacgggg cgctgcccgc 
 421 catcatgctg cctgtgtggt tcaccgacaa cttggaggcg gccgccacct acgtgcagaa 
 481 ccagagcgag gactgcctgt acctcaacct ctacgtgccc accgaggacg gtccgctcac 
 541 aaaaaaacgt gacgaggcga cgctcaatcc gccagacaca gatatccgtg accctgggaa 
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 601 gaagcctgtg atgctgtttc tccatggcgg ctcctacatg gaggggaccg gaaacatgtt 
 661 cgatggctca gtcctggctg cctatggcaa cgtcattgta gccacgctca actaccgtct 
 721 tggggtgctc ggttttctca gcaccgggga ccaggctgca aaaggcaact atgggctcct 
 781 ggaccagatc caggccctgc gctggctcag tgaaaacatc gcccactttg ggggcgaccc 
 841 cgagcgtatc accatctttg gttccggggc aggggcctcc tgcgtcaacc ttctgatcct 
 901 ctcccaccat tcagaagggc tgttccagaa ggccatcgcc cagagtggca ccgccatttc 
 961 cagctggtct gtcaactacc agccgctcaa gtacacgcgg ctgctggcag ccaaggtggg 
 1021 ctgtgaccga gaggacagcg ctgaagctgt ggagtgtctg cgccggaagc cctcccggga 
 1081 gctggtggac caggacgtgc agcctgcccg ctaccacatc gcctttgggc ccgtggtgga 
 1141 tggcgacgtg gtccccgatg accctgagat cctcatgcag cagggagaat tcctcaacta 
 1201 cgacatgctc atcggcgtca accagggaga gggcctcaag ttcgtggagg actctgcaga 
 1261 gagcgaggac ggtgtgtctg ccagcgcctt tgacttcact gtctccaact ttgtggacaa 
 1321 cctgtatggc tacccggaag gcaaggatgt gcttcgggag accatcaagt ttatgtacac 
 1381 agactgggcc gaccgggaca atggcgaaat gcgccgcaaa accctgctgg cgctctttac 
 1441 tgaccaccaa tgggtggcac cagctgtggc cactgccaag ctgcacgccg actaccagtc 
 1501 tcccgtctac ttttacacct tctaccacca ctgccaggcg gagggccggc ctgagtgggc 
 1561 agatgcggcg cacggggatg aactgcccta tgtctttggc gtgcccatgg tgggtgccac 
 1621 cgacctcttc ccctgtaact tctccaagaa tgacgtcatg ctcagtgccg tggtcatgac 
 1681 ctactggacc aacttcgcca agactgggga ccccaaccag ccggtgccgc aggataccaa 
 1741 gttcatccac accaagccca atcgcttcga ggaggtggtg tggagcaaat tcaacagcaa 
 1801 ggagaagcag tatctgcaca taggcctgaa gccacgcgtg cgtgacaact accgcgccaa 
 1861 caaggtggcc ttctggctgg agctcgtgcc ccacctgcac aacctgcaca cggagctctt 
 1921 caccaccacc acgcgcctgc ctccctacgc cacgcgctgg ccgcctcgtc cccccgctgg 
 1981 cgccccgggc acacgccggc ccccgccgcc tgccaccctg cctcccgagc ccgagcccga 
 2041 gcccggccca agggcctatg accgcttccc cggggactca cgggactact ccacggagct 
 2101 gagcgtcacc gtggccgtgg gtgcctccct cctcttcctc aacatcctgg cctttgctgc 
 2161 cctctactac aagcgggacc ggcggcagga gctgcggtgc aggcggctta gcccacctgg 
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 2221 cggctcaggc tctggcgtgc ctggtggggg ccccctgctc cccgccgcgg gccgtgagct 
 2281 gccaccagag gaggagctgg tgtcactgca gctgaagcgg ggtggtggcg tcggggcgga 
 2341 ccctgccgag gctctgcgcc ctgcctgccc gcccgactac accctggccc tgcgccgggc 
 2401 accggacgat gtgcctctct tggcccccgg ggccctgacc ctgctgccca gtggcctggg 
 2461 gccaccgcca cccccaccgc ccccctccct tcatcccttc gggcccttcc ccccgccccc 
 2521 tcccaccgcc accagccaca acaacacgct accccacccc cactccacca ctcgggtata 
 2581 gggggtgggt ggggaggccc tcctccccgg ccctccctgg cccggccact ccgaaggcag 
 2641 ggaggaggac ttggcaactg gcttttctcc tgtggagtcg tcacacgcca tccagcagcg 
 2701 ctaaggtgga catgggattc ctccctgcga tgcgtgtctt tcccacgcag agaagcccag 
 2761 tctcttctct ggatctgggc ctttgaacaa ctggggggcg ttttctcccc cccattggga 
 2821 caccagtctt cggtgtgtgg aatgtggtat tttcccgcgt ggaggtgtgc tttctcacaa 
 2881 cggggtgtgt tttcccatgt gcagggtgag gttttttttt gccaccctgg acacatgttg 
 2941 gccccctcaa agaatttctg tggggatttg taccccagaa tcctgttccc ccatcccttc 
 3001 tcccacctcc tcccctctcc ctccccctgg agaccctgga agtggtgtgt tcacatacag 
 3061 tgacccttgg ccaccagacc acagaggatg gagcctggga agcagcgagg aaatcacagc 
 3121 cccctcgccc ctgcctccct tgcccctacc ccggcgaagc atgttccccc cgacgccccc 
 3181 cttggcacaa gtcagatgaa gcacgttctg ccggggaggc cctcaccttc cagagaggac 
 3241 agacacagat ttcctgctgg gggagggagg agtccacgca tcctgatgct gcctggaagc 
 3301 ttattttccc gtggccagga cgcatttctc tgagtggaaa caggttcttg catgtggatg 
 3361 tgtgtttccc caggcagacg gcccctctct tcccagcact tccctgcctc ccccaggcct 
 3421 caggcccagc acccagttcc tcctcacatg gcaggtgagc acagacttct agttggcagg 
 3481 agctgaggag ggtgaacaaa ccccgaggga ggcccggccc ttgctcccga gttgggggga 
 3541 gggggtgtgg caacgtgccc cccgcagagg ccacgcatgt ttgaccaaag ccctcattgt 
 3601 ggtccgagga cagccttttc cccaggcctc agagcattgc tcatccgtgc caaactgggt 
 3661 aggtggattt gagcggaaag actcccaaaa tgtgccaaga atttcccagt cccaggcagg 
 3721 gcaggggaaa ctaagggcaa gcaggataca gggcgaggga tgtggcaggt gagggggctc 
 3781 ccgcctgtgc cccttctcct caccatgtct cccccaccct gcctcagttc tccgttcccc 
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 3841 ttcatctccg tccccctctt tgaagctgtc cccatctcag tgtcagacca gccttctcct 
 3901 cagctgacca ccctcctctg acccacgccc cctccttgtc tgaaagaaag gagccttgaa 
 3961 tggtggaggg aggcagtggg gagaaaggtc tcaccggaca ggttgggaga atgaggtcag 
 4021 cggtgctggg gaacagatgg agggggcagt ggggacaggg cttgggcaga caccagcagg 
 4081 aataatttga aatgtgtgag gtgactcccc ggagggcctt gggcttgggc atttgggaaa 
 4141 agaatgatgt ctggaagggc ttaagggaca cagtggacga ggggagagtc ctcatctgct 
 4201 ggcattttgt ggggtgttag tgccaaactt gaataggggc tggggtgctg tcttccactg 
 4261 acacccaaat ccagaatccc tggtcttgag tccccagaac tttgcctctt gactgtccct 
 4321 tctcttccta cctccatcca tggaaaatta gttattttct gatcctttcc cctgcctggt 
 4381 ctagctcctc tccaaacagc catgccctcc aaatgctaga gacctgggcc ctgaaccctg 
 4441 tagacagatg ccctcagaat tggggcatgg gaggggggct gggggacccc atgattcagc 
 4501 cacggactcc aatgcccagc tcctctcccc aaaacaatcc cgacaatccc ttatccctac 
 4561 cccaaccctt tgcggctctg tacacatttt taaacctggc aaaagatgaa gagaatattg 
 4621 taaatataaa agtttaactg tt 
9.1.1.4 Compute pI/Mw 
Theoretical pI/Mw (average) for the user-entered sequence 
 10 20 30 40 50 60 
TYVQNQSEDC LYLNLYVPTE DGPLTKKRDE ATLNPPDTDI RDPGKKPVML FLHGGSYMEG 
 70 80 90 100 110 120 
TGNMFDGSVL AAYGNVIVAT LNYRLGVLGF LSTGDQAAKG NYGLLDQIQA LRWLSENIAH 
 130 140 150 160 170 180 
FGGDPERITI FGSGAGASCV NLLILSHHSE GLFQKAIAQS GTAISSWSVN YQPLKYTRLL 
 190 200 210 220 230 240 
AAKVGCDRED SAEAVECLRR KPSRELVDQD VQPARYHIAF GPVVDGDVVP DDPEILMQQG 
 250 260 270 280 290 300 
EFLNYDMLIG VNQGEGLKFV EDSAESEDGV SASAFDFTVS NFVDNLYGYP EGKDVLRETI 
 310 320 330 340 350 
KFMYTDWADR DNGEMRRKTL LALFTDHQWV APAVATAKLH ADYQSPV 
Theoretical pI/Mw: 4.66 / 38192.81 
9.1.2 Forward primer 
BLASTN 1.8.4-Paracel [2010-10-31], (Altschul et al., 1997) 
Query= 5F_H06 (1039 letters) 
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Database: genbank 
9,537,552 sequences; 28,719,530,764 total letters 
Sequences producing significant alignments: (bits) Value Score E 
gi|123980671|gb|DQ891239.2| Synthetic construct clone IMAGE:1000... 1750 0.0 
gi|157928141|gb|EU176566.1| Synthetic construct H. sapiens clo... 1750 0.0 
gi|21595790|gb|BC032555.1| H. sapiens Neuroligin-1, mRNA (cDNA... 1748 0.0 
gi|5689476|dbj|AB028993.1| H. sapiens mRNA for KIAA1070 protei... 1748 0.0 
gi|31317253|ref|NM_014932.2| H. sapiens Neuroligin-1 (NLGN1)... 1748 0.0 
gi|168278798|dbj|AB385423.1| Synthetic construct DNA, clone: pF1... 1746 0.0 
gi|114590433|ref|XM_001166397.1| PREDICTED: Pan troglodytes simi... 1725 0.0 
gi|114590431|ref|XM_001166321.1| PREDICTED: Pan troglodytes simi... 1725 0.0 
gi|114590435|ref|XM_001166442.1| PREDICTED: Pan troglodytes simi... 1629 0.0 
gi|109044231|ref|XM_001082898.1| PREDICTED: Macaca mulatta Neuro...1606 0.0 
gi|109044228|ref|XM_001082770.1| PREDICTED: Macaca mulatta Neuro...1606 0.0 
gi|109044234|ref|XM_001083506.1| PREDICTED: Macaca mulatta Neuro...1511 0.0 
gi|149731113|ref|XM_001494392.1| PREDICTED: Equus caballus Neuro...1376 0.0 
gi|194222596|ref|XM_001494331.2| PREDICTED: Equus caballus Neuro...1376 0.0 
gi|74003762|ref|XM_545297.2| PREDICTED: Canis familiaris similar... 1344 0.0 
gi|113912208|gb|BC122827.1| Bos taurus Neuroligin-1, mRNA (cDNA... 1225 0.0 
gi|194664213|ref|XM_608505.4| PREDICTED: Bos taurus Neuroligin-1... 1225 0.0 
gi|17105267|gb|AC092967.5| H. sapiens 3 BAC RP11-521A24 (Roswe... 983 0.0 
gi|114590437|ref|XM_001166231.1| PREDICTED: Pan troglodytes simi... 975 0.0 
gi|114590429|ref|XM_001166258.1| PREDICTED: Pan troglodytes simi... 975 0.0 
gi|114590427|ref|XM_001166019.1| PREDICTED: Pan troglodytes simi... 975 0.0 
gi|114590425|ref|XM_001166092.1| PREDICTED: Pan troglodytes simi... 975 0.0 
gi|114590423|ref|XM_001166352.1| PREDICTED: Pan troglodytes simi... 975 0.0 
gi|114590421|ref|XM_526383.2| PREDICTED: Pan troglodytes similar... 975 0.0 
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gi|114590419|ref|XM_001166291.1| PREDICTED: Pan troglodytes simi... 975 0.0 
gi|164693376|dbj|AK307813.1| H. sapiens cDNA, FLJ97761 975 0.0 
gi|254281190|ref|NM_001163387.1| Mus musculus Neuroligin-1 (Nlgn... 924 0.0 
gi|68533534|gb|BC098461.1| Mus musculus Neuroligin-1, mRNA (cDNA... 916 0.0 
gi|109044244|ref|XM_001083140.1| PREDICTED: Macaca mulatta Neuro... 864 0.0 




















9.1.3 NLGN1 reverse primer 
BLASTN 1.8.4-Paracel [2010-10-31], (Altschul et al., 1997). 
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Query= 6R_H07 (1106 letters) 
Database: genbank 
9,537,552 sequences; 28,719,530,764 total letter 
Sequences producing significant alignments: (bits) Value Score E 
gi|21595790|gb|BC032555.1| H. sapiens Neuroligin-1, mRNA (cDNA... 2089 0.0 
gi|5689476|dbj|AB028993.1| H. sapiens mRNA for KIAA1070 protei... 2089 0.0 
gi|31317253|ref|NM_014932.2| H. sapiens Neuroligin-1 (NLGN1)... 2089 0.0 
gi|123980671|gb|DQ891239.2| Synthetic construct clone IMAGE:1000... 2089 0.0 
gi|157928141|gb|EU176566.1| Synthetic construct H. sapiens clo... 2089 0.0 
gi|168278798|dbj|AB385423.1| Synthetic construct DNA, clone: pF1... 2089 0.0 
gi|114590433|ref|XM_001166397.1| PREDICTED: Pan troglodytes simi... 2058 0.0 
gi|114590431|ref|XM_001166321.1| PREDICTED: Pan troglodytes simi... 2058 0.0 
gi|109044231|ref|XM_001082898.1| PREDICTED: Macaca mulatta Neuro...1939 0.0 
gi|109044228|ref|XM_001082770.1| PREDICTED: Macaca mulatta Neuro...1939 0.0 
gi|149731113|ref|XM_001494392.1| PREDICTED: Equus caballus Neuro...1685 0.0 
gi|194222596|ref|XM_001494331.2| PREDICTED: Equus caballus Neuro...1685 0.0 
gi|74003762|ref|XM_545297.2| PREDICTED: Canis familiaris similar... 1661 0.0 
gi|114590435|ref|XM_001166442.1| PREDICTED: Pan troglodytes simi... 1604 0.0 
gi|113912208|gb|BC122827.1| Bos taurus Neuroligin-1, mRNA (cDNA... 1542 0.0 
gi|194664213|ref|XM_608505.4| PREDICTED: Bos taurus Neuroligin-1... 1542 0.0 
gi|109044234|ref|XM_001083506.1| PREDICTED: Macaca mulatta Neuro...1485 0.0 
gi|114590427|ref|XM_001166019.1| PREDICTED: Pan troglodytes simi... 1114 0.0 
gi|114590425|ref|XM_001166092.1| PREDICTED: Pan troglodytes simi... 1114 0.0 
gi|114590421|ref|XM_526383.2| PREDICTED: Pan troglodytes similar... 1114 0.0 
gi|109044240|ref|XM_001082256.1| PREDICTED: Macaca mulatta Neuro...1106 0.0 
gi|109044225|ref|XM_001082382.1| PREDICTED: Macaca mulatta Neuro...1106 0.0 
gi|164693376|dbj|AK307813.1| H. sapiens cDNA, FLJ97761 955 0.0 
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gi|17105267|gb|AC092967.5| H. sapiens 3 BAC RP11-521A24 (Roswe... 954 0.0 
gi|114590437|ref|XM_001166231.1| PREDICTED: Pan troglodytes simi... 946 0.0 
gi|114590429|ref|XM_001166258.1| PREDICTED: Pan troglodytes simi... 946 0.0 
gi|114590423|ref|XM_001166352.1| PREDICTED: Pan troglodytes simi... 946 0.0 
gi|114590419|ref|XM_001166291.1| PREDICTED: Pan troglodytes simi... 946 0.0 
gi|254281190|ref|NM_001163387.1| Mus musculus Neuroligin-1 (Nlgn... 898 0.0 
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9.2 Appendix for Chapter 4 























Tubulin -4B chain; TUBB4B 14852 50255 493 423 49 46 87.9 445 
TBB4A
1 
Tubulin -4A chain; TUBB4A 14487 50010 491 411 48 44 88.1 444 
TBB2A
1
 Tubulin -2A chain; TUBB2A 13826 50274 448 393 47 46 87.9 445 
TBB5
1
 Tubulin  chain; TUBB 13058 50095 445 386 49 47 88.1 444 
TBB3
1
 Tubulin -3 chain; TUBB3 9705 50856 304 259 34 29 69.3 450 
TBB6
1
 Tubulin -6 chain; TUBB6 4914 50281 161 128 23 19 46.2 446 
TBB8
1
 Tubulin -8 chain; TUBB8 3176 50257 166 120 18 14 32.9 444 
TBB1
1
 Tubulin -1 chain; TUBB1 782 50865 35 28 6 5 11.1 451 
TBB2B
1
 Tubulin -2B chain; TUBB2B 12629 50377 429 373 46 45 84.3 445 
TBB8L
1
 Tubulin -8 chain-like protein LOC260334 2672 50168 133 108 15 12 31.3 444 
YI016
5 Putative tubulin  chain-like protein 
ENSP00000290377 




 Tubulin -1A chain; TUBA1A 10156 50788 266 244 42 39 74.5 451 
TBA4A
1
 Tubulin -4A chain; TUBA4A  9298 50634 249 232 40 39 75 448 
TBA8
1
 Tubulin -8 chain; TUBA8 5698 50746 143 124 19 19 37.9 449 
TBA1B
1
 Tubulin -1B chain; TUBA1B 10684 50804 285 260 44 41 74.5 451 
TBA3C
1
 Tubulin -3C/D chain; TUBA3C 8278 50612 194 186 28 27 55.6 450 
TBA1C
1
 Tubulin -1C chain; TUBA1C 8097 50548 238 216 38 35 65.7 449 
TBA3E
1
 Tubulin -3E chain; TUBA3E 5962 50568 146 133 22 20 46 450 
TBAL3
1
 Tubulin  chain-like 3; TUBAL3 1001 50675 46 40 6 4 13.5 446 
TBA4B
5 
Putative tubulin-like protein -4B; TUBA4B 571 27819 13 12 2 2 10.8 241 
ATPB
1
 ATP synthase subunit , mitochondrial; ATP5B 8652 56525 242 216 40 37 80.7 529 
DPYL2
1
 Dihydropyrimidinase-related protein 2; DPYSL2 6512 62711 184 156 38 34 80.4 572 
DPYL1
1
 Dihydropyrimidinase-related protein 1; CRMP1 931 62487 27 25 10 9 25.5 572 
DPYL3
1
 Dihydropyrimidinase-related protein 3; DPYSL3 491 62323 16 11 7 4 16.3 570 
DPYS
1






































-transporting ATPase  chain 1; ATP4A 135 115756 8 7 2 2 2.7 1035 
ACTB
1
 Actin, cytoplasmic 1; ACTB 5799 42052 189 176 28 25 78.9 375 
ACTC
1 
Actin,  cardiac muscle 1; ACTC1 4116 42334 150 138 20 18 42.2 377 
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ACTA
1
 Actin, aortic smooth muscle; ACTA2 3877 42381 138 126 17 15 39.3 377 
POTEE
1
 POTE ankyrin domain family member E; POTEE 1726 122882 72 58 11 7 11.7 1075 
POTEF
1 
POTE ankyrin domain family member F; POTEF  1714 123020 74 56 8 5 8 1075 
POTEI
3
 POTE ankyrin domain family member I; POTEI 1142 122858 54 47 8 4 9 1075 
ACTBM
5
 Putative -actin-like protein 3; POTEKP 768 42331 16 16 2 2 7.2 375 
ACTBL
1
 -actin-like protein 2; ACTBL2 708 42318 36 19 7 5 19.7 376 
POTEJ
3
 POTE ankyrin domain family member J; POTEJ 289 118740 28 11 8 2 11.8 1038 
G3P
1
 Glyceraldehyde-3-phosphate dehydrogenase; GAPDH 5506 36201 156 140 26 24 67.2 335 
MDHM
1
 Malate dehydrogenase, mitochondrial; MDH2 5231 35937 112 101 26 22 78.1 338 
HBB
1
 Hemoglobin subunit ; HBB 4991 16102 147 139 18 18 96.6 147 
HBD
1
 Hemoglobin subunit ; HBD 1426 16159 54 50 9 9 80.3 147 
HBE
1
 Hemoglobin subunit ; HBE1 307 16249 18 14 3 1 25.2 147 
SPTN1
1
 Spectrin  chain, non-erythrocytic 1; SPTAN1 4837 285163 163 122 62 45 33.7 2472 
AP1G2
1
 AP-1 complex subunit g-like 2; AP1G2 23 87917 3 1 2 1 2.3 785 
SPTB2
1
 Spectrin  chain, non-erythrocytic 1; SPTBN1 4742 275237 133 122 48 43 25.2 2364 
SPTN2
1
 Spectrin  chain, non-erythrocytic 2; SPTBN2 64 272526 12 2 9 2 4.8 2390 
SPTB1
1
 Spectrin  chain, erythrocytic; SPTB 39 247171 14 1 10 1 5.9 2137 
KCRB
1
 Creatine kinase B-type; CKB 4638 42902 132 119 26 25 80.3 381 
KPYM
1
 Pyruvate kinase isozymes M1/M2; PKM 3904 58470 140 121 30 27 62.5 531 
KPYR
1
 Pyruvate kinase isozymes R/L; PKLR 260 62191 15 12 4 2 6.4 574 
GNAO
1
 Guanine nucleotide-binding protein Go subunit ; GNAO1 3882 40595 86 79 16 14 43.8 354 
GNAI2
1
 Guanine nucleotide-binding protein Gi subunit -2; GNAI2  1294 40995 35 32 8 6 23.4 355 
GNAI1
1
 Guanine nucleotide-binding protein Gi subunit -1; GNAI1 1130 40905 34 31 6 5 14.1 354 
GNAI3
1
 Guanine nucleotide-binding protein Gk subunit ; GNAI3 1026 41076 35 27 6 3 13.6 354 
GNAL
1
 Guanine nucleotide-binding protein Golf subunit ; GNAL 910 44794 25 23 3 2 5.2 381 
GNA12
1 
Guanine nucleotide-binding protein subunit -12; GNA12 726 44422 18 17 2 1 7.6 381 
ENOA
1
 -enolase; ENO1 3730 47481 107 95 26 23 81.1 434 
ENOG
1
 -enolase; ENO2 2874 47581 86 73 21 20 63.8 434 
ENOB
1
 -enolase; ENO3 1036 47299 32 22 11 7 33.9 434 
ATPA
1
 ATP synthase subunit , mitochondrial; ATP5A1 3653 59828 134 111 28 22 45.6 553 
STXB1
1
 Syntaxin-binding protein 1; STXBP1 pe 1  3118 67925 120 103 30 26 56.1 594 
CH60
1
 60 kDa heat shock protein, mitochondrial; HSPD1 2996 61187 78 63 21 16 54.1 573 
PPIA
1




Peptidyl-prolyl cis-trans isomerase A-like 
4A/B/C; PPIAL4A 
344 18398 7 7 1 1 8.5 164 
ALDOA
1
 Fructose-bisphosphate aldolase A; ALDOA 2753 39851 80 69 20 15 79.1 364 
ALDOC
1 
Fructose-bisphosphate aldolase C; ALDOC 1963 39830 58 45 15 11 40.7 364 
NSF
1




Guanine nucleotide-binding protein Gi/Gs/Gt 
subunit -1; GNB1 
2435 38151 60 51 17 15 61.5 340 




Guanine nucleotide-binding protein Gi/Gs/Gt 
subunit -2; GNB2 
1118 38048 38 29 15 11 47.6 340 
GBB4
1
 Guanine nucleotide-binding protein subunit -4; GNB4 96 38284 7 4 5 2 24.7 340 
SYN1
1
 Synapsin-1; SYN1 2364 74237 90 76 30 27 52.2 705 
SYN2
1
 Synapsin-2; SYN2 903 63093 27 25 7 7 13.6 582 
SRGP3
1






/calmodulin-dependent protein kinase II 
subunit ; CAMK2A 






/calmodulin-dependent protein kinase II 
subunit ; CAMK2B 






/calmodulin-dependent protein kinase II 
subunit ; CAMK2G 






/calmodulin-dependent protein kinase II 
subunit ; CAMK2D 




V-type proton ATPase subunit B, brain isoform; 
ATP6V1B2 




V-type proton ATPase subunit B, kidney 
isoform; ATP6V1B1 
642 57196 18 15 4 3 12.7 513 
DYN1
1
 Dynamin-1; DNM1 2225 97746 89 76 26 20 38.2 864 
DYN3
1
 Dynamin-3; DNM3 988 98084 43 36 9 7 14 869 
DYN2
1
 Dynamin-2; DNM2 235 98345 19 15 6 4 9.9 870 
HXK1
1
 Hexokinase-1; HK1 2116 103561 66 57 18 18 23.2 917 
HKDC1
1
 Putative hexokinase HKDC1; HKDC1 77 103790 12 4 6 2 10.1 917 
HXK2
1
 Hexokinase-2; HK2 55 103739 16 3 5 1 6.1 917 
HSP7C
1
 Heat shock cognate 71 kDa protein; HSPA8 2103 71082 71 63 21 19 37.2 646 
HSP71
1
 Heat shock 70 kDa protein 1A/1B; HSPA1A 466 70294 19 13 9 8 18.3 641 
HSP72
1
 Heat shock-related 70 kDa protein 2; HSPA2 713 70263 29 22 9 6 16.3 639 
HS71L
1
 Heat shock 70 kDa protein 1-like; HSPA1L 323 70730 15 9 6 5 9.4 641 
HSP76
1 
Heat shock 70 kDa protein 6; HSPA6 292 71440 10 10 4 4 8.4 643 
HSP77
5
 Putative heat shock 70 kDa protein 7; HSPA7 58 40448 3 3 2 2 6.8 367 
MBP
1
 Myelin basic protein; MBP 2072 33097 130 103 19 14 37.2 304 
CN37
1




Serine/threonine-protein phosphatase 2B 
catalytic subunit  isoform; PPP3CA 




Serine/threonine-protein phosphatase 2B 
catalytic subunit  isoform; PPP3CC 
80 58777 14 12 2 1 4.5 512 
CLH1
1
 Clathrin heavy chain 1; CLTC pe 1  1963 193260 81 64 30 23 21.7 1675 
CLH2
1
 Clathrin heavy chain 2; CLTCL1 92 189020 8 5 6 3 4 1640 
VATA
1




Tyrosine-protein phosphatase non-receptor type 
substrate 1; SIRPA 
1744 55446 61 49 14 12 36.5 504 
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SIRBL
1
 Signal-regulatory protein -1 isoform 3; SIRPB1 731 43674 39 28 8 6 23.9 398 
SIRB1
1
 Signal-regulatory protein -1; SIRPB1 250 43640 11 9 3 3 10.3 398 
SIRPG
1
 Signal-regulatory protein ; SIRPG  102 42870 10 7 4 3 10.1 387 
VATE1
1
 V-type proton ATPase subunit E 1; ATP6V1E1 1728 26186 52 46 11 9 48.2 226 
TPPP
1
 Tubulin polymerization-promoting protein; TPPP 1725 23850 40 38 9 8 50.7 219 
ACON
1
 Aconitate hydratase, mitochondrial; ACO2 1722 86113 60 47 16 15 29.4 780 
1433Z
1
 14-3-3 protein /; YWHAZ 1549 27899 46 44 11 10 45.3 245 
1433G
1
 14-3-3 protein g; YWHAG 1167 28456 55 41 16 13 62.3 247 
1433B
1
 14-3-3 protein /; YWHAB 738 28179 41 28 9 6 45.1 246 
1433E
1
 14-3-3 protein ; YWHAE 590 29326 15 11 5 4 32.5 255 
1433F
1
 14-3-3 protein ; YWHAH 460 28372 31 21 10 7 42.3 246 
1433T
1
 14-3-3 protein ; YWHAQ 80 28032 10 6 5 3 26.5 245 
1433S
1
 14-3-3 protein sigma; SFN 50 27871 4 2 2 1 6.5 248 
NCAM1
1
 Neural cell adhesion molecule 1; NCAM1 1540 95370 63 49 15 11 23 858 
IGSF8
1
 Immunoglobulin superfamily member 8; IGSF8 1382 65621 37 32 13 11 36.4 613 
KCRU
1
 Creatine kinase U-type, mitochondrial; CKMT1A 1345 47406 52 39 18 14 57.8 417 
HBA
1
 Hemoglobin subunit ; HBA1 1339 15305 58 46 10 10 69.7 142 
ANK2
1
 Ankyrin-2; ANK2 1326 435957 58 40 28 18 10.3 3957 
ANK3
1
 Ankyrin-3; ANK3 28 482394 16 1 13 1 4.7 4377 
CNTN1
1 
Contactin-1; CNTN1  1276 114104 62 49 19 16 22.1 1018 
PGK1
1
 Phosphoglycerate kinase 1; PGK1 1250 44985 46 38 18 14 64.3 417 
PGK2
1
 Phosphoglycerate kinase 2; PGK2 128 45166 6 4 4 2 24.7 417 
GFAP
1
 Glial fibrillary acidic protein; GFAP 1206 49907 48 39 18 16 55.1 432 
K2C1
1
 Keratin, type II cytoskeletal 1; KRT1 44 66170 3 1 3 1 5.9 644 
HS90A
1
 Heat shock protein HSP 90-; HSP90AA1 1183 85006 24 21 9 8 13 732 
HS90B
1
 Heat shock protein HSP 90-; HSP90AB1 1090 83554 23 19 10 8 14.2 724 
ENPL
1
 Endoplasmin; HSP90B1 87 92696 2 2 2 2 3.1 803 
TRAP1
1 
Heat shock protein 75 kDa, mitochondrial; TRAP1 220 80345 10 3 2 1 3.7 704 
H90B3
5 
Putative heat shock protein HSP 90--3; HSP90AB3P 162 68624 4 3 3 2 4.5 597 
H90B4
5
 Putative heat shock protein HSP 90- 4; HSP90AB4P 149 58855 3 2 2 1 6.7 505 
HS904
5
 Putative heat shock protein HSP 90- A4; HSP90AA4P 129 47796 3 2 2 1 5.3 418 
H90B2
1
 Putative heat shock protein HSP 90- 2; HSP90AB2P 101 44492 2 2 1 1 3.1 381 
G6PI
1
 Glucose-6-phosphate isomerase; GPI 1175 63335 38 30 12 9 37.3 558 
CSPG2
1
 Versican core protein; VCAN 1163 374585 42 32 15 8 8.5 3396 
PRDX2
1
 Peroxiredoxin-2; PRDX2 1159 22049 51 41 12 9 40.9 198 
PRDX1
1
 Peroxiredoxin-1; PRDX1 1139 22324 37 36 6 5 34.2 199 
PRDX4
1
 Peroxiredoxin-4; PRDX4 270 30749 7 7 1 1 4.4 271 
STX1B
1
 Syntaxin-1B; STX1B 1139 33452 40 32 12 10 36.8 288 
STX1A
1
 Syntaxin-1A; STX1A 450 33174 20 16 8 6 35.8 288 
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STX2
1
 Syntaxin-2; STX2 40 33377 5 2 2 1 5.9 288 
UCHL1
1







-transporting ATPase subunit -1; ATP1B1 1094 35438 37 32 8 6 32.3 303 
GLNA
1
 Glutamine synthetase; GLUL 1094 42665 22 22 5 5 23.3 373 
PHB
1
 Prohibitin; PHB  1089 29843 30 26 11 10 68.4 272 
NFASC
1
 Neurofascin; NFASC 1042 150789 44 36 16 13 15.5 1347 
THY1
1
 Thy-1 membrane glycoprotein; THY1 1036 18151 31 30 4 4 18 161 
NFL
1
 Neurofilament light polypeptide; NEFL 1023 61536 39 32 15 13 37.8 543 
AINX
1
 -internexin; INA 309 55528 26 15 12 8 29.5 499 
NFM
1
 Neurofilament medium polypeptide; NEFM 247 102468 22 12 11 4 18.7 916 
NFH
1
 Neurofilament heavy polypeptide; NEFH 209 112639 12 8 5 2 4 1026 
DESM
1 
Desmin; DES 23 53560 3 1 2 1 5.7 470 
GRP75
1
 Stress-70 protein, mitochondrial; HSPA9 1006 73920 29 23 9 7 18 679 
VAMP2
1
 Vesicle-associated membrane protein 2; VAMP2 996 12712 19 19 5 5 43.1 116 
VAMP3
1
 Vesicle-associated membrane protein 3; VAMP3 226 11359 7 7 2 2 33 100 
VAMP1
1
 Vesicle-associated membrane protein 1; VAMP1 113 13008 5 5 1 1 7.6 118 
MIF
1
 Macrophage migration inhibitory factor; MIF 988 12639 39 32 6 5 46.1 115 
MDHC
1
 Malate dehydrogenase, cytoplasmic; MDH1 984 36631 21 20 6 5 20.4 334 
MYPR
1
 Myelin proteolipid protein; PLP1 962 30855 27 24 5 4 18.1 277 
COX5A
1
 Cytochrome c oxidase subunit 5A, mitochondrial; COX5A 940 16923 37 28 10 8 58 150 
CX6B1
1
 Cytochrome c oxidase subunit 6B1; COX6B1 931 10414 32 29 6 5 84.9 86 
ATPO
1
 ATP synthase subunit O, mitochondrial; ATP5O 920 23377 33 30 10 7 52.1 213 
EAA1
1
 Excitatory amino acid transporter 1; SLC1A3 919 59705 20 17 4 3 9.4 542 
TENR
1
 Tenascin-R; TNR 914 151805 31 26 10 9 13.6 1358 
AATM
1
 Aspartate aminotransferase, mitochondrial; GOT2 898 47886 36 33 13 11 37.2 430 
TKT
1
 Transketolase; TKT 890 68519 33 26 9 9 23.1 623 
ATP5H
1
 ATP synthase subunit , mitochondrial; ATP5H 851 18537 34 26 9 7 62.7 161 
PGAM1
1
 Phosphoglycerate mutase 1; PGAM1 847 28900 33 27 11 7 46.9 254 
PGAM4
1
 Probable phosphoglycerate mutase 4; PGAM4 649 28930 27 21 9 5 34.3 254 
PGAM2
1
 Phosphoglycerate mutase 2; PGAM2 pe 1  295 28919 12 8 4 2 17.8 253 
COF1
1
 Cofilin-1; CFL1 844 18719 25 24 6 6 56.6 166 
COF2
1
 Cofilin-2; CFL2 237 18839 10 10 3 3 19.9 166 
SNP25
1
 Synaptosomal-associated protein 25; SNAP25 824 23528 27 21 11 8 61.7 206 
EAA2
1
 Excitatory amino acid transporter 2; SLC1A2 822 62577 28 25 9 8 21.3 574 
TPIS
1




Voltage-dependent anion-selective channel 
protein 1; VDAC1 




V-type proton ATPase 116 kDa subunit  
isoform 1; ATP6V0A1 
788 97148 36 28 15 12 20.1 837 
PRDX5
1
 Peroxiredoxin-5, mitochondrial; PRDX5 777 22301 32 27 10 6 72.9 214 
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MOG
1
 Myelin-oligodendrocyte glycoprotein; MOG 766 28574 13 13 3 3 16.2 247 
VDAC2
1 Voltage-dependent anion-selective channel 
protein 2; VDAC2 
761 32060 35 30 6 6 25.9 294 
ATP5I
1
 ATP synthase subunit e, mitochondrial; ATP5I 742 7928 24 20 7 4 71 69 
SEPT7
1
 Septin-7; SEPT7 740 50933 27 24 8 7 24.3 437 
SEPT8
1
 Septin-8; SEPT8 321 56234 15 14 4 4 11.8 483 
SEPT6
1
 Septin-6; SEPT6 288 50084 18 14 6 5 18.2 434 
SEP11
1
 Septin-11; SEPT11 338 49652 17 14 5 4 14.2 429 
SEP14
1
 Septin-14; SEPT14 173 50449 12 8 2 1 4.2 432 
SEP10
1




Pyruvate dehydrogenase E1 component subunit 
, mitochondrial; PDHB 
739 39550 26 26 6 6 32.6 359 
ICAM5
1
 Intercellular adhesion molecule 5; ICAM5 pe 1  731 98766 18 16 7 5 10.8 924 
PCSK1
1




Peptidyl-prolyl cis-trans isomerase NIMA-
interacting 1; PIN1 
691 18346 15 15 4 4 43.6 163 
ADT3
1
 ADP/ATP translocase 3; SLC25A6 674 33073 31 24 10 10 38.6 298 
ADT2
1
 ADP/ATP translocase 2; SLC25A5 499 33059 26 22 7 7 24.2 298 
ADT1
1
 ADP/ATP translocase 1; SLC25A4 478 33271 29 18 11 9 38.9 298 
ADT4
1




Protein kinase C and casein kinase substrate in 
neurons protein 1; PACSIN1 pe 1  
648 51276 22 21 10 9 32.2 444 
CATD
1
 Cathepsin D; CTSD 634 45037 21 18 7 6 22.6 412 
L1CAM
1
 Neural cell adhesion molecule L1; L1CAM 631 140885 19 17 9 7 10.7 1257 
DHE3
1
 Glutamate dehydrogenase 1, mitochondrial; GLUD1 622 61701 30 23 15 10 30.6 558 
DHE4
1
 Glutamate dehydrogenase 2, mitochondrial; GLUD2 361 61738 13 11 6 4 14 558 
DHPR
1




cAMP-dependent protein kinase type II- 
regulatory subunit; PRKAR2B 




cAMP-dependent protein kinase type II- 
regulatory subunit; PRKAR2A 
102 45832 6 3 4 2 13.9 404 
STMN1
1
 Stathmin; STMN1 586 17292 9 8 2 1 18.1 149 
AT2B4
1
 Plasma membrane Ca
2+
-transporting ATPase 4; ATP2B4 582 139030 39 26 15 12 17.2 1241 
AT2B2
1
 Plasma membrane Ca
2+
-transporting ATPase 2; ATP2B2 389 137987 20 14 8 7 8.6 1243 
AT2B1
1
 Plasma membrane Ca
2+
-transporting ATPase 1; ATP2B1 297 139637 26 15 9 8 10.4 1258 
AT2B3
1
 Plasma membrane Ca
2+






581 24792 13 10 5 3 41.4 227 
MAP1B
1
 Microtubule-associated protein 1B; MAP1B 573 271665 52 19 19 9 13.4 2468 
MAP1A
1
 Microtubule-associated protein 1A; MAP1A 196 306781 15 8 9 4 5.2 2803 




Succinate dehydrogenase [ubiquinone] 
flavoprotein subunit, mitochondrial; SDHA 





Cytochrome b-c1 complex subunit 1, 
mitochondrial; UQCRC1 
564 53297 23 21 10 9 36 480 
MAP2
1 




Cytochrome c oxidase subunit 5B, 
mitochondrial; COX5B 
539 13915 32 23 6 5 54.3 129 
ACTN1
1
 -actinin-1; ACTN1 507 103563 25 15 10 8 20.1 892 
ACTN4 -actinin-4; ACTN4 403 105245 9 9 3 3 4.1 911 
ACTN2 -actinin-2; ACTN2 44 104358 3 1 2 1 2.6 894 
SFXN1
1
 Sideroflexin-1; SFXN1 494 35881 18 13 8 5 46.9 322 
SFXN3
2 
Sideroflexin-3; SFXN3 338 36298 10 9 4 4 17.2 325 
GRP78
1 
78 kDa glucose-regulated protein; HSPA5 483 72402 16 14 9 7 22.2 654 
CADM2
2




Cytochrome b-c1 complex subunit 2, 
mitochondrial; UQCRC2 
475 48584 13 12 5 4 22.7 453 
BASP1
1
 Brain acid soluble protein 1; BASP1 474 22680 13 8 4 2 44.5 227 
EHD3
1
 EH domain-containing protein 3; EHD3 472 60906 12 11 5 4 15.3 535 
PEBP1
1




V-type proton ATPase 16 kDa proteolipid 
subunit; ATP6V0C 
469 15725 4 4 1 1 20 155 
LSAMP
1
 Limbic system-associated membrane protein; LSAMP 466 37883 18 13 6 4 26.9 338 
E41L3
1
 Band 4.1-like protein 3; EPB41L3 459 121458 14 12 9 7 11.8 1087 
DYHC1
1
 Cytoplasmic dynein 1 heavy chain 1; DYNC1H1 456 534809 40 19 25 11 9.6 4646 
AP2M1
1
 AP-2 complex subunit µ; AP2M1 424 49965 15 12 4 4 12 435 
CAP2
1
 Adenylyl cyclase-associated protein 2; CAP2 420 53076 12 7 4 3 11.7 477 
GDIA
1
 Rab GDP dissociation inhibitor ; GDI1 417 51177 16 14 4 4 10.7 447 
GDIB
1
 Rab GDP dissociation inhibitor ; GDI2 247 51087 9 8 2 2 4.9 445 
SCOT1
1 Succinyl-CoA:3-ketoacid coenzyme A 
transferase 1, mitochondrial; OXCT1 




Succinyl-CoA:3-ketoacid coenzyme A 
transferase 2, mitochondrial; OXCT2 
95 56731 2 2 1 1 2.3 517 
THIL
1
 Acetyl-CoA acetyltransferase, mitochondrial; ACAT1 412 45456 13 12 5 5 30.9 427 
OPA1
1
 Dynamin-like 120 kDa protein, mitochondrial; OPA1 407 112131 14 9 7 4 12.6 960 
RAB3A
1
 Ras-related protein Rab-3A; RAB3A 407 25196 8 7 3 3 10.9 220 
RAB3D
1
 Ras-related protein Rab-3D; RAB3D 33 24480 2 1 1 1 3.7 219 
RAC1
1
 Ras-related C3 botulinum toxin substrate 1; RAC1 402 21835 19 16 7 5 28.1 192 
RAC2
1
 Ras-related C3 botulinum toxin substrate 2; RAC2 100 21814 6 4 3 2 17.2 192 
OPCM
1 
Opioid-binding protein/cell adhesion molecule; OPCML 391 38496 25 14 8 4 29.6 345 
TMOD2
1
 Tropomodulin-2; TMOD2  389 39571 9 9 3 3 16 351 
PARK7
1
 Protein DJ-1; PARK7 388 20050 12 11 4 4 19 189 
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TCPE
1




Cytochrome b-c1 complex subunit Rieske, 
mitochondrial; UQCRFS1 




Putative cytochrome b-c1 complex subunit 
Rieske-like protein 1; UQCRFS1P1 
368 31081 17 15 2 2 12 283 
RAP2A
1
 Ras-related protein Rap-2a; RAP2A 368 20830 7 7 2 2 15.3 183 
CADM3
1
 Cell adhesion molecule 3; CADM3 364 43729 14 12 4 4 21.4 398 
RAP1A
1
 Ras-related protein Rap-1A; RAP1A 363 21316 9 9 2 2 7.6 184 
HSPB1
1
 Heat shock protein -1; HSPB1 358 22826 9 9 3 3 21 205 
SEPT5
1
 Septin-5; SEPT5 350 43206 17 14 7 6 30.9 369 
DCTN2
1




NADH dehydrogenase [ubiquinone] 1  
subcomplex subunit 5; NDUFA5 





[acylating], mitochondrial; ALDH6A1 
342 58259 13 12 6 6 23 535 
NCAM2
1
 Neural cell adhesion molecule 2; NCAM2 341 93786 9 8 3 2 5.1 837 
SYT1
1
 Synaptotagmin-1; SYT1 336 47885 13 10 5 4 17.5 422 
EF1A2
1
 Elongation factor 1- 2; EEF1A2 336 50780 19 10 8 4 35 463 
EF1A1
1











Single-stranded DNA-binding protein, 
mitochondrial; SSBP1 
331 17249 13 10 5 3 44.6 148 
AP2A1
1
 AP-2 complex subunit -1; AP2A1 324 108561 16 13 8 6 10.8 977 
AP2A2
1
 AP-2 complex subunit -2; AP2A2 261 104807 16 12 8 5 14 939 
4F2
1
 4F2 cell-surface antigen heavy chain; SLC3A2 318 68180 12 10 3 3 6.8 630 
DDAH1
1 N(G),N(G)-dimethylarginine 
dimethylaminohydrolase 1; DDAH1 
315 31444 15 14 4 3 35.1 285 
K6PP
1
 6-phosphofructokinase type C; PFKP 310 86454 18 11 9 5 13.1 784 
FUMH
1
 Fumarate hydratase, mitochondrial; FH 308 54773 12 9 6 3 24.7 510 
HECAM
1
 Hepatocyte cell adhesion molecule; HEPACAM 308 46226 11 7 5 3 22.8 416 
LEG1
1




Guanine nucleotide-binding protein Gi/Gs/Go 
subunit -2; GNG2 




NADH dehydrogenase [ubiquinone] 1  
subcomplex subunit 8; NDUFA8 
291 20548 12 10 4 3 27.9 172 
SEPT2
1
 Septin-2; SEPT2 289 41689 14 8 7 4 33.2 361 
SNAG
1
 -soluble NSF attachment protein; NAPG 288 35066 11 7 5 3 25.6 312 
ATP5L
1
 ATP synthase subunit , mitochondrial; ATP5L 285 11421 8 8 3 3 40.8 103 
ATPG
1
 ATP synthase subunit , mitochondrial; ATP5C1 281 33032 11 9 4 3 25.5 298 
SEPT3
1
 Neuronal-specific septin-3; SEPT3 280 40963 13 11 4 3 17.9 358 




NADH dehydrogenase [ubiquinone] 1  
subcomplex subunit 13; NDUFA13 
280 16688 18 16 4 3 51.4 144 
PRDX6
1
 Peroxiredoxin-6; PRDX6 280 25133 6 5 2 1 15.2 224 
TCPB
1
 T-complex protein 1 subunit ; CCT2 278 57794 15 8 6 3 20.4 535 
NNTM
1
 NAD(P) transhydrogenase, mitochondrial; NNT 277 114564 10 9 5 4 8.7 1086 
PRIO
1




Thioredoxin-dependent peroxide reductase, 
mitochondrial; PRDX3 
272 28017 10 9 4 3 21.1 256 
PDXK
1
 Pyridoxal kinase; PDXK 271 35308 11 9 3 2 13.8 312 
AP2B1
1
 AP-2 complex subunit ; AP2B1 269 105398 20 12 10 6 15.5 937 
AP1B1
1
 AP-1 complex subunit -1; AP1B1 79 105482 12 2 5 1 7.9 949 
SH3G2
1
 Endophilin-A1; SH3GL2 269 40108 13 13 5 5 13.1 352 
SH3G1
1






269 58034 12 7 7 3 22.6 535 
TAU
1




NADH dehydrogenase [ubiquinone] 1  
subcomplex subunit 2; NDUFA2 
266 11029 10 8 3 3 45.5 99 
LDHB
1
 L-lactate dehydrogenase B chain; LDHB 264 36900 19 15 6 4 37.7 334 
K6PF
1




Serine/threonine-protein phosphatase 2A 65 kDa 
regulatory subunit A  isoform; PPP2R1A 




Serine/threonine-protein phosphatase 2A 65 kDa 
regulatory subunit A  isoform; PPP2R1B 




NADH dehydrogenase [ubiquinone] Fe-S 
protein 7, mitochondrial; NDUFS7 
258 23833 4 3 2 1 17.8 213 
GPM6A
1
 Neuronal membrane glycoprotein M6A; GPM6A 258 31930 11 8 5 3 14.7 278 
CH10
1
 10 kDa heat shock protein, mitochondrial; HSPE1 257 10925 17 15 5 4 45.1 102 
NEGR1
1
 Neuronal growth regulator 1; NEGR1 255 39379 11 7 5 4 15.8 354 
CISD1
1
 CDGSH Fe-S domain-containing protein 1; CISD1 255 12362 5 5 1 1 16.7 108 
BRK1
1
 Protein BRICK1; BRK1 254 8796 5 4 2 1 29.3 75 
CNTP1
1 
Contactin-associated protein 1; CNTNAP1 254 158220 8 4 5 2 5.3 1384 
IMMT
1
 Mitochondrial inner membrane protein; IMMT 253 84026 17 9 7 5 16.5 758 
TERA
1
 Transitional endoplasmic reticulum ATPase; VCP 252 89950 19 11 9 6 18.1 806 
S12A5
2
 Solute carrier family 12 member 5; SLC12A5 249 127470 10 6 5 2 4.3 1139 
S12A4
1
 Solute carrier family 12 member 4; SLC12A4 180 121712 5 4 2 1 2.1 1085 
NIPS1
1 
Protein NipSnap homolog 1; NIPSNAP1 248 33460 8 7 4 3 15.1 284 
EFTU
1
 Elongation factor Tu, mitochondrial; TUFM 244 49852 14 9 8 6 19.9 452 
AATC
1
 Aspartate aminotransferase, cytoplasmic; GOT1 243 46447 12 8 6 4 20.1 413 
COX7C
1
 Cytochrome c oxidase subunit 7C, mitochondrial; COX7C 239 7298 8 7 3 3 65.1 63 
CISY
1
 Citrate synthase, mitochondrial; CS 239 51908 11 8 4 3 19.1 466 
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SATT
1




Guanine nucleotide-binding protein Gi/Gs/Go 
subunit -3; GNG3 




Cytochrome c oxidase subunit 4 isoform 1, 
mitochondrial; COX4I1 
231 19621 15 14 5 4 40.8 169 
RALB
1
 Ras-related protein Ral-B; RALB 231 23508 6 5 2 1 9.7 206 
FA49B
1
 Protein FAM49B; FAM49B 230 37010 5 4 2 1 8 324 
PGCB
1
 Brevican core protein; BCAN 230 100539 13 9 3 2 4.3 911 
E41L1
1
 Band 4.1-like protein 1; EPB41L1 230 99012 10 8 5 3 9.6 881 
AOFB
1




Complement component 1 Q subcomponent-
binding protein, mitochondrial; C1QBP 






-binding mitochondrial carrier protein 
Aralar1; SLC25A12 
221 75114 11 8 5 3 12.8 678 
RAB10
1
 Ras-related protein Rab-10; RAB10 221 22755 9 9 2 2 9 200 
CY1
1
 Cytochrome c1, heme protein, mitochondrial; CYC1 220 35741 12 11 3 3 13.8 325 
SYPH
1
 Synaptophysin; SYP 220 34109 7 7 4 4 22.7 313 
ATP5J
1




Hydroxyacyl-coenzyme A dehydrogenase, 
mitochondrial; HADH 
214 34329 8 6 2 2 9.6 314 
HS12A
1
 Heat shock 70 kDa protein 12A; HSPA12A 211 75217 12 8 6 3 14.5 675 
FLOT1
1




Ubiquitin-like modifier-activating enzyme 1; 
UBA1 
211 118858 6 5 5 4 8.9 1058 
FLOT2
1 







ATPase 2; ATP2A2 






ATPase 1; ATP2A1 




Actin-related protein 2/3 complex subunit 5-like 
protein; ARPC5L 
203 16931 6 6 3 3 25.5 153 
SYFA
1
 Phenylalanine—tRNA ligase  subunit; FARSA  203 57585 4 4 1 1 2.8 508 
GNAQ
1
 Guanine nucleotide-binding protein Gq subunit ; GNAQ 203 42400 15 6 4 2 17.3 359 
GNA11
1
 Guanine nucleotide-binding protein subunit -11; GNA11 70 42382 12 3 3 2 13.1 359 
MAP6
1
 Microtubule-associated protein 6; MAP6 pe 1  199 86680 6 4 4 2 7.1 813 
MGST3
1
 Microsomal glutathione S-transferase 3; MGST3 197 16734 7 4 3 2 35.5 152 
MPCP
1
 Phosphate carrier protein, mitochondrial; SLC25A3 197 40525 12 11 4 3 13.5 362 
PEA15
1
 Astrocytic phosphoprotein PEA-15; PEA15 pe 1  196 15088 6 6 2 2 21.5 130 
RAB7A
1
 Ras-related protein Rab-7a; RAB7A 190 23760 4 3 3 2 16.9 207 
PURA
1
 Transcriptional activator protein Pur-; PURA 190 35003 6 5 2 2 8.4 322 
NB5R3
1
 NADH-cytochrome b5 reductase 3; CYB5R3 190 34441 5 4 2 1 10.3 301 




Trifunctional enzyme subunit , mitochondrial; 
HADHA 




NADH dehydrogenase [ubiquinone] Fe-S 
protein 8, mitochondrial; NDUFS8 
187 24203 10 10 3 3 17.6 210 
VISL1
1
 Visinin-like protein 1; VSNL1 187 22299 10 9 3 3 23 191 
NDKB
1
 Nucleoside diphosphate kinase B; NME2 186 17401 11 9 3 3 31.6 152 
NDKA
1
 Nucleoside diphosphate kinase A; NME1 175 17309 8 8 2 2 19.1 152 
NDK8
1
 Putative nucleoside diphosphate kinase; NME2P1 109 15690 9 5 3 2 34.3 137 
CAZA2
1
 F-actin-capping protein subunit -2; CAPZA2  186 33157 6 6 2 2 9.8 286 
CAZA1
1
 F-actin-capping protein subunit -1; CAPZA1 135 33073 5 4 2 1 9.1 286 
IDHP
1
 Isocitrate dehydrogenase [NADP], mitochondrial; IDH2 185 51333 13 10 6 4 18.4 452 
NDRG2
1
 Protein NDRG2; NDRG2 184 41114 14 12 4 3 28.8 371 
BIN1
1
 Myc box-dependent-interacting protein 1; BIN1 181 64887 11 7 4 2 8.1 593 
RAB5B
1 
Ras-related protein Rab-5B; RAB5B 177 23920 4 4 1 1 6.5 215 
DCLK1
1
 Serine/threonine-protein kinase DCLK1; DCLK1 175 82743 6 4 3 2 5 740 
VATG2
1
 V-type proton ATPase subunit G 2; ATP6V1G2 175 13653 6 5 2 1 35.6 118 
RLA1
1
 60S acidic ribosomal protein P1; RPLP1 175 11621 4 4 1 1 14 114 
ETFA 
Electron transfer flavoprotein subunit , 
mitochondrial; ETFA 
174 35400 6 4 3 1 18.9 333 
PHB2
1
 Prohibitin-2; PHB2 173 33276 11 9 6 4 29.8 299 
CLCB
1
 Clathrin light chain B; CLTB 169 25289 5 5 3 3 13.5 229 
COX6C
1
 Cytochrome c oxidase subunit 6C; COX6C 169 8776 8 7 3 3 28 75 
SHLB2
1
 Endophilin-B2; SH3GLB2 169 44175 5 5 5 5 20.3 395 
VA0D1
1
 V-type proton ATPase subunit d 1; ATP6V0D1 167 40759 11 9 3 2 11.1 351 
IMB1
1
 Importin subunit -1; KPNB1 167 98420 4 4 2 2 3.4 876 
ECHM
1
 Enoyl-CoA hydratase, mitochondrial; ECHS1 167 31823 11 9 4 3 21.7 290 
PPT1
1
 Palmitoyl-protein thioesterase 1; PPT1 167 34627 4 4 2 2 13.7 306 
CAPZB
1
 F-actin-capping protein subunit ; CAPZB 166 31616 6 6 2 2 17.3 277 
CSRP1
1
 Cysteine and glycine-rich protein 1; CSRP1 165 21409 4 3 1 1 7.8 193 
PROF1
1
 Profilin-1; PFN1 164 15216 3 3 2 2 22.9 140 
CBR1
1
 Carbonyl reductase [NADPH] 1; CBR1 162 30641 17 8 5 3 24.9 277 
CBR3
1
 Carbonyl reductase [NADPH] 3; CBR3 76 31230 4 3 2 1 10.1 277 
MK01
1
 Mitogen-activated protein kinase 1; MAPK1 162 41762 6 4 2 2 10.3 360 
SNAB
1
 -soluble NSF attachment protein; NAPB 160 33878 9 5 5 2 24.8 298 
SNAA
1
 -soluble NSF attachment protein; NAPA 153 33667 5 4 2 1 14.2 295 
VATH
1
 V-type proton ATPase subunit H; ATP6V1H 159 56417 8 7 3 2 12.6 483 
PALM
1
 Paralemmin-1; PALM 157 42221 8 4 4 2 18.3 387 
ATPK
1




Isocitrate dehydrogenase [NAD] subunit , 
mitochondrial; IDH3A  
156 40022 6 4 3 1 10.1 366 




NADH dehydrogenase [ubiquinone] 1  
subcomplex subunit 6; NDUFA6 




Solute carrier family 2, facilitated glucose 
transporter member 3; SLC2A3 
151 54345 3 3 1 1 4 496 
RTN4
1
 Reticulon-4; RTN4 148 130250 13 6 3 1 4.9 1192 
PTGDS
1
 Prostaglandin-H2 D-isomerase; PTGDS 148 21243 3 2 1 1 8.4 190 
NPTN
1
 Neuroplastin; NPTN 146 44702 10 8 3 1 9.5 398 
FSCN1
1
 Fascin; FSCN1 145 55123 5 3 3 1 13.4 493 
NDE1
1
 Nuclear distribution protein nudE homolog 1; NDE1 144 38842 4 2 2 1 8.1 346 
TCPQ
1 
T-complex protein 1 subunit ; CCT8 144 60153 6 4 4 3 11.7 548 
M2OM
1 Mitochondrial 2-oxoglutarate/malate carrier 
protein; SLC25A11 
143 34211 11 8 4 2 14.3 314 
ALBU
1
 Serum albumin; ALB 140 71317 10 6 7 4 15.8 609 
DLG2
1
 Disks large homolog 2; DLG2 139 97948 6 4 4 2 6.8 870 
DLG4
1
 Disks large homolog 4; DLG4 pe 1  105 80788 5 4 3 2 8 724 
DLG1
1




NADH dehydrogenase [ubiquinone] Fe-S 
protein 6, mitochondrial; NDUFS6 
138 14045 2 2 1 1 19.4 124 
TAGL3
1




NADH dehydrogenase [ubiquinone] 1  
subcomplex subunit 9, mitochondrial; NDUFA9 
136 42654 9 3 3 1 11.1 377 
COX2
1
 Cytochrome c oxidase subunit 2; MT-CO2 134 25719 5 5 3 3 19.4 227 
NRCAM
1
 Neuronal cell adhesion molecule; NRCAM 133 144655 8 6 5 3 5.7 1304 
CRYAB
1
 -crystallin B chain; CRYAB 132 20146 7 4 5 4 48 175 
ACO13
1
 Acyl-coenzyme A thioesterase 13; ACOT13 131 15065 7 3 4 1 22.9 140 
CD81
1
 CD81 antigen; CD81 131 26476 6 4 2 1 16.5 236 
AP180
1
 Clathrin coat assembly protein AP180; SNAP91 128 92672 6 5 2 1 4.1 907 
NIPS2
1




NADH dehydrogenase [ubiquinone] 1  
subcomplex subunit 1; NDUFB1 
125 7014 4 4 2 2 32.8 58 
CRYM
1
 Thiomorpholine-carboxylate dehydrogenase; CRYM 125 33925 6 5 2 2 13.4 314 
ADDB
1
 -adducin; ADD2 124 81260 8 7 4 3 5.9 726 
ADDA
1




CB1 cannabinoid receptor-interacting protein 1; 
CNRIP1 




Receptor-type tyrosine-protein phosphatase ; 
PTPRZ1 
122 255683 4 3 2 1 1.9 2315 
ARPC3
1
 Actin-related protein 2/3 complex subunit 3; ARPC3 121 20761 2 2 1 1 13.5 178 
TPM3L
5




 PH and SEC7 domain-containing protein 3; PSD3 120 116646 8 3 7 2 8.8 1048 
AMPH
1
 Amphiphysin; AMPH 119 76381 6 4 5 3 12.4 695 
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TPM4
1
 Tropomyosin -4 chain; TPM4 118 28619 11 7 5 2 30.6 248 
TPM1
1




Mitochondrial import receptor subunit TOM70; 
TOMM70A 




NADH dehydrogenase [ubiquinone] 1  
subcomplex subunit 4; NDUFB4 
117 15256 5 4 2 1 17.8 129 
QCR7
1 
Cytochrome b-c1 complex subunit 7; UQCRB 117 13522 9 6 6 4 71.2 111 
OPALI
2
 Opalin; OPALIN 117 15787 5 4 1 1 5.7 141 
STX7
1




Cytochrome b-c1 complex subunit 6, 
mitochondrial; UQCRH 
117 11017 4 4 2 2 34.1 91 
VGF
1
 Neurosecretory protein VGF; VGF 116 67275 5 4 3 2 10.9 615 
MOES
1




Mitochondrial import receptor subunit TOM22 
homolog; TOMM22 
115 15512 5 5 1 1 17.6 142 
RS7
1
 40S ribosomal protein S7; RPS7 114 22113 10 4 3 2 22.2 194 
QCR8
1
 Cytochrome b-c1 complex subunit 8; UQCRQ 114 9900 3 2 2 1 29.3 82 
APOD
1






111 62137 6 4 3 2 7.5 563 
RAB1B
1
 Ras-related protein Rab-1B; RAB1B 110 22328 5 2 3 1 19.9 201 
NEUM
1
 Neuromodulin; GAP43 108 24902 8 3 3 1 18.5 238 
TCPH
1
 T-complex protein 1 subunit ; CCT7 107 59842 6 3 5 2 12.2 543 
RAB14
1




Platelet-activating factor acetylhydrolase IB 
subunit ; PAFAH1B3 
106 25832 3 2 2 1 14.3 231 
ACTY
1
 -centractin; ACTR1B 105 42381 4 4 2 2 9 376 
TLN1
1
 Talin-1; TLN1 103 271766 20 2 8 1 3.8 2541 
CPLX2
1
 Complexin-2; CPLX2 102 15499 7 5 2 2 9 134 
VATC1
1
 V-type proton ATPase subunit C 1; ATP6V1C1 102 44085 15 3 6 1 26.2 382 
EF2
1
 Elongation factor 2; EEF2 101 96246 4 3 3 2 8.9 858 
KGUA
1
 Guanylate kinase; GUK1 100 21769 2 1 2 1 12.7 197 
BSN
1 
Protein bassoon; BSN 99 418324 19 4 15 3 8.2 3926 
WDR37
2
 WD repeat-containing protein 37; WDR37 98 55316 4 4 2 2 5.7 494 
KAD1
1
 Adenylate kinase isoenzyme 1; AK1 96 21735 15 6 5 4 35.1 194 
MYH10
1 






-dependent neutral amino acid transporter 
SLC6A17; SLC6A17 
95 81747 5 2 3 1 6.9 727 
GABT
1
 4-aminobutyrate aminotransferase, mitochondrial; ABAT 94 57087 7 2 5 2 16.2 500 
CAH2
1
 Carbonic anhydrase 2; CA2 91 29285 4 3 1 1 6.2 260 
SNG1
1
 Synaptogyrin-1; SYNGR1 91 25667 4 4 1 1 5.2 233 
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CYFP1
1
 Cytoplasmic FMR1-interacting protein 1; CYFIP1 91 146742 4 3 3 2 2.9 1253 
CYFP2
1
 Cytoplasmic FMR1-interacting protein 2; CYFIP2 73 150298 4 2 3 1 5.4 1278 
NPTX1
2 
Neuronal pentraxin-1; NPTX1 90 47606 4 3 2 1 7.4 432 
CLCA
1
 Clathrin light chain A; CLTA 90 27174 4 3 2 1 12.5 248 
LDHA
1
 L-lactate dehydrogenase A chain; LDHA 90 36950 8 5 4 2 21.1 332 
LDH6B
1
 L-lactate dehydrogenase A-like 6B; LDHAL6B 16 42372 5 1 3 1 11 381 
LRC47
1
 Leucine-rich repeat-containing protein 47; LRRC47 90 64004 6 2 4 1 10.6 583 
KPCG
1
 Protein kinase C g type; PRKCG 89 79652 4 3 3 2 6 697 
KPCA
1






88 34240 2 1 2 1 8.8 308 
FKBP8
1




Phosphatidylinositol 5-phosphate 4-kinase type-
2 ; PIP4K2A 
88 46424 4 4 1 1 2.5 406 
NCEH1
1




Tubulin polymerization-promoting protein 
family member 3; TPPP3 
87 19145 3 2 3 2 30.7 176 
RASK
1
 GTPase KRas; KRAS 87 21927 8 6 3 1 21.7 189 
MYL6
1
 Myosin light polypeptide 6; MYL6 84 17090 8 3 2 1 19.2 151 
PCBP2
1
 Poly(rC)-binding protein 2; PCBP2 84 38955 5 4 3 2 16.4 365 
TPP1
1 
Tripeptidyl-peptidase 1; TPP1 83 61723 6 5 2 2 5 563 
RAB5C
1
 Ras-related protein Rab-5C; RAB5C 83 23696 3 2 2 2 16.2 216 
RAB5A
1




Membrane-associated progesterone receptor 
component 1; PGRMC1 




Superoxide dismutase [Mn], mitochondrial; 
SOD2 
83 24878 3 2 2 1 10.4 222 
GSTT1
1




Cytochrome c oxidase subunit 7A2, 
mitochondrial; COX7A2 
82 9390 9 5 3 2 60.2 83 
SV2A
1
 Synaptic vesicle glycoprotein 2A; SV2A 81 83440 7 2 4 1 7 742 
MTCH2
1
 Mitochondrial carrier homolog 2; MTCH2 81 33936 3 3 2 2 10.2 303 
CTNB1
1
 Catenin -1; CTNNB1 79 86069 4 1 3 1 4.6 781 
RAN
1 




Succinate dehydrogenase [ubiquinone] Fe-S 
subunit, mitochondrial; SDHB 




 Cytochrome b5 type B; CYB5B 78 16436 2 2 1 1 8.9 146 
MAON
2
 NADP-dependent malic enzyme, mitochondrial; ME3 78 67653 2 2 1 1 3.8 604 
PROF2
1
 Profilin-2; PFN2 78 15378 2 2 1 1 10 140 
ALDH2
1
 Aldehyde dehydrogenase, mitochondrial; ALDH2 77 56859 3 2 2 1 6.4 517 
VAT1
1
 Synaptic vesicle membrane protein VAT-1 homolog; VAT1 77 42122 2 1 1 1 3.1 393 
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NTRI
1
 Neurotrimin; NTM 77 38518 5 3 3 2 9.3 344 
FBX2
1
 F-box only protein 2; FBXO2 77 33706 4 2 2 2 9.8 296 
SCG2
1
 Secretogranin-2; SCG2 75 70897 5 2 3 1 9.2 617 
SNG3
2
 Synaptogyrin-3; SYNGR3 75 24768 2 2 1 1 5.2 229 
PRRT2
1
 Proline-rich transmembrane protein 2; PRRT2 74 35208 5 4 1 1 3.5 340 
MYO5A Unconventional myosin-Va; MYO5A pe 1  73 216979 9 4 6 3 4.3 1855 
MYO5C Unconventional myosin-Vc; MYO5C 24 203994 11 1 4 1 3.5 1742 
NDUS1 
NADH-ubiquinone oxidoreductase 75 kDa 
subunit, mitochondrial; NDUFS1 
73 80443 9 6 4 2 11.3 727 
PDIA3 Protein disulfide-isomerase A3; PDIA3 72 57146 5 2 4 1 7.1 505 
UBP5 Ubiquitin carboxyl-terminal hydrolase 5; USP5 71 96638 8 6 5 5 10.4 858 
UBP13
1
 Ubiquitin carboxyl-terminal hydrolase 13; USP13 23 98006 3 1 3 1 3.7 863 
COR1A
1




Guanine nucleotide-binding protein Gi/Gs/Go 
subunit -7; GNG7 
71 7631 2 2 1 1 20.6 68 
IF4A1
1
 Eukaryotic initiation factor 4A-I; EIF4A1 70 46353 6 2 3 1 8.4 406 
GDIR1
1
  GDP-dissociation inhibitor 1; ARHGDIA 69 23250 3 1 2 1 27.5 204 
PDCD5
1
 Programmed cell death protein 5; PDCD5 69 14276 2 2 1 1 10.4 125 
SYUB
1




-aminoadipic semialdehyde dehydrogenase; 
ALDH7A1 
68 59020 3 3 2 2 6.9 539 
RAB1A
1
 Ras-related protein Rab-1A; RAB1A 68 22891 7 4 5 4 31.7 205 
CADM4
1
 Cell adhesion molecule 4; CADM4 67 43215 5 2 3 1 10.1 388 
GELS
1 
Gelsolin; GSN 67 86043 3 2 2 1 9.6 782 
GNAZ
2




IQ motif and SEC7 domain-containing protein 1; 
IQSEC1 
65 109103 8 2 4 1 4.9 963 
DLRB1
1 










Mitochondrial import inner membrane 
translocase subunit Tim13; TIMM13 
64 10721 2 1 2 1 23.2 95 
NEBL
1
 Nebulette; NEBL 64 116609 11 2 5 1 6 1014 
MAG
1





protein 1; GDAP1 
63 41548 2 2 1 1 3.4 358 
UK114
1
 Ribonuclease UK114; HRSP12 62 14542 5 4 3 2 34.3 137 
BACH
1 Cytosolic acyl coenzyme A thioester hydrolase; 
ACOT7 
61 42454 3 2 2 1 9.7 380 
K0513
2
 Uncharacterized protein KIAA0513; KIAA0513 60 47066 1 1 1 1 3.4 411 
GPM6B
1
 Neuronal membrane glycoprotein M6-b; GPM6B 60 29882 4 4 1 1 4.9 265 
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ES1
1
 ES1 protein homolog, mitochondrial; C21orf33 60 28495 3 2 2 1 10.1 268 
NFS1
1
 Cysteine desulfurase, mitochondrial; NFS1 pe 1  59 50563 4 2 2 1 7.2 457 
SEPT9
1
 Septin-9; SEPT9 59 65646 6 2 4 1 6.7 586 
NPM
1
 Nucleophosmin; NPM1 59 32726 3 3 1 1 7.1 294 
NPY
1




Low molecular weight phosphotyrosine protein 
phosphatase; ACP1 




ATP synthase subunit -like protein, 
mitochondrial; ATP5EP2 
58 5860 2 1 1 1 15.7 51 
HNRPK
1 
Heterogeneous nuclear ribonucleoprotein K; HNRNPK 57 51230 4 3 1 1 3.7 463 
LY6H
2
 Lymphocyte antigen 6H; LY6H 57 15286 5 3 2 1 21.4 140 
KPCB
1
 Protein kinase C  type; PRKCB 56 77960 7 5 3 2 6 671 
HSP74
1
 Heat shock 70 kDa protein 4; HSPA4 56 95127 4 2 3 2 4.5 840 
HS105
1
 Heat shock protein 105 kDa; HSPH1 55 97716 6 1 4 1 6.4 858 
KCY
1
 UMP-CMP kinase; CMPK1 56 22436 1 1 1 1 6.6 196 
IF4H
1
 Eukaryotic translation initiation factor 4H; EIF4H 56 27425 7 4 3 2 26.6 248 
EPN1
1
 Epsin-1; EPN1 55 60370 9 1 4 1 8.2 576 
GLU2B
1




NADH dehydrogenase [ubiquinone] Fe-S 
protein 3, mitochondrial; NDUFS3 
54 30337 2 1 2 1 14 264 
AUXI
1 Putative tyrosine-protein phosphatase auxilin; 
DNAJC6 
54 100675 5 2 3 2 6.1 913 
SCRN1
1
 Secernin-1; SCRN1 53 46980 11 2 3 2 11.4 414 
NMDZ1
1




Serine-threonine kinase receptor-associated 
protein; STRAP 
52 38756 1 1 1 1 6 350 
GLSK
1
 Glutaminase kidney isoform, mitochondrial; GLS 52 74269 5 3 4 2 10.3 669 
RTN3
1
 Reticulon-3; RTN3 51 113169 2 2 1 1 1.5 1032 
PCBP1
1
 Poly(rC)-binding protein 1; PCBP1 51 37987 6 4 3 2 21.9 356 
DLDH
1
 Dihydrolipoyl dehydrogenase, mitochondrial; DLD 51 54713 4 4 2 2 6.7 509 
DOPD
1 
D-dopachrome decarboxylase; DDT 51 12818 5 3 2 2 27.1 118 
DDTL
2
 D-dopachrome decarboxylase-like protein; DDTL 41 14414 2 2 1 1 15.7 134 
K1045
1
 Protein KIAA1045; KIAA1045 51 45905 4 1 4 1 15.5 400 
MTMR5
1
 Myotubularin-related protein 5; SBF1 50 210294 7 2 3 1 2.6 1867 
ARPC4
1
 Actin-related protein 2/3 complex subunit 4; ARPC4 50 19768 4 2 2 1 13.7 168 
NCKP1
1




NADH dehydrogenase [ubiquinone] 1  subcomplex 
subunit 10, mitochondrial; NDUFA10 
50 41067 3 1 2 1 9 355 
DEST
1
 Destrin; DSTN 50 18950 6 3 4 2 31.5 165 
SCG1
1
 Secretogranin-1; CHGB 49 78343 2 2 1 1 1.8 677 
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ARP2
1




NADH dehydrogenase [ubiquinone] Fe-S 
protein 2, mitochondrial; NDUFS2 
48 52911 5 3 3 2 13.2 463 
CX04A
1
 Protein CXorf40A; CXorf40A 47 18051 5 3 1 1 8.9 158 
AP2S1
1




SH3 domain-binding glutamic acid-rich-like 
protein 3; SH3BGRL3 




Pyruvate dehydrogenase E1 component subunit 
, somatic form, mitochondrial; PDHA1 
47 43952 2 2 1 1 3.1 390 
RHOB











Microtubule-actin cross-linking factor 1, 
isoforms 1/2/3/5; MACF1 
46 843033 37 2 19 1 2.9 7388 
ST134
5
 Putative protein FAM10A4; ST13P4 45 27561 3 1 2 1 12.1 240 
NDRG1
1
 Protein NDRG1; NDRG1 45 43264 2 2 1 1 9.4 394 
PLEC
1




Brain-specific angiogenesis inhibitor 1-
associated protein 2; BAIAP2 
45 61115 5 2 4 2 10.7 552 
H2B1D
1
 Histone H2B type 1-D; HIST1H2BD 45 13928 3 1 2 1 22.2 126 
VGLU3
1
 Vesicular glutamate transporter 3; SLC17A8 44 65861 3 1 3 1 6.6 589 
GHC1
1




43 47464 2 1 1 1 8.2 429 
OMGP
1
 Oligodendrocyte-myelin glycoprotein; OMG 43 50032 6 3 2 1 8.4 440 
SYAC
1 
Alanine–tRNA ligase, cytoplasmic; AARS 42 107484 6 1 6 1 7.4 968 
IGS21
2
 Immunoglobulin superfamily member 21; IGSF21 42 52202 3 1 3 1 16.5 467 
RL6
1
 60S ribosomal protein L6; RPL6 41 32765 2 2 2 2 9 288 
CALX
1
 Calnexin; CANX 41 67982 2 1 2 1 8.1 592 
EF1B
1
 Elongation factor 1-; EEF1B2 41 24919 1 1 1 1 5.8 225 
MPP2
1 
MAGUK p55 subfamily member 2; MPP2 41 64882 2 1 2 1 6.4 576 
TTYH1
2 




BTB/POZ domain-containing protein KCTD16; 
KCTD16 
39 49962 1 1 1 1 2.8 428 
DREB
1




Microtubule-associated protein RP/EB family 
member 3; MAPRE3 
39 32247 3 2 2 1 10 281 
CDC42
1
 Cell division control protein 42 homolog; CDC42 38 21587 2 2 1 1 12.6 191 
RLA2
1
 60S acidic ribosomal protein P2; RPLP2 38 11658 1 1 1 1 18.3 115 
SERA
1
 D-3-phosphoglycerate dehydrogenase; PHGDH 38 57356 3 1 2 1 4.5 533 
CUTA
1
 Protein CutA; CUTA 36 19218 4 3 3 2 41.9 179 
ERP29
1
 Endoplasmic reticulum resident protein 29; ERP29 36 29032 1 1 1 1 3.8 261 
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MARE2
1 Microtubule-associated protein RP/EB family 
member 2; MAPRE2 
36 37236 1 1 1 1 4 327 
UN45B
2




NADH dehydrogenase [ubiquinone] 1  
subcomplex subunit 10; NDUFB10 
36 21048 2 2 2 2 17.4 172 
CAD13
1
 Cadherin-13; CDH13 36 78694 1 1 1 1 3.1 713 
RTCB
1
 tRNA-splicing ligase RtcB homolog; C22orf28 35 55688 3 2 2 1 3.8 505 
TCPG
1




Mitochondrial import inner membrane 
translocase subunit Tim8 A; TIMM8A 
34 11219 1 1 1 1 17.5 97 
CD47
1 
Leukocyte surface antigen CD47; CD47 33 35590 9 1 3 1 10.2 323 
PYGB
1
 Glycogen phosphorylase, brain form; PYGB 33 97319 3 2 2 1 5.5 843 
CAP1
1
 Adenylyl cyclase-associated protein 1; CAP1 32 52325 5 2 2 1 8.8 475 




Serine/threonine-protein phosphatase 2A 
catalytic subunit  isoform; PPP2CA 




NADH dehydrogenase [ubiquinone] Fe-S 
protein 5; NDUFS5 
32 12737 1 1 1 1 11.3 106 
PVRL1
1
 Poliovirus receptor-related protein 1; PVRL1 31 57465 3 1 2 1 8.9 517 
DPYL5
1




Isocitrate dehydrogenase [NAD] subunit , 
mitochondrial; IDH3B 
31 42442 2 1 2 1 11.7 385 
CTRO
1




Small glutamine-rich tetratricopeptide re-peat-
containing protein ; SGTA  
31 34270 1 1 1 1 4.8 313 
UB2V1
1
 Ubiquitin-conjugating enzyme E2 variant 1; UBE2V1 31 16598 16 1 3 1 23.8 147 
LGUL
1
 Lactoylglutathione lyase; GLO1 31 20992 2 2 1 1 8.7 184 
LASP1
1
 LIM and SH3 domain protein 1; LASP1 31 30097 3 2 2 1 9.2 261 
PFD3
1




NADH dehydrogenase [ubiquinone] 1  
subcomplex subunit 9; NDUFB9 




NADH dehydrogenase [ubiquinone] 1 
subcomplex subunit 12; NDUFA12 
30 17104 1 1 1 1 12.4 145 
BDH2
1
 3-hydroxybutyrate dehydrogenase type 2; BDH2 30 27049 1 1 1 1 8.6 245 
KAD5
1
 Adenylate kinase isoenzyme 5; AK5 30 63863 7 1 3 1 7.1 562 
WDR1
1
 WD repeat-containing protein 1; WDR1 29 66836 2 1 2 1 9.1 606 
ARP3B
1




Cytochrome c oxidase subunit 6A1, 
mitochondrial; COX6A1 
29 12147 3 1 3 1 53.2 109 
RBP2
1
 E3 SUMO-protein ligase RanBP2; RANBP2 29 362365 14 1 7 1 2.2 3224 
TOLIP
1
 Toll-interacting protein; TOLLIP 29 30490 4 1 2 1 9.1 274 
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CHL1
1
 Neural cell adhesion molecule L1-like protein; CHL1 29 136070 4 2 3 1 3.6 1208 
DEMA
1




NADH dehydrogenase [ubiquinone] 1  
subcomplex subunit 6; NDUFB6 
29 15479 2 1 1 1 19.5 128 
TF
1
 Tissue factor; F3 29 33332 1 1 1 1 5.1 295 
ODO1
1
 2-oxoglutarate dehydrogenase, mitochondrial; OGDH 28 117059 5 1 3 1 4.4 1023 
MPC2
1
 Mitochondrial pyruvate carrier 2; MPC2 28 14327 4 1 3 1 43.3 127 
OTUB1
1 




Leucine-rich repeat-containing protein 8B; 
LRRC8B 
28 93528 2 1 1 1 1.7 803 
GLP1R
1
 Glucagon-like peptide 1 receptor; GLP1R 28 53960 4 1 1 1 1.9 463 
SYNPO
1




NADH dehydrogenase [ubiquinone] 1  
subcomplex subunit 4; NDUFA4 
27 9421 3 1 1 1 12.3 81 
DNM1L
1 
Dynamin-1-like protein; DNM1L 27 82339 11 2 5 2 9.1 736 
HUWE1
1 




Microtubule-associated proteins 1A/1B light 
chain 3B; MAP1LC3B 
27 14679 2 1 1 1 12.8 125 
CAMKV
2
 CaM kinase-like vesicle-associated protein; CAMKV 27 54662 1 1 1 1 5.2 501 
SIM2
1
 Single-minded homolog 2; SIM2 26 73914 8 1 4 1 9.9 667 
NP1L1
1
 Nucleosome assembly protein 1-like 1; NAP1L1 26 45631 2 1 1 1 2.8 391 
C1TC
1
 C-1-tetrahydrofolate synthase, cytoplasmic; MTHFD1 26 102180 3 1 3 1 5.3 935 
GIT1
1




Probable phospholipid-transporting ATPase IA; 
ATP8A1 




Lipoamide acyltransferase component of 
branched-chain -keto acid dehydrogenase 
complex, mitochondrial; DBT 
26 53852 4 2 3 1 11 482 
WDR13
1




component of 2-oxoglutarate dehydrogenase 
complex, mitochondrial; DLST 
26 49067 3 2 2 1 9.1 453 
HPLN2
1




FXYD domain-containing ion transport regulator 
7; FXYD7 
25 8689 2 1 1 1 20 80 
CADM1
1
 Cell adhesion molecule 1; CADM1 25 48935 1 1 1 1 5.2 442 
RUFY1
1
 RUN & FYVE domain-containing protein 1; RUFY1 25 80851 3 1 2 1 3.8 708 
AAK1
1
 AP2-associated protein kinase 1; AAK1 25 104562 6 1 5 1 8.8 961 
ACLY
1
 ATP-citrate synthase; ACLY 24 121674 7 1 4 1 5.5 1101 
RTN1
1
 Reticulon-1; RTN1 24 83851 2 2 1 1 3 776 
TBCA
1
 Tubulin-specific chaperone A; TBCA 24 12904 2 1 2 1 17.6 108 
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ITSN1
1
 Intersectin-1; ITSN1 23 196155 5 1 3 1 2.8 1721 
CD59
1
 CD59 glycoprotein; CD59 23 14795 2 1 1 1 10.2 128 
PUS7
1




Histidine triad nucleotide-binding protein 2, 
mitochondrial; HINT2 
23 17208 2 1 2 1 20.9 163 
DPY30
1
 Protein dpy-30 homolog; DPY30 23 11243 1 1 1 1 20.2 99 
LHPP
1 Phospholysine phosphohistidine inorganic 
pyrophosphate phosphatase; LHPP 





containing protein 3, mitochondrial; CHCHD3 
23 26421 2 1 2 1 9.3 227 
TUSC2
1
 Tumor suppressor candidate 2; TUSC2 23 12066 3 1 2 1 40.9 110 
D39U1
1
 Epimerase family protein SDR39U1; SDR39U1 22 34840 4 2 2 1 9.1 319 
PAP1L
2 
Polyadenylate-binding protein 1-like; PABPC1L 22 68976 5 2 4 1 10.1 614 
MYL6B
1
 Myosin light chain 6B; MYL6B 22 22864 3 2 2 1 13.9 208 
ATP6
1
 ATP synthase subunit ; MT-ATP6 22 24801 1 1 1 1 4.4 226 
ABI1
1
 Abl interactor 1; ABI1 22 55161 3 1 1 1 3.7 508 
AT5F1
1
 ATP synthase subunit , mitochondrial; ATP5F1 22 28947 6 2 2 1 10.5 256 
RM12
1




Pleckstrin homology domain-containing family 
A member 8; PLEKHA8 
21 58908 5 1 5 1 12.1 519 
PRAF2
1
 PRA1 family protein 2; PRAF2 21 19588 2 2 2 2 16.3 178 
DECR
1
 2,4-dienoyl-CoA reductase, mitochondrial; DECR1 21 36330 2 1 2 1 11 335 
CXA1
1
 Gap junction -1 protein; GJA1 21 43494 2 1 1 1 5.2 382 
ADDG
1 -adducin; ADD3 21 79447 2 1 2 1 4.7 706 
AFG32
1 
AFG3-like protein 2; AFG3L2 20 88984 6 1 5 1 11.4 797 
CRBG3
2 / crystallin domain-containing protein 3; CRYBG3 20 117378 6 1 3 1 2.7 1022 
RSSA
1 
40S ribosomal protein SA; RPSA 20 32947 4 2 3 1 17.3 295 
GLOD4
1
 Glyoxalase domain-containing protein 4; GLOD4 20 35170 4 1 4 1 16.6 313 
NDUV1
1 NADH dehydrogenase [ubiquinone] flavoprotein 
1, mitochondrial; NDUFV1 
20 51469 2 1 2 1 8.2 464 
HPLN4
2 Hyaluronan & proteoglycan link protein 4; 
HAPLN4 




Programmed cell death 6-interacting protein; 
PDCD6IP 
19 96590 2 1 1 1 3.9 868 
SLN11
1
 Schlafen family member 11; SLFN11 19 104309 1 1 1 1 1.3 901 
PK1L2
1
 Polycystic kidney disease protein 1-like 2; PKD1L2 19 275595 4 1 2 1 1.5 2459 
TCPZ
1
 T-complex protein 1 subunit ; CCT6A 18 58444 4 1 4 1 10.2 531 
RDH14
1 




Pleckstrin homology domain-containing family 
H member 1; PLEKHH1 
18 152733 11 1 6 1 5.9 1364 




NADH dehydrogenase [ubiquinone] 1  
subcomplex subunit 7; NDUFA7 
17 12601 1 1 1 1 20.4 113 
QOR
1
 Quinone oxidoreductase; CRYZ 17 35356 3 1 1 1 3.3 329 
CAND2
1 Cullin-associated NEDD8-dissociated protein 2; 
CAND2 





component of pyruvate dehydrogenase complex, 
mitochondrial; DLAT 
17 69466 13 1 4 1 9.6 647 
COTL1
1
 Coactosin-like protein; COTL1 17 16049 1 1 1 1 11.3 142 
AK1A1
1
 Alcohol dehydrogenase [NADP
+
]; AKR1A1 17 36892 2 1 2 1 6.5 325 
PCCB
1 
Propionyl-CoA carboxylase  chain, mitochondrial; PCCB 17 58806 1 1 1 1 2.4 539 
CG025
1 






16 24792 1 1 1 1 10.6 218 
DBNL
1
 Drebrin-like protein; DBNL 16 48463 4 1 3 1 13.3 430 
AK1BA
1




Phosphatidylinositol 5-phosphate 4-kinase type-
2; PIP4K2C 







 exchange transporter 4; CLCN4 16 85774 19 2 2 1 2.9 760 
NDRG3
1






 voltage-gated channel subfamily G member 
2; KCNG2 
16 52176 6 1 1 1 4.7 466 
ANXA6
1
 Annexin A6; ANXA6 16 76168 3 1 3 1 5.8 673 
ITIH3
1
 Inter--trypsin inhibitor heavy chain H3; ITIH3 15 100072 2 1 2 1 4.3 890 
SYUA
1
 -synuclein; SNCA 15 14451 4 1 2 1 22.1 140 
GCSH
1
 Glycine cleavage system H protein, mitochondrial; GCSH 15 19101 1 1 1 1 13.3 173 
UBP20
1




Coiled-coil domain-containing protein 19, 
mitochondrial; CCDC19 
15 65803 19 1 3 1 7.3 551 
DMXL2
1
 DmX-like protein 2; DMXL2 15 342962 17 1 10 1 4.6 3036 
AQP8
2




Mitochondrial import inner membrane 
translocase subunit Tim9; TIMM9 
15 10599 2 1 1 1 16.9 89 
THIM
1
 3-ketoacyl-CoA thiolase, mitochondrial; ACAA2 15 42354 1 1 1 1 7.1 397 
PRAF3
1
 PRA1 family protein 3; ARL6IP5 15 21600 3 1 2 1 18.1 188 
SYNE1
1
 Nesprin-1; SYNE1 14 1017127 29 1 21 1 3.5 8797 
REC8
2
 Meiotic recombination protein REC8 homolog; REC8 14 62916 20 1 2 1 4.8 547 
F86C2
5
 Putative protein FAM86C2P; FAM86C2P 14 18865 3 1 3 1 26.7 165 
SORCN
1





sulfate synthase 2; PAPSS2 
14 70027 6 1 1 1 2.6 614 
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RL11
1 
60S ribosomal protein L11; RPL11 13 20468 1 1 1 1 7.9 178 
SV2B
2 
Synaptic vesicle glycoprotein 2B; SV2B 13 78248 2 1 2 1 4.4 683 
THIC
1 
Acetyl-CoA acetyltransferase, cytosolic; ACAT2 13 41838 3 1 3 1 18.9 397 
RIF1
1




DNA-directed RNA polymerase II subunit 
RPB1; POLR2A 
13 218408 5 1 4 1 1.9 1970 
FETA
1
 -fetoprotein; AFP 13 70458 1 1 1 1 2.6 609 
Notes: The MASCOT software arranges the proteins in order of their score, and then groups similar 
proteins in score order below each initial entry. 
1
, Abbreviated protein name; all names in this table 
had the suffix “_HUMAN”; the superscripted number after the name gives the protein existence (PE) 
score in the Uniprot database, for which 5 levels of evidence are provided: 1, evidence at the protein 
level, 2, evidence at the transcript level, 3, inferred from homology, 4, predicted, 5, uncertain; 
2
, All 





Molecular Mass, Da; 
5
, Nº of Matches; 
6
, Nº of significant matches; 
7
, Nº of sequences found; 
8
, Nº of 
significant sequences found; 
9
, % Cover of the sequence; 
10
, Length in Nº of amino acid residues. 
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 Heat shock protein HSP 90-; HSP90AA1 2316 85006 109 86 25 20 32 732 
HS90B
1
 Heat shock protein HSP 90-; HSP90AB1 2117 83554 105 77 27 20 35.1 724 
ENPL
1
 Endoplasmin; HSP90B1 542 92696 36 24 13 9 19.7 803 
TRAP1
1 
Heat shock protein 75 kDa, mitochondrial; TRAP1 594 80345 14 12 1 1 2 704 
HS904
5 
Putative heat shock protein HSP 90- A4; HSP90AA4P 430 47796 17 17 2 2 5.7 418 
H90B3
5
 Putative heat shock protein HSP 90--3; HSP90AB3P 401 68624 39 21 12 8 14.4 597 
HS902
1
 Putative heat shock protein HSP 90- A2; HSP90AA2 331 39454 17 14 3 3 9.3 343 
H90B2
1 
Putative heat shock protein HSP 90- 2; HSP90AB2P 327 44492 23 15 7 4 16 381 
H90B4
5
 Putative heat shock protein HSP 90- 4; HSP90AB4P 217 58855 8 8 2 2 5.5 505 
HS905
1 
Putative heat shock protein HSP 90- A5; HSP90AA5P 53 38942 12 5 6 3 15.3 334 
ENPLL
5






































-transporting ATPase  chain 2; ATP12A 133 116292 14 8 4 4 3.3 1039 
HXK1
1 
Hexokinase-1; HK1 2134 103561 129 90 40 33 39.1 917 
HKDC1
2
 Putative hexokinase HKDC1; HKDC1 53 103790 10 3 4 1 4.7 917 
HXK2
1
 Hexokinase-2; HK2 43 103739 8 2 5 2 6.2 917 
HXK3
1
 Hexokinase-3; HK3 38 100616 6 1 4 1 5.3 923 
CLH1
1
 Clathrin heavy chain 1; CLTC 1623 193260 76 55 29 23 21.5 1675 
CLH2
1
 Clathrin heavy chain 2; CLTCL1 482 189020 17 13 7 5 4.1 1640 
DYN1
1
 Dynamin-1; DNM1 1503 97746 104 67 28 24 35.1 864 
DYN3
1
 Dynamin-3; DNM3 341 98084 38 19 11 7 15.7 869 
DYN2
1
 Dynamin-2; DNM2 357 98345 31 19 6 5 7.2 870 
ACON
1
 Aconitate hydratase, mitochondrial; ACO2 1185 86113 54 38 16 13 27.4 780 
UBA1
1
 Ubiquitin-like modifier-activating enzyme 1; UBA1 914 118858 33 27 14 13 18.9 1058 
MYPR
1
 Myelin proteolipid protein; PLP1 876 30855 41 30 6 5 24.9 277 
SPTB2
1
 Spectrin  chain, non-erythrocytic 1; SPTBN1 777 275237 50 31 27 14 15.1 2364 
SPTN2
1
 Spectrin  chain, non-erythrocytic 2; SPTBN2 54 272526 13 3 6 2 3.1 2390 
ACTN1
1
 -actinin-1; ACTN1 703 103563 33 24 10 7 15.1 892 
ACTN4
1 -actinin-4; ACTN4 684 105245 37 23 13 6 18.8 911 
ACTN2
1
 -actinin-2; ACTN2 194 104358 8 5 5 2 8.1 894 
ACTN3
1
 -actinin-3; ACTN3 149 103917 5 3 3 1 4.2 901 
NNTM
1
 NAD(P) transhydrogenase, mitochondrial; NNT 633 114564 47 29 15 11 18.8 1086 
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PYGB
1
 Glycogen phosphorylase, brain form; PYGB 633 97319 44 29 18 12 23 843 
PYGM
1
 Glycogen phosphorylase, muscle form; PYGM 267 97487 29 16 11 7 14.5 842 
PYGL
1
 Glycogen phosphorylase, liver form; PYGL 187 97486 13 10 3 3 2.7 847 
SPTN1
1
 Spectrin  chain, non-erythrocytic 1; SPTAN1 610 285163 65 34 36 16 17.4 2472 
GELS
1
 Gelsolin; GSN 513 86043 20 14 5 5 9.2 782 
CAND1
1
 Cullin-associated NEDD8-dissociated protein 1; CAND1 504 137999 32 24 15 10 14.8 1230 
UBP5
1
 Ubiquitin carboxyl-terminal hydrolase 5; USP5 462 96638 29 20 12 9 18.3 858 
TERA
1




Katanin p60 ATPase-containing subunit A-like 2; 
KATNAL2 
126 61557 7 4 2 1 4.8 538 
AP2A1
1
 AP-2 complex subunit -1; AP2A1 432 108561 38 23 15 14 17.6 977 
AP2A2
1
 AP-2 complex subunit -2; AP2A2 376 104807 27 18 14 10 18.6 939 
E41L3
1
 Band 4.1-like protein 3; EPB41L3 397 121458 24 13 14 8 17.8 1087 
ICAM5
1
 Intercellular adhesion molecule 5; ICAM5 375 98766 19 14 9 6 13.1 924 
HS74L
1
 Heat shock 70 kDa protein 4L; HSPA4L 373 95479 22 14 11 6 16.2 839 
HS105
1
 Heat shock protein 105 kDa; HSPH1 327 97716 25 15 15 8 22.8 858 
HSP74
1




V-type proton ATPase 116 kDa subunit a isoform 1; 
ATP6V0A1 
349 97148 36 18 12 8 16.1 837 
AMPH
1
 Amphiphysin; AMPH 329 76381 28 15 10 8 17.6 695 
EAA1
1
 Excitatory amino acid transporter 1; SLC1A3 313 59705 10 7 5 2 12.9 542 
EF2
1
 Elongation factor 2; EEF2 300 96246 17 12 9 5 12.8 858 
NFASC
1
 Neurofascin; NFASC 292 150789 17 12 6 4 5.4 1347 
CNTN1
1
 Contactin-1; CNTN1 289 114104 37 21 13 9 16.7 1018 
PSA
1 
Puromycin-sensitive aminopeptidase; NPEPPS 277 103895 39 18 19 12 21.8 919 
PSAL
2 Puromycin-sensitive aminopeptidase-like protein; 
NPEPPSL1 
58 54226 11 4 9 3 20.9 478 
CSPG2
1
 Versican core protein; VCAN 274 374585 16 9 8 4 3 3396 
EAA2
1
 Excitatory amino acid transporter 2; SLC1A2 272 62577 7 4 4 2 9.6 574 
ODO1
1
 2-oxoglutarate dehydrogenase, mitochondrial; OGDH 253 117059 29 13 12 9 13.1 1023 
OGDHL
1
 2-oxoglutarate dehydrogenase-like, mitochondrial; OGDHL 89 115264 20 10 10 7 12.4 1010 
DPP6
1
 Dipeptidyl aminopeptidase-like protein 6; DPP6 246 98154 17 9 6 4 9.5 865 
ANK2
1
 Ankyrin-2; ANK2 227 435957 33 10 21 6 6.7 3957 
ANK1
1
 Ankyrin-1; ANK1 16 207334 4 1 3 1 2.6 1881 
PYC
1
 Pyruvate carboxylase, mitochondrial; PC 223 130293 19 10 8 4 9.2 1178 
SYAC
1
 Alanine--tRNA ligase, cytoplasmic; AARS 217 107484 8 7 4 3 5.6 968 
ADDA
1
 -adducin; ADD1 216 81304 9 6 5 3 9.5 737 
4F2
1




Cytosolic 10-formyltetrahydrofolate dehydrogenase; 
ALDH1L1 
205 99622 17 9 11 6 15.5 902 
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MAG
1
 Myelin-associated glycoprotein; MAG 202 69880 12 8 6 4 14.1 626 
TBA1A
1
 Tubulin -1A chain; TUBA1A 199 50788 14 8 5 4 17.7 451 
TBA3C
1
 Tubulin -3C/D chain; TUBA3C 49 50612 9 4 4 3 14.4 450 
TBA4A
1
 Tubulin -4A chain; TUBA4A 42 50634 8 3 4 2 15.6 448 
TBA8
1
 Tubulin -8 chain; TUBA8 27 50746 5 1 4 1 13.1 449 
UBB
1
 Polyubiquitin-B; UBB 199 25803 8 6 3 2 14.4 229 
LONM
1
 Lon protease homolog, mitochondrial; LONP1 197 106936 20 9 12 5 13.2 959 
KCRB
1
 Creatine kinase B-type; CKB 193 42902 6 4 3 2 10 381 
NCAM1
1
 Neural cell adhesion molecule 1; NCAM1 192 95370 14 9 8 6 13.5 858 
TENR
1
 Tenascin-R; TNR 179 151805 10 3 6 2 5.4 1358 
C1TC
1
 C-1-tetrahydrofolate synthase, cytoplasmic; MTHFD 176 102180 13 8 9 5 13.7 935 
SV2A
1
 Synaptic vesicle glycoprotein 2A; SV2A 162 83440 8 8 3 3 3.6 742 
ADDB
1
 -adducin; ADD2 159 81260 7 4 2 2 3.6 726 
NFM
1
 Neurofilament medium polypeptide; NEFM 158 102468 7 4 4 2 4.9 916 
NFH
1
 Neurofilament heavy polypeptide; NEFH 158 112639 5 3 3 1 2.8 1026 
GANAB
1
 Neutral -glucosidase AB; GANAB 150 107263 13 6 6 3 8.2 944 
IMB1
1
 Importin subunit -1; KPNB1 150 98420 4 3 2 1 3.7 876 
EPHA4
1
 Ephrin type-A receptor 4; EPHA4 149 111443 10 7 4 3 5.3 986 
EPHA3
1
 Ephrin type-A receptor 3; EPHA3 36 111714 2 2 1 1 1.3 983 
EPHA2
1
 Ephrin type-A receptor 2; EPHA2 32 109679 4 1 3 1 4.6 976 
NCAM2
1
 Neural cell adhesion molecule 2; NCAM2 147 93786 9 4 6 2 9.8 837 
NCKP1
1 
Nck-associated protein 1; NCKAP1 138 130018 12 6 7 4 7.9 1128 
SYIM
1
 Isoleucine--tRNA ligase, mitochondrial; IARS2 126 114688 8 3 6 2 8.7 1012 
CYFP2
1
 Cytoplasmic FMR1-interacting protein 2; CYFIP2 123 150298 10 6 5 2 4.4 1278 
CYFP1
1
 Cytoplasmic FMR1-interacting protein 1; CYFIP1 104 146742 9 3 3 1 3.4 1253 
IMMT
1
 Mitochondrial inner membrane protein; IMMT 117 84026 17 8 8 5 13.5 758 
E41L1
1
 Band 4.1-like protein 1; EPB41L1 116 99012 20 11 9 8 13.2 881 
MAP1B
1
 Microtubule-associated protein 1B; MAP1B 115 271665 12 7 7 4 4.3 2468 
CALX
1
 Calnexin; CANX 115 67982 8 8 3 3 5.2 592 
MOG
1
 Myelin-oligodendrocyte glycoprotein; MOG 114 28574 4 3 2 2 10.1 247 
MYO1D
1
 Unconventional myosin-Id; MYO1D 114 116927 10 4 6 1 9.7 1006 
MAP2
1
 Microtubule-associated protein 2; MAP2 113 199860 9 3 7 2 18.4 478 
NRCAM
1
 Neuronal cell adhesion molecule; NRCAM 110 144655 6 4 4 3 4.4 1304 
KIF5C
1
 Kinesin heavy chain isoform 5C; KIF5C 108 109997 17 8 11 4 15.5 957 
KIF5A
1
 Kinesin heavy chain isoform 5A; KIF5A 97 118161 10 5 5 2 5.9 1032 
CTNB1
1
 Catenin -1; CTNNB1 105 86069 11 6 7 4 12.7 781 
AP180
1
 Clathrin coat assembly protein AP180; SNAP91 94 92672 7 2 4 1 5.3 907 
TBB2A
1
 Tubulin -2A chain; TUBB2A 82 50274 5 4 3 2 7.9 445 
TBB2B
1
 Tubulin -2B chain; TUBB2B 64 50377 3 2 2 1 4.3 445 
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DLG4
1
 Disks large homolog 4; DLG4 81 80788 13 6 8 5 14.6 724 
LPHN1
1
 Latrophilin-1; LPHN1 80 164609 3 2 2 1 1.8 1474 
AP2B1
1
 AP-2 complex subunit ; AP2B1 77 105398 11 5 8 3 10 937 
ESYT1
1
 Extended synaptotagmin-1; ESYT1 76 123293 2 2 1 1 1.2 1104 
ACTB
1
 Actin, cytoplasmic 1; ACTB 73 42052 6 2 3 1 15.2 375 
CNTP1
1
 Contactin-associated protein 1; CNTNAP1 70 158220 3 2 2 1 1.7 1384 
AT2A2
1
 Sarcoplasmic/endoplasmic reticulum Ca
2+
 ATPase 2; ATP2A2 69 116336 9 3 5 2 6.3 1042 
AT2A1
1
 Sarcoplasmic/endoplasmic reticulum Ca
2+
 ATPase 1; ATP2A1 40 111550 5 1 3 1 3.2 1001 
EF1A2
1
 Elongation factor 1- 2; EEF1A2 66 50780 4 2 3 1 10.8 463 
L2GL1
1
 Lethal(2) giant larvæ protein homolog 1; LLGL1 62 116657 2 2 1 1 1.1 1064 
HIP1R
1
 Huntingtin-interacting protein 1-related protein; HIP1R 61 119999 8 2 5 1 6.5 1068 
PLEC
1
 Plectin; PLEC 61 533462 19 3 18 3 5 4684 
PGCB
1
 Brevican core protein; BCAN 60 100539 3 1 2 1 2.5 911 
CTND2
1
 Catenin -2; CTNND2 60 133658 7 2 5 1 5.9 1225 
DYHC1
1
 Cytoplasmic dynein 1 heavy chain 1; DYNC1H1 59 534809 13 4 9 1 2.5 4646 
OMGP
1
 Oligodendrocyte-myelin glycoprotein; OMG 59 50032 7 4 2 2 6.6 440 
MAP1A
1




Disintegrin and metalloproteinase domain-
containing protein 22; ADAM22 
58 102991 1 1 1 1 1.5 906 
PREP
1
 Presequence protease, mitochondrial; PITRM1 pe 1  58 118407 2 2 1 1 1.2 1037 
PDE2A
1 cGMP-dependent 3',5'-cyclic phosphodiesterase; 
PDE2A pe 1  
57 107360 5 4 3 2 4.5 941 
E41L2
1
 Band 4.1-like protein 2; EPB41L2 54 113032 7 3 3 2 3.5 1005 
AT2B1
1
 Plasma membrane Ca
2+
-transporting ATPase 1; ATP2B1 51 139637 6 1 6 1 6.2 1258 
ATPA
1
 ATP synthase subunit , mitochondrial; ATP5A1 50 59828 4 1 3 1 8.1 553 
NLGN3
1











Leucine-rich repeat and immunoglobulin-like domain-
containing nogo receptor-interacting protein 1; LINGO1 
47 70687 5 2 3 1 4.7 620 
BRSK1
1
 Serine/threonine-protein kinase BRSK1; BRSK1 47 85604 7 1 5 1 8.1 778 
WDR47
1 
WD repeat-containing protein 47; WDR47 47 103424 6 1 5 1 7.8 919 
EFR3B
2
 Protein EFR3 homolog B; EFR3B 46 93397 2 1 2 1 3.1 817 
SND1
1







-dependent GABA transporter 1; SLC6A1 44 67827 4 2 2 1 5.5 599 
CAD13
1
 Cadherin-13; CDH13 44 78694 4 3 3 2 4.2 713 
AUXI
1
 Putative tyrosine-protein phosphatase auxilin; DNAJC6 43 100675 5 2 5 2 8 913 
BIN1
1
 Myc box-dependent-interacting protein 1; BIN1 43 64887 8 2 4 1 10.1 593 
ACLY
1
 ATP-citrate synthase; ACLY 43 121674 5 3 4 2 5.4 1101 
EXOC4
1
 Exocyst complex component 4; EXOC4 42 111170 4 2 3 1 4.7 974 
SV2B
2
 Synaptic vesicle glycoprotein 2B; SV2B 40 78248 3 2 2 1 4.1 683 
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NELL2
1
 Protein kinase C-binding protein NELL2; NELL2 39 96359 1 1 1 1 1.1 816 
CTNA2
1
 Catenin -2; CTNNA2 37 106045 9 1 9 1 12.9 953 
GRIA2
1
 Glutamate receptor 2; GRIA2 37 99385 8 4 4 4 5.9 883 
GRIA1
1 
Glutamate receptor 1; GRIA1 34 102240 8 2 4 2 5.5 906 
EEA1
1
 Early endosome antigen 1; EEA1 37 163337 2 1 2 1 1.8 1411 
BCAS3
1




Hepatocyte growth factor-regulated tyrosine kinase 
substrate; HGS 
35 86708 1 1 1 1 1.5 777 
KIF2A
1
 Kinesin-like protein KIF2A; KIF2A 35 80589 5 2 4 1 5.7 706 
GIT1
1
 ARF GTPase-activating protein GIT1; GIT1 35 85030 4 2 2 2 3.9 761 
SNG1
1
 Synaptogyrin-1; SYNGR1 34 25667 1 1 1 1 5.2 233 
K2C1
1
 Keratin, type II cytoskeletal 1; KRT1 34 66170 5 2 3 2 5 644 
GFAP
1
 Glial fibrillary acidic protein; GFAP 22 49907 5 2 4 2 11.1 432 
K2C4
1
 Keratin, type II cytoskeletal 4; KRT4 22 57649 4 1 2 1 3.7 534 
FAK2
1
 Protein-tyrosine kinase 2-; PTK2B 33 117112 15 3 9 2 12.2 1009 
ANFY1
1
 Ankyrin repeat & FYVE domain-containing protein 1; ANKFY1 32 129915 4 1 4 1 5 1169 
NMDZ1
1
 Glutamate receptor ionotropic, NMDA 1; GRIN1 32 105990 7 1 4 1 5.9 938 
SYGP1
1
 Ras GTPase-activating protein SynGAP; SYNGAP1 32 149160 7 1 5 1 6.1 1343 
USO1
1
 General vesicular transport factor p115; USO1 31 108740 2 2 2 2 2.3 962 
TPPC9
1
 Trafficking protein particle complex subunit 9; TRAPPC9 31 129817 2 1 1 1 0.8 1148 
ITAV
1 
Integrin -V; ITGAV 31 117048 3 1 3 1 4.5 1048 
NMD3A
1
 Glutamate receptor ionotropic, NMDA 3A; GRIN3A 31 126525 34 1 1 1 0.6 1115 
COPG2
1
 Coatomer subunit -2; COPG2 30 98700 8 1 4 1 5.7 871 
PLCA
2
 1-acyl-sn-glycerol-3-phosphate acyltransferase ; AGPAT1 30 32038 2 1 1 1 3.5 283 
IPO5
1
 Importin-5; IPO5 29 125032 3 2 2 2 2.3 1097 
TBCD
1
 Tubulin-specific chaperone D; TBCD 29 134283 5 1 3 1 3.8 1192 
ADDG
1
 -adducin; ADD3 28 79447 3 2 2 1 3.4 706 
INP4A
1
 Type I inositol 3,4-bisphosphate 4-phosphatase; INPP4A 28 111539 3 1 3 1 4.6 977 
NED4L
1




SH3-containing GRB2-like protein 3-interacting 
protein 1; SGIP1 
27 89453 6 3 3 2 4 828 
GRIA3
1
 Glutamate receptor 3; GRIA3 26 101662 3 1 2 1 4 894 
UTRO
1
 Utrophin; UTRN 26 396444 7 1 6 1 2.3 3433 
BASP1
1
 Brain acid soluble protein 1; BASP1 26 22680 1 1 1 1 12.3 227 
IQEC1
1
 IQ motif & SEC7 domain-containing protein 1; IQSEC1 26 109103 1 1 1 1 1.5 963 
SRCN1
1
 SRC kinase signaling inhibitor 1; SRCIN1 25 112670 9 1 6 1 10.2 1055 
SORT
1
 Sortilin; SORT1 25 92979 4 1 3 1 4.5 831 
MLL4
1




 Exportin-2; CSE1L 25 111145 5 1 4 1 4.5 971 
CRNS1
1
 Carnosine synthase 1; CARNS1 24 89910 1 1 1 1 1.3 827 
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KPCE
1
 Protein kinase C  type; PRKCE 24 84989 2 2 1 1 2.4 737 
AP3B2
1
 AP-3 complex subunit -2; AP3B2 24 119612 2 1 1 1 1.3 1082 
DICER
1
 Endoribonuclease Dicer; DICER1 24 221279 3 1 1 1 0.4 1922 
LR10B
4
 Leucine-rich repeat-containing protein 10B; LRRC10B 24 32864 4 1 3 1 14.7 292 
SYNE3
1
 Nesprin-3; SYNE3 23 112774 4 1 4 1 6.4 975 
MVP
1 
Major vault protein; MVP 23 99551 4 1 3 1 4.1 893 
FOLH1
1
 Glutamate carboxypeptidase 2; FOLH1 22 84506 3 1 3 1 5.7 750 
PTPRS
1
 Receptor-type tyrosine-protein phosphatase S; PTPRS 22 218159 7 2 5 1 4.1 1948 
A4
1
 Amyloid A4 protein; APP 22 87914 4 2 3 1 5.6 770 
MBP
1 
Myelin basic protein; MBP 22 33097 4 1 1 1 3.9 304 
SYN1
1
 Synapsin-1; SYN1 22 74237 2 1 2 1 5.8 705 
IL25
1
 Interleukin-25; IL25 21 20887 5 2 1 1 5.6 177 
EMC1
1
 ER membrane protein complex subunit 1; EMC1 21 112145 2 1 1 1 1.3 993 
SPTN4
1
 Spectrin  chain, non-erythrocytic 4; SPTBN4 21 290005 9 1 7 1 3.8 2564 
DPP10
1
 Inactive dipeptidyl peptidase 10; DPP10 21 91401 2 1 2 1 3.6 796 
APOB
1
 Apolipoprotein B-100; APOB 20 516651 4 1 4 1 1.2 4563 
DDX58
1
 Probable ATP-dependent RNA helicase DDX58; DDX58 19 108014 14 2 4 1 3.9 925 
ZMYM3
1
 Zinc finger MYM-type protein 3; ZMYM3 18 156101 4 1 4 1 2.7 1370 
LPIN1
2
 Phosphatidate phosphatase LPIN1; LPIN1 18 99287 4 1 3 1 6.2 890 
UBE4A
1
 Ubiquitin conjugation factor E4 A; UBE4A 17 123565 5 1 3 1 4.1 1066 
PLLP
1
 Plasmolipin; PLLP 17 20087 1 1 1 1 12.6 182 
CCL28
1
 C-C motif chemokine 28; CCL28 17 14670 3 1 3 1 18.9 127 
TAU
1 
Microtubule-associated protein tau; MAPT 17 79108 4 1 2 1 3.2 758 
NXPE2
2




Down syndrome cell adhesion molecule-like protein 
1; DSCAML1 
15 226147 2 1 2 1 1.1 2053 
DYH9
1
 Dynein heavy chain 9, axonemal; DNAH9 15 515599 17 1 16 1 4.4 4486 
MK06
1
 Mitogen-activated protein kinase 6; MAPK6 15 83256 4 1 3 1 6.4 721 
LRC52
1 
Leucine-rich repeat-containing protein 52; LRRC52 14 35731 2 1 2 1 12.5 313 
FBX47
2
 F-box only protein 47; FBXO47 13 52846 20 1 2 1 8 452 
CO2A1
1 
Collagen -1(II) chain; COL2A1 13 142782 3 1 2 1 2.4 1487 
Notes as for Table 4.3 
